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Chapter 1
Introduction
General introduction 11
1.1 GenerAL InTroduCTIon
Due to new diagnostic and treatment options, people live longer and are more likely to 
suffer from chronic diseases. Moreover, patients no longer behave passively and often 
pressure health care providers for access to drugs, diagnostics, services, and devices 
that they consider effective. This leads to an increasing demand for health care services 
and a raise in health care expenditures. Health care systems in many countries face the 
challenge of responding to this growing demand for health care.1,2
Health care innovations can be used to respond to this challenge, as they might help 
to make health care become more convenient, more effective and less expensive, so 
that more care can be provided with the same resources and health care can remain 
accessible to everyone.
Three kinds of health care innovations can be defined.3 The first type of innovation 
changes the way consumers buy and use care. The second type uses technology to 
develop new products and treatments and improves care. The third type generates 
new business models, like the horizontal or vertical integration of separate health care 
organisations or activities.
This doctoral thesis addresses the implications of two health care innovations. One 
in glaucoma care and one in chronic lymphocytic leukaemia. The implications are ex-
pressed in terms of costs and health effects. Furthermore, in the case of one innovation, 
the implications of relations between professions are also discussed. 
1.2 HeALTH TeCHnoLoGy AssessMenT
Health Technology Assessment (HTA) is a multi-disciplinary analysis which can be used 
to obtain information about the economic and health implications as well as the social 
(e.g. accessibility) and organisational implications (e.g. feasibility and professionalism) 
of the development, diffusion, and use of health care innovations.4 
The aim of HTA is to inform the formulation of safe, effective, health care policies that 
are patient focused and seek to achieve best value.5 
An economic evaluation is commonly used to assess the economic impact within an 
HTA analysis. A distinction can be made between full and partial economic evaluations. 
Full economic evaluations are generally defined as the “comparative analysis of alterna-
tive courses of action in terms of their costs and consequences”,6 whereas partial eco-
nomic evaluations focus on either costs and resource use or (health) effects. Examples of 
full economic evaluations are cost-effectiveness, cost-utility and cost-benefit analyses, 
and examples of partial economic evaluations are cost analyses, cost-description studies 
and cost-outcome descriptions. Although partial economic evaluations provide more 
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limited information about the cost and/or consequences of a health care innovation 
than full economic evaluations, they may nevertheless contribute useful evidence for an 
understanding of economic aspects of health care innovations. For instance, the descrip-
tion of costs related to chronic lymphocytic leukaemia (CLL) reveals for which treatment 
choices, chemo(immuno-)therapy proved to be the main cost driver. This gives insight 
into the consequences of future changes in the treatment of CLL with regard to the 
share of therapy costs in the total CLL related costs. 
Economic evaluations can be based on different types of patient data sources. An eco-
nomic evaluation can be performed alongside a (randomised) clinical trial, or be based 
on observational data (real world practice). A third option is to use published data on 
clinical trials or observational studies for an economic evaluation. Each method has its 
own potentials and methodological problems, which will be included in the general 
discussion. 
The social, ethical and organisational implications within an HTA analysis cannot be 
fully assessed using an economic evaluation only. A qualitative approach is more suit-
able for obtaining this information. When an economic evaluation is combined with a 
qualitative study this is referred to as multi-method research or mixed method research. 
This combination has been applied in the assessment of the innovation in glaucoma 
care. 
This thesis addresses the costs and consequences of two health care innovations using 
different types of economic evaluations and different data sources of two diseases. The 
first innovation is an example of a new business model in glaucoma care, the transfer 
of tasks from glaucoma specialists to optometrists and ophthalmic technicians. The 
second innovation is the development of a new treatment option (technology) for CLL: 
fludarabine. The next two paragraphs introduce the two diseases, their prevalence and 
burden.
1.3 GLAuCoMA
Glaucoma is a group of eye conditions characterised by damage to the optic nerve.7 
The optic nerve consists of numerous nerve fibres that carry images to the brain. When 
glaucoma damages the optic nerve fibres, blind spots develop. If it is left untreated, 
or when treatment cannot prevent further damage to the optic nerve, glaucoma may 
eventually lead to blindness. 
In its early stages, glaucoma has no obvious signs in the majority of patients. As the 
disease progresses and more damage occurs, blank spots develop in the patient’s periph-
eral (side) vision. These blank spots can, to a certain extent, be filled in by the brain with 
information from the surrounding area.8 Blank spots might therefore not be noticed by 
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the patient until the optic nerve has become severely damaged and the spots become 
large. This underlines the importance of performing regular eye examinations when a 
patient is at high risk of developing glaucoma or once glaucoma has been diagnosed. 
The damage to the optic nerve is usually, but not always, associated with an increased 
pressure within the eye (intraocular pressure). This pressure is due to a build-up of a 
fluid (aqueous humour) that flows in and out of the eye. In a healthy eye, this fluid exits 
the eye through a drainage system at the angle where the iris and the cornea meet. In 
the most prevalent type of glaucoma, the angle where the iris and the cornea meet 
remains open, but the drainage channels in the angle are partially blocked (open-angle 
glaucoma). This causes the fluid to drain out of the eye too slowly, building pressure 
within the eye. In the second main group of glaucoma, closed-angle glaucoma, the 
angle between the cornea and the iris is completely blocked. This results in a rapidly 
increasing eye pressure, requiring immediate treatment. 
Obviously, patients with a high intraocular pressure are at risk of developing glau-
coma. Other risk factors are a high age, an African-American background and a family 
history of glaucoma. 
Prevalence and burden of glaucoma
The total number of patients with glaucoma in the Netherlands is estimated to be 162,500 
of whom 96,200 patients have open-angle glaucoma. This represents approximately 1% 
and 0.6% of the total population, respectively.9 In an extensive international review, a 
similar prevalence rate was found.10 This rate increases with age, and varies according 
to ethnicity. The true number of people with glaucoma is probably much higher, since 
large screening studies found that more than half of the identified cases of glaucoma 
were previously undiagnosed.11-14 
Even in early stage glaucoma, when the visual acuity has not been affected, glaucoma 
can have an impact on the health-related quality of life due to, for example, the loss of a 
driving licence.10,14 The overall burden increases as glaucomatous damage and vision loss 
progresses.14 The WHO estimates that due to impaired vision and blindness related to 
glaucoma, the disease is responsible for 1.3 million disability-adjusted life years (DALYs) 
among the 2.7 billion DALYs in the world in 2012 (WHO).
Most studies about the costs of glaucoma mainly focus on the direct medical cost of 
glaucoma. These studies show that the costs of glaucoma are considerable and are ris-
ing over the years. Indirect non-medical costs of glaucoma are, however, not negligible. 
Loss of productivity is less relevant in the largest part of this (older) patient group, but 
the costs of institutionalisation, care provision and home adaptations are relevant in pa-
tients with visual impairment.15 The greater part of medical costs is spent on medication, 
with new, better, and more easily tolerated, but more expensive medication replacing 
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older and less expensive types. The economic burden of glaucoma is directly related to 
the severity of the disease.10,14
In the Netherlands, information on the costs of glaucoma is not readily available. The 
only information on direct medical costs of visual disorders is presented as aggregated 
costs. The costs of glaucoma, cataract, refraction errors, blindness, visual impairment 
and other eye disorders amounted to €2.8 million in 2011, which is 3.2% of the total 
health care expenditure.16 
Treatment of glaucoma
Glaucoma cannot be cured, and damage to the optic nerve is irreversible, but treatment 
and regular monitoring can prevent a further loss of vision in people with glaucoma. 
Glaucoma treatment aims to lower the intraocular pressure. This can be achieved by 
medication (eye drops), laser treatment or surgery.
Glaucoma treatment often starts with medication. These medicines can work in two 
ways. They either aim to increase the outflow of fluid or to reduce the production of 
fluid, with both methods resulting in a lower intraocular pressure.
When medication is not tolerated or ineffective, laser treatment or another type of 
surgery may be performed. Laser trabeculoplasty uses high-energy laser beams to help 
fluid drain more easily from the eye. During a trabeculectomy, a small piece of eye tissue 
is removed at the base of the cornea through which fluid drains from the eye. This helps 
the fluid drain more easily. As a result, the eye pressure will be lowered. In some cases of 
advanced glaucoma, a drainage implant is placed in the eye to facilitate draining fluid 
from the eye.
When the treatment in patients with glaucoma has been effective, and the progres-
sion of the disease has come to a halt, patients are considered to be “stable glaucoma 
patients”. Research in this thesis focuses on monitoring and treating patients with stable 
glaucoma and those at high risk of developing glaucoma.
1.4 CHronIC LyMPHoCyTIC LeuKAeMIA
CLL is the most common type of leukaemia in the western world. It is a cancer of the lym-
phocytes (a type of white blood cells), characterised by their uncontrolled cell division 
that crowds out healthy blood cells. Due to a shortage of healthy white and red blood 
cells, a patient with CLL may develop infections and anaemia. Early symptoms of CLL are, 
however, usually minimal and diagnosis often follows a routine blood test that returns a 
high lymphocyte blood count. Some CLL patients present with enlarged lymph nodes.
The clinical course of CLL is highly variable.17 Survival from the time of diagnosis 
ranges from several months to 20 or more years, depending on prognostic factors.18,19 
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The first prognostic indices including lymphadenopathy, hepatomegaly, splenomegaly, 
anaemia and thrombocytopenia were developed by Rai and Binet17,20 to define disease 
stages (see Table 1.1). Patients who are diagnosed at an early stage (Binet A, Rai 0) have 
a median estimated survival time of more than 10 years, intermediate stage patients 
(Binet B, Rai I/II) a survival time of 7 years and advanced patients (Binet C, Rai III/IV) have 
a median survival time of 1.5 years.21 More recently, molecular based prognostic markers 
have been defined such as chromosomal abnormalities22 and mutational status of the 
immunoglobulin genes.23
Prevalence and burden of Chronic Lymphocytic Leukaemia
CLL is primarily a disease of older adults, with a median age of 70 years at the time of 
diagnosis.24 CLL affects roughly 3 to 6 people per 100,000 population.25,26 In the Nether-
lands, 600 to 700 patients are diagnosed with CLL every year,27 with twice as many males 
as females. As shown in Figure 1.1, the incidence of CLL increases with age and peaks at 
60 to 80 years.26,28,29 The real number of people with CLL is probably higher, because of 
the asymptomatic character of the disease at the start of the disease course.
Because of the prolonged survival, which was usually about ten years in past decades, 
but which can extend to a normal life expectancy,30 the prevalence is much higher than 
the incidence.
Although CLL is often asymptomatic at the earliest stages, the awareness of living 
with an incurable disease can by itself have a profound impact on health related quality 
of life (HRQoL).31 As the disease progresses, patients can also experience disease-related 
Table 1.1. Classification of CLL patients by Rai and Binet
rai classification Binet classification
Stage 0.
Lymphocytosis. No enlarged lymph nodes, spleen, or 
liver, and with near normal red blood cell and platelet 
counts.
Stage A.
Fewer than 3 areas of lymphoid tissue 
are enlarged, with no anaemia or 
thrombocytopenia.Stage I.
Lymphocytosis plus enlarged lymph nodes. The spleen 
and liver are not enlarged, with near normal red blood 
cell and platelet counts. Stage B.
3 or more areas of lymphoid tissue are enlarged, 
with no anaemia or thrombocytopenia.
Stage II.
Lymphocytosis and an enlarged spleen (and/or liver). The 
red blood cell and platelet counts are near normal.
Stage III.
Lymphocytosis plus anaemia. Near normal platelet 
counts. Stage C.
Presence of anaemia and/or thrombocytopenia.Stage IV. 
Lymphocytosis plus thrombocytopenia, with or without 
anaemia, enlarged lymph nodes, spleen, or liver.
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symptoms and the toxic effects of therapy like fatigue, weight loss, bleeding, and recur-
rent or persistent infections.32,33 Despite these effects, little is known about the HRQoL 
of patients living with CLL.31,34,35 The available information on HRQoL is often based on 
clinical trials, which represent only a small part of all CLL patients in clinical practice. 
Only a few studies were performed in the complete population of CLL patients. These 
studies conclude that CLL has a profound impact on HRQoL when compared to the 
general population36,37 and that HRQoL differs between men and women.38 The WHO 
estimates that CLL is responsible for 10.6 million DALYs per year which is 0.3% of the total 
number of annual DALYs.39 
The three studies that present an overview of the longitudinal costs of CLL are all 
based on administrative claim data and show that the medical cost attributable to CLL 
ranges from €5000 to €1200 per year (2011 level) in Germany and are almost $68000 
(€50320, 2011) through lifetime in the USA.40-42 These studies concluded, contrary to an 
older review,43 that it is not the therapy costs, but rather the usage of physicians and 
inpatient care that are the main cost drivers of CLL treatment.
Treatment of Chronic Lymphocytic Leukaemia
Although generally considered incurable, CLL can be treated and current standard 
chemotherapy regimens have been shown to prolong survival. 
As randomised clinical trials44,45,46 failed however to show a statistically significant dif-
ference in survival between early versus deferred treatment of patients with asymptom-
atic, low risk (Rai 0/ Binet A) CLL, the majority of CLL patients are not treated immediately 
after diagnosis. They will first be monitored through a watch and wait approach. Around 
one third of patients never even require treatment. 
Treatment is indicated only upon disease progression and/or the development of 
CLL related symptoms.47 CLL treatment aims to control the disease and its symptoms. 
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Figure 1.1 Annual incidence of chronic lymphocytic leukaemia in the Netherlands.
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Treatment possibilities are (a combination of ) chemotherapy, radiation therapy, im-
munotherapy, and bone marrow transplantation. Symptoms are sometimes treated 
surgically (removal of enlarged spleen) or by radiation therapy (“de-bulking” swollen 
lymph nodes). 
The management of CLL has changed in recent decades. The development of purine 
analogues like fludarabine was the first breakthrough in the 1980s. Before that time, 
treatment of CLL revolved around chlorambucil. At the turn of the century, almost all pa-
tients were treated with single chemotherapeutics like chlorambucil and fludarabine.48 
At that time there was no evidence claiming that drug combinations were preferable 
to monotherapy. Treatment combinations like CHOP (cyclophosphamide, doxorubicine, 
vincristine and prednisone) were used, but usually not in the first line.48 Ten years later, 
especially after the introduction of monoclonal antibodies at the start of the twentieth 
century, multiple studies have shown improvement in progression-free survival with 
fludarabine based combinations.49-52
Although fludarabine was shown to give superior response rates to chlorambucil as 
primary therapy,53,54 there is no evidence that early use of fludarabine monotherapy 
improves overall survival, and some clinicians therefore prefer to reserve fludarabine for 
relapsed disease.
The first time that the overall survival was improved by the choice of a first-line treat-
ment, was in a large randomised trial comparing chemo-immunotherapy (fludarabine, 
cyclophosphamide, and rituximab - known as FCR) with chemotherapy (fludarabine 
and cyclophosphamide). Besides the overall survival, FCR also resulted in an improved 
response rate and progression-free survival in CLL patients selected for a good physical 
condition.47 
1.5 THesIs AIMs
The overall aim of this thesis is to evaluate the health benefits and costs of health care 
innovations, illustrated in two different disease areas: glaucoma and CLL. 
Population aging increases the number of glaucoma patients and already leads to 
higher workloads for glaucoma specialists. If stable glaucoma patients were monitored 
by optometrists and ophthalmic technicians in a glaucoma follow-up unit (GFU) rather 
than by glaucoma specialists, then the specialists’ workloads and waiting lists might be 
reduced. We therefore compared costs and quality of care at the hospital-based GFU 
with those of the usual care by glaucoma specialists in the Rotterdam Eye Hospital in 
a randomised clinical trial. Furthermore we explored how stakeholders perceived the 
feasibility of transferring hospital-based monitoring of stable glaucoma patients to 
primary care optometrists.
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In the past decades, the number of treatment options for CLL has increased rapidly. 
Since health care is under increasing pressure, cost-effectiveness data of new versus 
existing treatment options are urgently needed. That is especially true in countries like 
the Netherlands where expensive drugs are to be evaluated during the first years of tem-
porary admittance in order to obtain unconditional reimbursement. In an observational 
study, we followed Dutch CLL patients for 6.4 years on average to get an overview of 
the management of CLL. A comprehensive cost calculation was performed to produce 
a transparent overview of different cost categories that would identify the main cost 
drivers during the complete course of CLL treatment, presented per treatment line and 
per type of treatment. Information about the longitudinal quality of life of CLL patients 
over time was collected during the prospective part of the same study. 
research questions
The aim of the research as described in the previous paragraphs has been translated into 
the following research questions:
Glaucoma
I. Is the quality of care delivered to stable glaucoma patients and to patients at risk 
of glaucoma by the hospital-based GFU similar to the quality of care delivered by 
glaucoma specialists in the Rotterdam Eye Hospital?
II. What are the costs of the care provided by the GFU in monitoring and treating stable 
glaucoma patients and patients at risk of glaucoma when compared with those of 
the usual care provided by glaucoma specialists in the Rotterdam Eye Hospital?
III. How do stakeholders perceive the feasibility of implementing substitution of person 
(from ophthalmologists to allied health professionals) and setting (from a hospital to 
primary care) for glaucoma care at the Rotterdam Eye Hospital, and what are their 
supporting and opposing arguments?
Chronic lymphocytic leukaemia
IV. How is CLL managed in the Netherlands and what is its clinical effectiveness in daily 
clinical practice? 
V. What are the main cost drivers during the complete course of CLL treatment includ-
ing the period before the start of treatment (watchful waiting)?
VI. What is the health related quality of life (HRQoL) of an unselected population of 
patients with chronic lymphocytic leukaemia (CLL) including untreated patients?
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1.6 THesIs ouTLIne
The research conducted to address the questions listed above is described in the next 
six chapters of this thesis. Each chapter addresses a separate research question. Part 
1, which comprises the first three chapters is concerned with the randomised clinical 
trial investigating optometrists to substitute for ophthalmologists in glaucoma care. 
It describes the clinical effects of this substitution within the hospital (Chapter 2), the 
cost-effectiveness (Chapter 3) and the feasibility of extending this substitution allowing 
primary care optometrists to substitute for ophthalmologists (Chapter 4).
The second part of this thesis, addresses the management (Chapter 5), resource 
use and costs of CLL (Chapter 6) and the long-term quality of life of patients with CLL 
(Chapter 7) based on an observational study conducted in 19 Dutch hospitals. 
Chapter 8 of this thesis provides a discussion of the results and explores the implica-
tions of the findings for health care providers, managers and researchers. Implications 
for future research projects are summarised and discussed in this chapter as well.

Chapter 2
Shared care in monitoring stable glaucoma 
patients: a randomised controlled trial
K.M. Holtzer-Goor, E.J. van Vliet, E. van Sprundel, T. Plochg, M.A. Koopmanschap, 
N.S. Klazinga, H.G. Lemij
Accepted for publication in Journal of Glaucoma
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suMMAry
Purpose. Comparing the quality of care provided by a hospital-based shared care glau-
coma follow-up unit with care as usual. 
Methods. This randomised controlled trial included stable glaucoma patients and pa-
tients at risk for developing glaucoma. Patients in the Usual Care group (n=410) were 
seen by glaucoma specialists. In the glaucoma follow-up unit group (n=405), patients 
visited the glaucoma follow-up unit twice followed by a visit to a glaucoma specialist. 
The main outcome measures were: compliance to the working protocol by glaucoma 
follow-up unit employees; difference in intraocular pressure between baseline and at 
≥18 months; and patient satisfaction. 
Results. Glaucoma follow-up unit employees closely adhered to the working protocol 
for the measurement of intraocular pressure, visual acuity and GDx (≥97.5% of all visits). 
Humphrey Field Analyser examinations were not performed as frequently as prescribed 
by the working protocol, but more often than in the Usual Care group. In a small minor-
ity of patients that required back-referral, the protocol was disregarded, notably when 
criteria were only slightly exceeded. There was no statistically significant difference in 
changes in intraocular pressure between the two treatment groups (p=0.854). Patients 
were slightly more satisfied with the glaucoma follow-up unit employees than with the 
glaucoma specialists (scores: 8.56 vs. 8.40; p=0.006). 
Conclusions. In general, the hospital-based shared care glaucoma follow-up closely 
observed its working protocol and patients preferred it slightly over the usual care 
provided by medical doctors. The glaucoma follow-up unit operated satisfactorily and 
might serve as a model for shared care strategies elsewhere. 
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2.1 InTroduCTIon 
Glaucoma is a progressive condition that requires lifelong observation and management. 
Quigley and Broman55 predicted in 2006 an approximate 30% increase in the number 
of glaucoma patients worldwide by 2020, with the need for lifelong monitoring. This 
increase is caused by a longer life expectancy, enhanced societal expectations, and new 
diagnostic technologies.56-59 It may thus be difficult for ophthalmologists worldwide to 
meet the growing demands of glaucoma patients.
One solution to manage the growing gap between the number of ophthalmologists 
and the demand for their services would be to increase the number of ophthalmolo-
gists; this appears unlikely because of limited resources.2 Another possible solution 
might be to deliver care more efficiently through a transfer of tasks in glaucoma care.60,61 
In patients at a low risk of becoming significantly visually impaired during their life-
time, monitoring of the disease probably does not have to be performed entirely by 
an ophthalmologist but by (community) optometrists and ophthalmic technicians.62-64 
Suitable patients for such follow-up would be those in which the glaucoma is relatively 
mild, has stabilized or progresses at a relatively low rate or is not even apparent yet. 
In the latter group, follow-up would be merely required because the patients carried 
an increased risk of developing the disease, for instance in those with a positive family 
history. To meet the future demands of ophthalmic care, the shared care option merits 
consideration and study. 
The Bristol Shared Care Glaucoma Study,65-69 carried out over a decade ago, is to our 
knowledge the only study in which transfer of glaucoma care to community optom-
etrists was studied and found to be successful. We believe that transferring glaucoma 
patients to community optometrists is not feasible in most countries, although there is 
little data available about shared care in the various countries. We showed earlier that 
the Rotterdam Eye Hospital (REH) in the Netherlands attempted to refer stable glaucoma 
patients in 2001 to community optometrists for some of their regular glaucoma follow-
up visits.70,71 In that particular project, the standard of care was substituted not only by 
health care provider (the glaucoma specialist by an optometrist) but also by setting (the 
hospital by the optic dispensary). It turned out that this substitution by both health care 
provider and setting was not successful. Both glaucoma specialists and patients were 
unfamiliar with the skills and knowledge of optometrists and questioned the quality of 
their care. As a result, few patients actually visited the optometrists. Unfortunately, the 
steady increase in glaucoma patients greatly exceeded the resources at the REH, so that 
it had to close its doors to new glaucoma patients in 2003. 
To address this problem, the REH initiated an intermediate step of substitution of 
health care provider only. In a hospital-based Glaucoma Follow-up Unit (GFU), staffed by 
an optometrist and ophthalmic technicians, relatively low-risk glaucoma patients were 
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monitored by means of a standard protocol. These patients included those that had only 
mild or moderate glaucoma and were thought to be stable, as well as those patients 
who were glaucoma suspects without proven disease. The purpose of this substitution 
of care was that it would alleviate the burden of care by glaucoma specialists, allowing 
them to treat patients with more complicated or advanced glaucoma and also opening 
the hospital’s doors to new patients. Because the GFU was located in the hospital (i.e., in 
a setting familiar to the patients), the patients were expected to have more confidence 
in the GFU, compared to community based optometrists. They were thought to be more 
willing to visit it. In the GFU, ophthalmic technicians and optometrists could become 
familiar with monitoring glaucoma. If necessary, supervision by glaucoma specialists 
would be relatively easy to obtain. 
The aim of this randomised controlled trial (RCT) was to determine whether the qual-
ity of care in the in-hospital GFU was similar to that of glaucoma specialists.
2.2 MATerIALs And MeTHods
study organisation
The GFU was located in the REH. The REH is the only independent eye hospital in the 
Netherlands and functions as a tertiary referral centre for ophthalmic care. The Ethics 
Review Committee of the Erasmus Medical Centre, Rotterdam, approved the study.
Inclusion criteria
The inclusion criteria used in this study have previously been described in detail.72 In 
brief, eligible patients were at risk for glaucoma or had stable glaucoma in one or both 
eyes, had not undergone laser surgery for diabetic retinopathy and had no other clini-
cally significant ocular disease. The best corrected distance visual acuity (BCVA) in each 
eye was ≥ 0.20 Snellen decimal equivalent, the refractive error was between +5 and –8 
diopters (spherical equivalent) and the patient had no visual field loss within the central 
10˚.
Eyes were considered to be glaucomatous if they had typical thinning or notching of 
the neuroretinal rim of the optic nerve head, with or without disc haemorrhages, visual 
field defects, peripapillary atrophy and/or elevated IOP. Glaucoma was defined as stable 
if the glaucoma specialist scheduled the next appointment in 6 or more months. 
Furthermore, the patient file had to contain information about the actual ophthalmic 
medication, the target pressure (TP) and the results of the examination of the optic disc, 
macula, and the peripheral fundus. 
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Patient selection and randomisation
Patients who had already been referred to the GFU before the start of this trial, as well 
as newly referred patients, were checked for eligibility. All eligible patients received oral 
and written information about the study during their next visit. All participants were 
randomly allocated to either the GFU group or the Usual Care group after giving their 
informed consent. 
To avoid glaucoma specialists affecting the allocation of patients, central randomisa-
tion by the researchers was performed using stratification by 2 variables: the referring 
glaucoma specialist, and the time to the next scheduled visit, being either 6 months or 
more than 6 months. Patients were followed during a median period of 2 year.
usual care vs. Glaucoma Follow-up unit
In the Usual Care group, the patients were seen by glaucoma specialists. In the GFU 
group, every patient visited the GFU twice, followed by a visit to a glaucoma specialist. 
Table 2.1. Provided care in the glaucoma specialist group and theg Glaucoma Follow-up Unit group with 
criteria for back referral to the glaucoma specialist
Activity Glaucoma specialist GFu Criteria for back referral 
by GFu
Short history Every visit Every visit
IOP 1 Every visit Every visit IOP>TP
Medical prescriptions Every visit Every visit
Optic disc assessment Every visit NA
Snellen visual acuity At least once yearly Every visit Decline in visual acuity of ≥ 
2 lines
GDx ECC 2 Approximately once yearly Every visit Suspicion of progression. In 
case of first GDx ECC: NFI > 35 
and/or left/right asymmetry 
and/or local defect
HFA 24-2 3 Approximately once yearly Yearly in moderate 
to advanced visual 
field damage4
Suspicion of progression
Overall judgment Every visit Every visit
Timing next appointment Every visit Every visit
1 IOP by Goldmann applanation tonometry
2 GDx ECC scanning laser polarimetry images 
3 Humphrey Field Analyzer, standard 24-2 test algorithm (HFA 24-2) 
4 Criteria moderate to advanced visual field damage: the mean deviation of the last performed visual field 
was < -5dB 
GFU: glaucoma follow-up unit; IOP: intraocular pressure; NA: not applicable; NFI: nerve fiber indicator; TP: 
target pressure.
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For the GFU, the next visit was always scheduled after the same time interval as before, 
as long as the glaucoma was considered to be stable. 
The GFU employees observed a strict working protocol; they could call in the assis-
tance of a glaucoma specialist whenever required. If specified criteria were exceeded, 
the GFU was supposed to refer the patients back to a glaucoma specialist, within a 
predetermined time-frame. The elements of ‘care as usual’ and of the working protocol 
in the GFU, including the criteria for back-referral to the glaucoma specialist, have been 
shown in Table 2.1. The most important reasons for referring the patients from the GFU 
back to the glaucoma specialists were loss of visual acuity, an IOP that was higher than 
the predetermined target pressure and/or any suspicion of glaucomatous progression 
on either visual fields or GDx.
Optic disc assessment was not carried out at the GFU, because ophthalmic techni-
cians in the Netherlands are not trained to do so. As a surrogate for examining the optic 
disc, the GFU personnel carried out a GDx ECC or a Humphrey Field Analyzer (HFA; both 
devices manufactured and distributed by Carl Zeiss Meditec Inc., Dublin, CA, USA) exam. 
Main outcome measures
For the definition of quality of care, we used the six aims of health care improvement as 
described by the Institute of Medicine: safe, patient-centered, timely, equitable, effec-
tive, and efficient care.73
The safety of care provided by the GFU was derived from the extent to which its em-
ployees followed the working protocol. We scored how often the obligatory examina-
tions and ancillary tests (per protocol) were carried out and how often the patients were 
back-referred to the glaucoma specialists, as well as how often the glaucoma specialists 
were called upon for advice in case criteria were exceeded. 
The patient-centeredness was measured by using the consumer quality index, an ex-
isting questionnaire for patient satisfaction, which had been tested previously in other 
patient populations for validity and reliability.74 A translated version of the question-
naire has been provided as Appendix 2.1. The analysis focuses on five dimensions: 1) 
the overall mark given for the received care; 2) knowledge: the perceived knowledge 
of the health care provider; 3) information: how well the health care provider provided 
the patient with information; 4) courteousness: whether the patient was treated courte-
ously; 5) the patient’s opinion about the waiting area.
The effect in clinical productivity of glaucoma specialists was used as a measure for 
the timeliness and equity of care, since the establishment of the GFU was expected to 
decrease the workload of the glaucoma specialists, allowing the acceptance of new 
glaucoma patients. The effect in clinical productivity was expressed in the number of 
additional patients that could be accepted for treatment and was calculated as the 
difference in the average time spent per patient year by a glaucoma specialist in the 
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GFU group vs. the Usual care group. Visits to the glaucoma specialists were assumed to 
require 10 minutes, and giving advice 5 minutes. For patients in the GFU group who did 
not visit the glaucoma specialist yet -which they should, every third visit, one third of the 
visits was included in this calculation.
For the measurement of the effectiveness of care, several measures were used: a) the 
time till the next visit; it was thought that any reduction in that interval indicated that the 
patient required additional attention, indicating some form of additional concern over 
the clinical management of the disease; the time till the next scheduled visit reflected 
the overall clinical judgment of either the glaucoma specialist or the GFU employee, 
based on all available clinical information, such as history, IOP, appearance of the optic 
disc and/or of the GDx ECC scans, functional assessments (HFA visual fields) and toler-
ance of therapy b) mean difference in IOP (i.e., the IOP at baseline vs. the IOP at the last 
visit (if at least 18 months afterwards)), c) the results of the examinations and ancillary 
tests and, d) the number of treatment changes.
This manuscript does not present the results about the efficiency, since a cost-
effectiveness analysis of our data has been reported separately.72 
Visual field or GDx progression per se was not used as an outcome measure because 
we did not expect this patient population to progress in the relatively short time span 
of the study, since the patients either were assumed to be stable from its outset or only 
had a risk factor for glaucoma without any outright disease. 
data collection and quality assurance
To quantitatively assess the clinical outcomes and the provided care, Case Report Forms 
(CRF) were completed after each patient visit. The data were then checked indepen-
dently by one of the researchers and subsequently entered into a database. 
Patients’ experiences were scored after each visit and were reported per treatment 
group (GFU group or Usual Care group) as well as per type of health care provider, since 
the GFU group was followed up by GFU employees as well as by glaucoma specialists 
(the latter every third visit or sooner whenever back referred). 
The accuracy of the data was monitored regularly by selecting random samples of 
CRFs and patient questionnaires and then comparing the data in the database with the 
original forms.
statistical analysis
SPSS 22.0 was used for the statistical analysis. Treatment groups were compared by us-
ing a t-test for independent samples in normally distributed variables. If the data were 
not normally distributed, a chi-square test was used. The change in IOP and target IOP 
over time were analysed with a paired sampled t-test. All statistical tests were performed 
two-sided and at a 5% significance level.
28 Chapter 2
2.3 resuLTs
A total of 866 patients were enrolled. Patients who did not show up at any appointment 
(31 patients, 4%) and patients who moved their appointment to a date after the data 
collection period (13 patients, 2%) and 2 patients who underwent cataract surgery and 
had no glaucoma-related appointment during the study period were excluded from the 
analysis. Three others were excluded because they could not be monitored with the GDx 
and 2 patients withdrew their informed consent (see Figure 2.1). 
There were no statistically significant demographic and clinical differences between 
the remaining 410 patients in the Usual Care group and 405 patients in the GFU group 
(Table 2.2). These 815 patients had a total of 2100 visits, of which 1832 regular visits. 
Table 2.3 presents all types of visits, their numbers in the two treatment groups and 
their inclusion in the various parts of the analysis. The average time between visits was 
9.9 months (SD 3.4). 
 
 
Figure 1. Patient flow chart. This figure depicts the patient flow from randomization and allocation to 
analysis. 
Usual Care (n=439) 
♦ Received allocated care (n=410) 
♦ Did not receive allocated care (n=29) 
Reasons: 27 patients had no 
appointments in the study period (no 
show),  
2 patients could not be monitored by a 
GDx. 
Glaucoma Follow-up Unit (n=427) 
♦ Received allocated care (n=407) 
♦ Did not receive allocated care (n=20) 
Reasons: 19 patients had no 
appointments in the study period (no 
show), 
 1 patient could not be monitored by a 
GDx. 
Randomized (n=866) 
Analysed (n=410) 
♦ Excluded from analysis (n=0)  
Lost to follow-up (n=0)  Lost to follow-up: (n=2)  
Reason: care is too exhausting (1), 
withdrawal for unknown reason (1). 
 
Analysed (n=405) 
♦ Excluded from analysis (n=0)  
Analysis 
Follow-up 
Allocation 
Figure 2.1 Patient flow chart. This figure depicts the patient flow from randomisation and allocation to 
analysis.
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Table 2.2. Patient characteristics per treatment group at baseline and at end of study
Usual Care Group 
n=410
GFU Group 
n=405
P-value
At baseline
Age* 63.1 (11.9) 63.0 (12.1) 0.40 †
Men**  196 (47.8%) 187 (46.2%) 0.64 ‡
Diagnosis** 0.87 ‡
- Glaucoma 83 (20.2%) 73 (18.1%)
- Increased IOP 133 (32.4%) 138 (34.2%)
- Positive family history 15 (3.7%) 14 (3.5%)
- Glaucoma suspect (≥ 1 other risk factor) 179 (43.7%) 179 (44.3%)
IOP (mmHg)* 18.8 (4.0) 18.6 (3.9) 0.51 †
TP (mmHg)* 25.2 (5.3) 25.1 (5.1) 0.86 †
BCVA (logMAR value)* 0.05 (0.06) 0.05 (0.06) 0.59 †
Visual field loss (MD < –5 dB with HFA 24-2)** 56 (13.7%) 48 (11.9%) 0.50 ‡
At end of study (last visit at least after 18 M)
IOP (mmHg)* n= 332 vs. 344 18.3 (3.8) § 18.2 (3.7) § 0.73 †
TP (mmHg)* n= 332 vs. 344 21.4 (4.0) § 21.4 (3.7) § 0.79 †
BCVA (logMAR value)** n= 249 vs. 294 0.05 (0.07) § 0.04 (0.08) § 0.29 †
IOP+≥18m - IOPbaseline -0.33 (2.61) -0.37 (3.33) 0.854 †
* Mean and standard deviation; ** Number and percentage
† Independent samples t-test, ‡ Chi-square test 
§ P-value of paired samples t-test <0.05 for IOP and TP, and > 0.05 for BCVA. 
BCVA: Best corrected distance visual acuity; dB: decibel; GFU: glaucoma follow-up unit; HFA: Humphrey 
Field Analyzer; IOP: intraocular pressure; M: months; MD: mean deviation; TP: target intraocular pressure.
Table 2.3. The type of visits per treatment group and their inclusion in parts of the analysis
Usual Care 
group n=410
GFU group 
n=405
Included 
in analysis 
patient 
satisfaction
Included in analysis 
compliance 
with protocol / 
effectiveness
Total number of visits 919 1181
Of which regular checks in GFU 40* 813 ✓ ✓
Of which regular checks with glaucoma 
specialist
785 194 ✓ ✓
Of which additional visits to glaucoma 
specialist
48 131 ✓ ✓
Of which additional visits for tonometry 42 37 ✓
* These visits were planned when the glaucoma specialist did not realized that the patient was randomised 
to the specialist group. He/she, therefore, accidentally referred the patient to the GFU.
A&E: Accident and Emergency; GFU: glaucoma follow-up unit.
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safety: compliance of the GFu employees
Table 2.4 shows to what extent the GFU employees followed the working protocol; it 
displays how often the various examinations and ancillary tests were carried out and 
also how often the GFU referred the patients back to the glaucoma specialists or called 
on them for advice, as required by the protocol.
The IOP and visual acuity should be measured at all visits to the GFU. During those 
visits, the required tests were performed almost every time (> 99%) (Table 2.4). The GDx 
imaging should be performed with every visit to the GFU, and yearly for every visit to 
Table 2.4. Frequency and results of examinations and ancillary tests performed per group and per kind of 
health care provider
usual Care group GFu group P-value 
(between 
groups)
Glaucoma 
specialist
/resident
n*=833
GFU 
employees
n*=40
Glaucoma 
specialist / 
resident
n*=325
GFU 
employees
n*=813
IoP
Measurement and registration of IOP 
ODS
825 (99.0%) 40 (100%) 320 (98.5%) 810 (99.6%) 0.593 ‡
Of which IOP (OD and/or OS) > 
TPbaseline
86 (10.4%) 2 (5.0%) 69 (21.6%) 52 (6.4%) 0.699 ‡
Of which follow-up with glaucoma 
specialist
72 (86.7%)1 1 (50.0%) 44 (67.7%)2 37 (74.0%)3
Of which advice of glaucoma 
specialist was called upon
0 (0.0%) 1 (50.0%) 0 (0.0%) 7 (13.5%)
Of which change in medication 1 (1.2%) 0 (0.0%) 4 (5.8%) 0 (0.0%)
Of which change of TP 6 (11.6%) 0 (0.0%) 6 (13.0%) 0 (0.0%)
GFU referred to/consulted glaucoma 
specialist as per protocol
NA 40 (100%) NA 805 (99.0%)
Visual acuity
Measurement and registration of VA 
ODS
579 (69.5%) 39 (97.5%) 181 (55.7%) 809 (99.5%) <0.01 ‡
Of which decline in VA of ≥ 2 lines 37 (6.4%) 2 (5.1%) 17 (9.4%) 22 (2.7%) 0.032 ‡
Of which follow-up with glaucoma 
specialist
33 (91.7%)4 1 (100%)4 6 (50%)5 14 (66.7%)4
Of which advice of glaucoma 
specialist
3 (8.1%) 0 (0.0%) 1 (5.9%) 1 (4.5%)
GFU referred to/consulted glaucoma 
specialist as per protocol
NA 40 (100%) NA 807 (99.3%)
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Table 2.4. Frequency and results of examinations and ancillary tests performed per group and per kind of 
health care provider (continued)
usual Care group GFu group P-value 
(between 
groups)
Glaucoma 
specialist
/resident
n*=833
GFU 
employees
n*=40
Glaucoma 
specialist / 
resident
n*=325
GFU 
employees
n*=813
Gdx eCC
Number of visits that required a GDx 
ECC
569 (68.3%) 40 (100%) 325 (100%) 813 (100%) <0.01 ‡
Of which GDx ECC was performed 
and documented 
376 (66.1%) 40 (100%) 100 (30.8%) 792 (97.4%) <0.01 ‡
Of which the result was: “suspicion 
of progression”
24 (6.4%) 2 (5.0%) 3 (0.3%) 37 (4.7%) 0.431 ‡
Of which follow-up with glaucoma 
specialist
20 (86.7%)4 2 (100%) 2 (100%)4 32 (86.5%)
Of which advice of glaucoma 
specialist
0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (13.5%)
GFU referred to/consulted glaucoma 
specialist as per protocol
NA 40 (100%) NA 813 (100%)
HFA 24-2
Number of yearly regular visits of 
patients with visual field loss (MD< 
–5 dB)
83 (61.0%) 6 (85.7%) 22 (41.5%) 71 (74.7%) 0.916 ‡
HFA 24-2 performed and 
documented
15 (18.1%) 0 (0.0%) 2 (9.1%) 18 (25.4%) 0.708 ‡
Of which the result was: “suspicion 
of progression”
4 (4.8%) 0 (0.0%) 0 (0.0%) 5 (7.0%) 0.784 ‡
Of which follow-up with glaucoma 
specialist
4 (100%) 0 (0.0%) 0 (0.0%) 5 (100%)
GFU referred to/consulted glaucoma 
specialist as per protocol
NA 40 (100%) NA 813 (100%)
1 Missing values: n=3
2 Missing values: n=4
3 Missing values: n=2
4 Missing values: n=1
5 Missing values: n=5
* indicates the number of visits;† independent-sample t-test; ‡ Chi-square test
dB: decibel; GFU: glaucoma follow-up unit; HFA: Humphrey Field Analyzer ; IOP: intraocular pressure; M: 
months; MD: mean deviation; NA: not applicable; TP: target intraocular pressure; VA: visual acuity
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the glaucoma specialist. The GFU performed the GDx imaging in 97.5% of all visits. The 
HFA exam should be performed yearly in patients with moderate or severe vision loss in 
both treatment groups. In only 23.4% of all visits to the GFU that required an HFA exam 
per protocol, this test was performed. For the glaucoma specialist, this percentage was 
16.2%. 
For patients who fulfilled the criteria for back-referral, the GFU should in principle refer 
the patient back to the glaucoma specialist or else seek his advice. The GFU did this in all 
patients in whom there was suspected progressive glaucomatous damage on the GDx 
or HFA. In 84.6% of the visits that the IOP exceeded the TP, and in 68.2% of the visits that 
the visual acuity declined 2 or more lines, did the GFU comply with the working protocol. 
If the GFU employees did not follow the criteria for referral, the patients differed only 
slightly from these criteria (such as when the IOP exceeded the TP by no more than 2 
mmHg). 
Timeliness: clinical productivity of glaucoma specialists
The time invested by glaucoma specialists per patient per year was significantly lower 
in the GFU group than in the Usual Care group: 5.87 minutes vs. 13.71 minutes (Table 
2.5). For every patient that could be transferred to the GFU, on average 0.57 extra stable 
glaucoma patients (1 - (5.87/13.71)) could be treated in the REH. In our study period, 815 
patients were treated for glaucoma or their increased risk of developing glaucoma. If 
these patients were transferred to the GFU, an additional 464 extra stable glaucoma 
Table 2.5. Clinical productivity of glaucoma specialists
Usual Care group GFU group P-value
Number of visits per patient year* 1.39 (0.5) 1.37 (0.6) 0.561 †
- Follow-up consultations in GFU per year 0.05 (0.2) 0.97 (0.3)
-  Follow-up consultations with glaucoma 
specialist per year
1.28 (0.5) 0.35 (0.4)
-  Additional visits for tonometry after treatment 
change per year
0.06 (0.2) 0.04 (0.2)
- Visit to A&E department per year 0.01 (0.1) 0.01 (0.1)
Total amount of glaucoma specialist’s time spent 
on consultation and supervision per patient year 
in minutes
13.71 (5.9) 5.87 (4.3) <0.01 †
Clinical productivity (additional number of (stable) 
glaucoma patients that a glaucoma specialist could 
treat in the amount of time needed to treat one 
patient with usual care)
0.00 (0.5) 0.57 (0.3) <0.01 †
* Mean and standard deviation
† Independent samples t-test 
A&E: Accident and Emergency; GFU: glaucoma follow-up unit
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patients could, in principle, be accepted for treatment in the REH. Since the manage-
ment of new glaucoma patients will probably require more time than stable glaucoma 
patients, the number of extra glaucoma patients that could be accepted for treatment 
in the REH will be somewhat lower. 
effectiveness
Stability of (risk of developing) glaucoma
At the end of each visit, both the GFU employees and the glaucoma specialists deter-
mined whether the interval to the next visit could stay the same as before or should 
be shortened. Their decision was based on their overall judgment. Shortening of this 
interval was viewed as a sign that the patient required closer attention, either because 
of suspiciously unstable glaucoma, or because of an increased risk for that. The latter 
could for instance be the case when the IOP exceeded the target pressure or when a 
patient turned out to be intolerant to therapy, increasing the risk of noncompliance and 
subsequent progression of disease. The percentage of visits with a shortening in the 
interval to the next visit did not differ between the two groups. In the Usual Care group, 
this percentage was 15.1% and in the GFU group 16.0% (p=0.619). For the GFU group, this 
percentage was also 16.0% during the third visit to the glaucoma specialist, indicating 
that the GFU did not miss significantly more cases of suspected progression.
Difference in IOP
We analysed the IOPs of the 676 patients (83%) of which we had collected the IOP at 
baseline and at least 18 months later (344 patients of the GFU group and 332 of the Usual 
Care group). In case of any follow-up visits later than 18 months from baseline, the IOP 
measurement of the last visit was used. The average difference in IOP (IOP≥ 18 months since 
baseline - IOPbaseline) was -0.33 mmHg in the Usual Care group and -0.37 mmHg in the GFU 
group and did not differ statistically between treatment groups (p=0.854). In 40.3% vs. 
39.3% of patients for whom the IOP≥ 18 months since baseline was available, the last measurement 
of the IOP was higher than the IOP at baseline in the Usual Care group and GFU group 
respectively (p=0.619).
Results of the examinations and ancillary tests
Table 2.4 presents the frequency of the examinations and ancillary tests, as well as their 
results for the two treatment groups. Per treatment group, the results have been pre-
sented per type of health care provider (glaucoma specialists vs. GFU employees). The 
p-values reflect the statistical significance of the difference between the two treatment 
groups. The frequency of the tests and examinations has been described in the safety 
paragraph. Their results are presented here. 
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The results of the HFA and GDx were not different between the two treatment groups 
(see Table 2.4). The percentage of visits in which the IOP was higher than the TP was 
similar for the two treatment groups as well. However, the visual acuity declined with 
2 or more lines in 6.3% vs. 3.9% of the examinations in the Usual Care group and GFU 
group, respectively (p=0.032; see Table 2.5). 
Treatment changes
The glaucoma therapy was changed at least once during the study period in 14% 
of the patients in the GFU group and in 15% of the patients in the Usual Care group 
(p=0.603). The reasons for a change in therapy did not differ significantly between the 
two treatment groups as well. In half of the treatment changes, the IOP was the reason 
for changing the therapy. In approximately 20%, intolerance caused the change in medi-
cation, and in approximately 16% of cases, the therapy changed because of suspected 
progression in structure (by assessment of the optic nerve head or in the GDx images) 
or in function (HFA).
Patient centeredness: patient satisfaction
We received 1492 questionnaires from the patients (response rate 71%). Gender, diagno-
sis and time between visits did not differ between responders and non-responders, but 
the responders were significantly older than the non-responders (65.8 vs. 63.6 years of 
age, p<0.01).
Table 2.6 shows the results for most relevant items of the questionnaire. Since the 
patients in the GFU treatment group received care from GFU employees as well as 
Table 2.6. Patient satisfaction per treatment group and per health care provider
 
 
By treatment group By health care provider
GFU
N=806
Usual Care
N=686
P-value GFU
N=627
Glaucoma 
specialist
N=865
P-value
Overall mark (SD) 
Range: 1-10
8.50 (1.05) 8.42 (1.15) 0.147 8.56 (1.02) 8.40 (1.15) 0.006
N 785 676 615 846  
Knowledge (SD) 
Range: 1-4
3.84 (0.42) 3.83 (0.47) 0.749 3.82 (0.44) 3.84 (0.45) 0.319
N 698 625 539 784  
Information (SD) 
Range: 1-4
3.14 (0.76) 3.20 (0.70) 0.135 3.11 (0.75) 3.21 (0.72) 0.029
N 655 577 511 721  
Waiting area (SD) 
Range: 1-4
3.20 (0.62) 3.13 (0.67) 0.068 3.20 (0.59) 3.14 (0.67) 0.108
N 621 584   486 719  
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from the glaucoma specialists, the results have been presented per treatment group 
(GFU group vs. Usual Care group) as well as per health care provider (GFU employees 
vs. glaucoma specialists). When the health care providers were compared, the overall 
score for the GFU employees was slightly, but significantly, higher than the score of the 
glaucoma specialists. The GFU employees were given a significantly lower score than the 
glaucoma specialists for the dimension ‘information’ indicating how well the patients 
were informed about the test or treatment and its possible alternatives.
The dimension ‘courteousness’ could only be analysed partly because the patients 
frequently answered “not applicable” to 6 of the 8 appropriate questions. The 2 items 
that remained (question b: taking sufficient time to talk to the patient, and question c: 
giving sufficient information about what was exactly going to happen) showed higher 
scores for the GFU group than for the Usual Care group (question b: means; 3.87 vs. 3.78, 
P= 0.000 / question c: means; 3.84 vs. 3.73, P= 0.000).
2.4 dIsCussIon
In the Netherlands, like in other countries, we expect increasing numbers of glaucoma 
patients, resulting from an aging population. Therefore, the Dutch College of Ophthal-
mologists (NOG) has stated that ophthalmologists should share their care with sup-
porting personnel like optometrists and ophthalmic technicians.75 In the Netherlands, 
substituting glaucoma care within hospitals is currently taking place, and our current 
report is the first to extensively evaluate this type of substitution. 
In the 2-year follow-up of our study, we evaluated the transfer of monitoring stable 
glaucoma patients and those at risk of developing glaucoma to ophthalmic technicians 
and optometrists. Our study showed equivalence in clinical effectiveness regarding the 
(change in) IOP and ancillary tests when comparing the GFU group with the Usual Care 
group. Visual acuity declined in significantly more patients in the Usual Care group than 
in the GFU group. Since visual acuity was performed in fewer visits in the Usual Care 
group than in the GFU group, this difference in clinical outcome may have been caused 
by the selection of those patients who indicated to have difficulties with their sight. 
Moreover, the patients were pleased with the functioning of the GFU. In the same 
study, we have demonstrated that the monitoring of patients in the GFU was less ex-
pensive than the care by glaucoma specialists. This financial aspect has been published 
elsewhere.72 The GFU employees closely followed the working protocol. The only test 
that was not performed by the GFU and glaucoma specialists as frequently as prescribed 
by the working protocol was the visual field examination. A possible explanation for 
this might have been the logistics of ancillary testing. Since the HFA takes more time 
than the GDx, and it took place in another location, the GFU employees perhaps had 
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not scheduled sufficient time for the HFA and tried to catch up with their busy clinics by 
skipping this test altogether. Only in a small minority of patients requiring back-referral 
was the protocol disregarded, notably when criteria were only slightly exceeded.
Limitations of the study
One limitation of our study was that information about the provided care was extracted 
from the medical records. We adopted this approach, because we did not want to bother 
the glaucoma specialists with filling in case report forms during their already busy clin-
ics, as an added burden to their usual administrative tasks. This method may have in-
troduced errors. Therefore, the data entered in the database was checked by a research 
assistant. Nevertheless, we suspect that some provided care was left undocumented 
in the medical records. We did however get a good insight in whether the glaucoma 
specialists thought a patient showed any progression (by either the GDx, and/or HFA 24-
2, and/or judgment of the optic nerve head), because virtually every treatment change 
(which happened in case of instability, defined as deemed progression, a too high IOP 
and/or tolerance to therapy) was explained in the medical records. 
Another potential limitation of our study is that we incorporated the GDx in the GFU 
working protocol. We did this for several reasons. Firstly because it was already clinically 
used in the REH for glaucoma monitoring, and secondly because the GFU employees 
were already experienced in taking and assessing GDx images. In addition, the primary 
care optometrists, involved in the screening project that preceded the establishment of 
the GFU, had already access to and experience with this device. We thought this would 
be an advantage, if the monitoring of stable glaucoma patients were to be expanded 
to their optician shops in the future.71 A downside of using the GDx for monitoring our 
patients was that there was no progression software available; any progression detec-
tion therefore was subjective. We thought this would not pose a significant problem 
in the relatively short follow-up period of our study, because we expected very little, if 
any, progression in this selected group of patients that were thought to be stable from 
the outset. Since progression software for the GDx became available after we closed 
our trial, we think that a more objective approach of detecting any (rapid) progression 
has become available. On the other hand, the manufacturer of the GDx has recently 
discontinued its production, which will eventually lead to the total disappearance of the 
GDx in clinical use. Other imaging devices, such as those that feature optical coherence 
tomography (OCT), which also offer progression detection software algorithms, may 
turn out to be more appropriate for follow-up of glaucoma.
A main question about our current study is whether we really assessed the quality of 
care in the two treatment groups. In general terms, it is almost impossible to attribute 
the observed outcome to the process of care, because outcome is often affected by a 
multitude of factors in the structure and process of care.76 In our study, we did not use 
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glaucomatous progression as an outcome measure, for several reasons; (1) the GFU em-
ployees were, by law, not allowed to change the patients’ treatment. Therefore, the role 
of the GFU employees was limited to referring patients back to the glaucoma specialists 
whenever specific criteria of visual acuity or IOP were exceeded or whenever progressive 
glaucomatous damage was suspected; (2) moreover, glaucoma typically runs a very slow 
course. As mentioned earlier, we did not expect to be able to detect any glaucomatous 
progression in our 2-year study period, especially since only patients that were deemed 
stable were included in our study.77 
In our study, safety of care provided by the GFU employees was operationalized as the 
extent to which the working protocol was adhered to. The GFU should however, also be 
safe with regard to any other newly developed concomitant ocular disease. Although 
the GFU employees could potentially miss newly developed eye diseases, we thought 
the most common ones would be associated with a loss in visual acuity. That is why the 
assessment of the visual acuity was included in the working protocol of the GFU. In addi-
tion, any newly developed symptoms put forward in the history would prompt the GFU 
employees to ask the glaucoma specialists for advice. Having a GFU within the confines 
of a hospital offers the advantage of relatively easy communication with glaucoma spe-
cialists, which may be more difficult in external GFUs. In addition, we had every patient 
assigned to the GFU group pay every third visit to the glaucoma specialist, thereby again 
reducing the risk of any newly developed concomitant disease to pass undetected. The 
incidence of newly developed asymptomatic concomitant ocular disease turned out to 
be extremely low: only 1 case with a pseudo macular hole. It is therefore highly unlikely 
that significant newly developed concomitant disease would pass unnoticed in the GFU.
suggestions for further research
The study design for the GFU group – with every third visit to the glaucoma specialist – 
was chosen because of clinical reasons mentioned above. This study design might have 
introduced bias with regard to patient satisfaction. Patients might be satisfied with the 
GFU only because they knew that they would visit a glaucoma specialist after 2 visits to 
the GFU. Moreover, the GFU had more time available for each patient (20 minutes vs. 9 
minutes), which might have contributed to the higher satisfaction.76 Whether this bias 
really affects patient satisfaction could be subject of further research. 
Whether we could have the patients in the GFU group visit the glaucoma specialists 
less frequently, while maintaining the safety, remains to be determined. This will prob-
ably depend considerably on the way any glaucomatous progression may be detected 
reliably.
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Comparison with previous studies
Little is known about the safety of shared glaucoma care. We were only able to compare 
our findings with those of the Bristol shared care study.66 Patients in our study were 
less often referred back to a glaucoma specialist (19% vs. 55% back referrals). Possible 
reasons for this difference were the location of the GFU and the care structure. Contrary 
to Bristol, our GFU was situated in the hospital. The glaucoma specialists were only one 
floor away to answer any questions. In the GFU standard working protocol we also incor-
porated regular visits to the glaucoma specialist (every third visit), whereas no regular 
visits to glaucoma specialists were included Bristol.66 
We believe that setting up a GFU inside a hospital is probably easier to do than refer-
ring patients to primary care optometrists in their retail stores, because of the advantage 
of convenient access to glaucoma specialists. 
In medical specialties other than ophthalmology, there have been several studies into 
doctor-nurse substitution in the treatment of patients with chronic conditions. These 
studies into doctor-nurse substitution, as well as the Bristol study suggest that doctors 
and other health care providers generate similar health outcomes for patients.66,78 The 
findings of these studies concur with ours.
Conclusion
We conclude that it is safe to refer glaucoma patients that are thought to be stable to 
a GFU staffed by optometrists and ophthalmic technicians that follow a strict protocol 
within a hospital. Our study showed equivalence in quality of care when comparing 
monitoring by the GFU with usual care provided by glaucoma specialists. Similar shared 
care programs might therefore be adopted safely elsewhere. 
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APPendIx  
Appendix 2.1. Patient questionnaire. Dimension: Waiting Area 
The area where you were asked to wait had...
No Not really I suppose so Yes
a. a pleasant atmosphere ❏ ❏ ❏ ❏
b. enough seating ❏ ❏ ❏ ❏
c. comfortable chairs or benches ❏ ❏ ❏ ❏
d. sufficient materials to help you relax and pass the time (e.g. TV, 
magazines)
❏ ❏ ❏ ❏
e. sufficient facilities for you to get something to eat or drink ❏ ❏ ❏ ❏
dimension: Knowledge
The [ophthalmologist / GFU employee] who dealt with you during this visit... 
No Not really I suppose so Yes
a. was well informed about your condition ❏ ❏ ❏ ❏
b. was well informed about your treatment/tests ❏ ❏ ❏ ❏
dimension: Information
During this visit to the [ophthalmologist / GFU], did you know...
No Not really I suppose so Yes
a. why the particular test or treatment was necessary ❏ ❏ ❏ ❏
b. what the particular test or treatment involved ❏ ❏ ❏ ❏
c. how long the particular test or treatment would take ❏ ❏ ❏ ❏
d. whether the particular test or treatment would be painful ❏ ❏ ❏ ❏
e. what side effects or consequences the particular test or treatment 
might have
❏ ❏ ❏ ❏
f. whether other tests or treatment were possible ❏ ❏ ❏ ❏
dimension: Courteousness
The [ophthalmologist / GFU employee] who dealt with you during this visit… 
No Not really I suppose so Yes N/A
a. allowed you to help decide about new tests or treatments ❏ ❏ ❏ ❏ ❏
b. took sufficient time to talk to you ❏ ❏ ❏ ❏
c. gave sufficient information about what exactly was going to 
happen
❏ ❏ ❏ ❏
d. took care that you were not interrupted by other people while 
you were talking or being examined/tested
❏ ❏ ❏ ❏ ❏
e. kept to the agreements that had been made ❏ ❏ ❏ ❏ ❏
f. ensured that the care you received was geared to the care from 
other care providers
❏ ❏ ❏ ❏ ❏
g. gave support or help if you felt uncertain or tense ❏ ❏ ❏ ❏ ❏
h. explained your glaucoma medication clearly and understandably ❏ ❏ ❏ ❏ ❏
dimension: overall Mark
We would like to know how you feel about the care given to you by the [ophthalmologist / GFU employee].
What score, from 0 to 10, where 0 is the worst possible care and 10 the best possible care, would you give 
for the care you received from the [ophthalmologist / GFU employee] who dealt with you? ………….
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suMMAry
Background. Population aging increases the number of glaucoma patients, which leads 
to higher workloads of glaucoma specialists. If stable glaucoma patients were moni-
tored by optometrists and ophthalmic technicians in a glaucoma follow-up unit (GFU) 
rather than by glaucoma specialists, the specialists’ workload and waiting lists might be 
reduced. 
We compared costs and quality of care at the GFU with those of usual care by glau-
coma specialists in the Rotterdam Eye Hospital (REH) in a 30-month randomised clinical 
trial. Because quality of care turned out to be similar, we focus here on the costs.
Methods. Stable glaucoma patients were randomised between the GFU and the glau-
coma specialist group. Costs per patient year were calculated from four perspectives: 
patients, the Rotterdam Eye Hospital (REH), Dutch healthcare system, and society. The 
outcome measures were: compliance to the protocol; patient satisfaction; stability 
according to the practitioner; mean difference in IOP; results of the examinations; and 
number of treatment changes.
Results. Baseline characteristics (such as age, intraocular pressure and target pressure) 
were comparable between the GFU group (n=410) and the glaucoma specialist group 
(n=405). 
Despite a higher number of visits per year, mean hospital costs per patient year were 
lower in the GFU group (€139 vs. €161). Patients’ time and travel costs were similar. Health-
care costs were significantly lower for the GFU group (€230 vs. €251), as were societal 
costs (€310 vs. €339) (p<0.01). Bootstrap-, sensitivity- and scenario-analyses showed that 
the costs were robust when varying hospital policy and the duration of visits and tests.
Conclusion. We conclude that this GFU is cost-effective and deserves to be considered 
for implementation in other hospitals.
Cost-effectiveness of monitoring glaucoma patients in shared care 43
3.1 BACKGround
Glaucoma is a group of eye diseases characterized by damage to the optic nerve that 
causes gradual, irreversible visual field loss. It is often related to high intraocular pressure 
(IOP) and age. Usual care for glaucoma patients consists of diagnosis, lifelong monitor-
ing and treatment, and in most countries is currently provided by glaucoma specialists. 
Ophthalmic care in the Netherlands is currently being challenged by a high workload 
for glaucoma specialists and long waiting lists. Due to ageing of the population, the 
prevalence of glaucoma probably will increase strongly over time,55 possibly endanger-
ing access to glaucoma care as currently provided. Task substitution may be one way to 
ease this problem. 
Stable glaucoma patients and patients with a risk factor for developing glaucoma may 
not require care by a glaucoma specialist. Instead, monitoring by hospital optometrists 
or ophthalmic technicians may be sufficient. This would leave glaucoma specialists with 
more time for complex cases and new glaucoma patients, allocating their expertise more 
efficiently, and also reducing waiting lists. As optometrists and ophthalmic technicians 
are less expensive per hour than specialists, such task substitution might save costs. 
To date, only one study65,68,69,79,80 presented information about the efficiency of 
substitution in glaucoma care, and its consequences for both quality of care and cost-
effectiveness. However, that study compared care by glaucoma specialists with that by 
community optometrists rather than hospital optometrists. It concluded that glaucoma 
monitoring by community optometrists is effective, but not cost-effective in most situa-
tions. The outcomes were similar to those in specialist care, and the patients were satis-
fied. However, because of a (standard) shorter follow-up interval than in specialist care, 
community monitoring was more expensive.79 
We therefore conducted a randomised controlled trial (RCT) to determine the cost-
effectiveness of shared care in stable glaucoma patients in a hospital setting. We com-
pared usual care by glaucoma specialists and the care provided by optometrists and 
ophthalmic technicians within a glaucoma follow-up unit (GFU) in the Rotterdam Eye 
Hospital (REH) in terms of costs and quality of care. 
Because this paper focuses on the costs of the glaucoma care related to important 
aspects of the quality of care, we also measured patient satisfaction, the number of 
treatment changes, the change in IOP and the compliance to the standard working 
protocol. The quality of care is described in more detail elsewhere.81
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3.2 MATerIALs And MeTHods
randomised Controlled Trial
Patients who visited a glaucoma specialist or the GFU between September 2005 and 
April 2006 were invited to participate. The RCT was explained and written information 
was provided to them. The study was approved by the Review Board of Erasmus MC. 
To be eligible for the study, patients had to meet the following criteria: 
(1) the patient was diagnosed with stable glaucoma in one or both eyes (the next visit 
scheduled in 6 months or more) or had a risk factor for glaucoma, i.e. high IOP and/
or a positive family history. Eyes were considered to be glaucomatous if they had 
typical thinning or notching of the neuroretinal rim of the optic nerve head, with 
or without disc haemorrhages, visual field defects, peripapillary atrophy and/or and 
elevated IOP; 
(2) a glaucoma specialist of the REH referred the patient to the GFU; 
(3) the actual ophthalmic medication and the target pressure (TP) was recorded in the 
medical record. The target pressure was determined by the individual clinicians in all 
patients, where they took in consideration: the age of the patient, the appearance of 
the optic disc, the level of intraocular pressure, any co-morbidity and any other risk 
factors. For patients with a risk factor for glaucoma, the TP was by default 30 mmHg, 
unless other risk factors called for an explicitly lower TP; 
(4) an examination of the optic disc, macula, and the fundus periphery was performed; 
(5) the Snellen visual acuity in each eye was ≥ 20/100 and/or the patient had no visual 
field loss within the central 10˚, as measured by a Humphrey Field Analyser, standard 
24-2 test algorithm (HFA 24-2; Carl Zeiss Meditec, Dublin, CA, USA); 
(6) the refractive error was between +5 and –8 dioptres (spherical equivalent);
(7) no other significant ocular disease was present; 
(8) the patient had not undergone laser therapy for diabetic retinopathy.
Once the glaucoma specialist decided that the patient was suitable for the GFU, the 
patient was randomly allocated to a treatment group. In the glaucoma specialist group, 
the patients received care of glaucoma specialists and residents only. In the GFU group 
the patient visited the GFU twice followed by a visit to the glaucoma specialist or resi-
dent if the patient was stable. If necessary, the patient was seen by a glaucoma specialist 
earlier. The GFU employees (optometrist or ophthalmic technician level 1 or 2) provided 
care according to a standard working protocol (see Table 3.1) and under supervision of 
glaucoma specialists. 
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Identification and randomisation
Glaucoma specialists were asked to provide information about this study to eligible pa-
tients. Eligible patients were also identified by searching the patient files of the patients 
that were already referred by the glaucoma specialists to the GFU in the months preced-
ing the start of our study. They received information about the study during their next 
visit. All patients that were eligible and willing to participate were randomly allocated to 
a treatment group using a randomisation table. For the GFU patients that were allocated 
to the usual care group an appointment was made with the glaucoma specialist who 
referred them to the GFU.
To avoid glaucoma specialists influencing the allocation of patients, we used central 
randomisation by the researchers using stratification by 2 variables: the referring glau-
coma specialist, and the time to the next scheduled visit, being either 6 months or more 
than 6 months. 
Table 3.1. Provided care and criteria for back referral to the glaucoma specialist
Activity usual care GFu Criteria for back referral
Short history Every visit Every visit
IOP* Every visit Every visit IOP>TP
Medical prescriptions Every visit Every visit
Optic disc assessment Every visit Never
GDx ECC** At doctor’s request 
(approx. once yearly)
Every visit - Suspicion of progression
- In case of first GDxECC: 
NFI > 35 and/or left/right 
asymmetry and/or local 
defect.
HFA 24-2*** At doctor’s request 
(approx. once yearly)
Yearly in moderate to 
advanced visual field 
damage****
OR at doctor’s request
Suspicion of progression
Snellen visual acuity As required, at least once 
yearly
Every visit Decline in visual acuity of ≥ 
2 lines
Overall judgement Every visit Every visit
Timing next 
appointment
Every visit Every visit
* IOP by Goldmann applanation tonometry
** GDx ECC (Carl Zeiss Meditec, Dublin, CA, USA) scanning laser polarimetric images 
*** Humphrey Field Analyser, standard 24-2 test algorithm (HFA 24-2; Carl Zeiss Meditec, Dublin, CA, USA)
**** Criteria mild and moderate/severe visual field damage: the mean deviation (MD) of the last performed 
visual field was ≤ –5dB 
GFU: glaucoma follow-up unit; IOP: intraocular pressure; NFI: nerve fiber indicator; TP: target pressure.
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outcome measures
The outcome of the treatment was measured every visit. The outcome measures of 
the RCT were: 1) compliance of the GFU employees to the standard working protocol, 
2) patient satisfaction with the following items: a) overall mark for the received care; 
b) social interaction with the health care provider; c) expectations about the visit; d) 
perceived knowledge of the health care provider; e) waiting area, 3) stability according 
to the practitioner (whether the time till next visit should be significantly shorter than 
the time from the previous visit), 4) mean difference of the IOP (IOP at baseline vs. IOP at 
the last visit (if at least 24 months afterwards))1, 5) the results of the examinations and, 
6) the number of treatment changes. We did not use glaucomatous progression as an 
outcome measure, because we did not expect this patient population (with a risk factor 
for glaucoma or with stable glaucoma) to progress during the study. The change in IOP 
during the study has been used as outcome measure instead.
sample size and power analysis
We performed a post-hoc power analysis using our data to estimate the power (cer-
tainty) of our conclusion. We performed that analysis using two outcome parameters 
since quality of care has multiple dimensions: the stability of the patient according to 
the practitioner and the overall mark regarding patient satisfaction. The power of the 
study was >99% based on the stability outcome when using 5% as an acceptable differ-
ence, and >99% based on the overall mark when using a difference of 0.5 (on a 1-10 scale) 
as an acceptable difference between the treatment groups as well. 
Patients and visits
From September 2005 to March 2006, 866 patients were included of which 46 patients 
did not visit the hospital during the study period. Three others could not be monitored 
with the GDx and 2 patients withdrew their informed consent (see Figure 2.1). The 
remaining 815 patients had a total of 2100 visits. The average time between visits was 
8.8 months, SD ± 4.0. The mean age (63 years) and gender (53% women) was similar for 
the two treatment groups. There were no significant clinical imbalances between the 
groups as well (Table 3.2).
1  In a later stage of the analyses, it was decided to change this the definition of this measure into the 
difference in IOP from baseline until the last visit if at least 18 months later.
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study duration
The study duration depended on the allocated treatment group. Patients who were 
allocated to the usual care group on the day of their visit to the GFU, entered the study 
at their next visit (to the glaucoma specialist), whereas patients who were allocated to 
the GFU group, entered the study immediately. Therefore, the mean study duration was 
longer for the GFU group (1.81 year) than for the usual care group (1.43 year). This dif-
ference was statistically significant (p<0.001). Hence, for a better comparison, we will 
present the costs per patient year in most tables. The influence of this difference in study 
duration on the outcomes is probably minimal, because no major changes were made 
to the protocol.
economic evaluation
We conducted an RCT to measure the quality of care delivered by glaucoma specialists 
and by employees of the GFU. Alongside this RCT, we calculated the costs of glaucoma 
care from four perspectives. The perspectives used were those of the patient, the REH, 
the health care system and the society.
A difference in health outcomes between the GFU and the usual care group was not 
expected during this study, because of the slowly progressive nature of this disease. A 
literature review, searching for articles with glaucoma and co-management or shared 
care in the title or abstract, provided evidence of an equal quality of care by optometrists 
compared to ophthalmologists as well.69,80,82-92 Only one of the articles reported a varia-
tion in individual performances of optometrists, which makes education and accredita-
tion an essential prerequisite for co-management.84 All other articles reported good 
quality of care by optometrists, high levels of agreement between optometrists and a 
research clinic reference or ophthalmologists or comparable inter- and intra-observer 
variability in optic disc assessments. Therefore we will not present a cost-effectiveness 
ratio, but we will discuss the costs in relation to the quality of care. 
Table 3.2. Characteristics of included patients, by treatment group
Glaucoma Follow-up Unit 
(n=405)
Usual Care 
(n=410)
Gender, % of women 53.8 52.2
Mean age (SD, standard deviation) 63.0 (12.1) 63.1 (11.9)
Mean time till next visit in months (SD) 9.8 (2.9) 9.5 (2.9)
Right eye Left eye Right eye Left eye
Mean intraocular pressure (SD) 18.7 (4.1) 18.5 (4.1) 18.8 (4.2) 18.8 (4.1)
Mean target intraocular pressure (SD) 25.1 (5.2) 25.2 (5.2) 25.2 (5.4) 25.1 (5.4)
SD: Standard Deviation
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Identification cost items and measurement of the utilisation per cost item
We interviewed health care professionals and patients to identify relevant cost items in 
the field of medical consumption, implementation of GFU, and patient time and travel 
costs. 
During the RCT, the medical procedures performed and the medication prescribed 
each visit were recorded in a case report form. The different types of hospital visits were 
a visit to: a glaucoma specialist, a resident, and three types of GFU visits, as there were 
three different types of personnel within the GFU (optometrist, ophthalmic technician 
level 1, and ophthalmic technician level 2). Per health care provider, the duration of 
10 study related visits was measured. The duration of an HFA and GDx test were also 
measured in 10 patients. 
Every visit, glaucoma patients were given a questionnaire to report their travelling 
distance, mode of transport, travelling time, waiting time and working status, in order to 
calculate the time and travelling costs. We also examined the fraction of visits in which 
the GFU employees asked a glaucoma specialist for advice over time. In addition, we 
performed a logistic regression to determine which variables influenced the probability 
of asking advice.
The substitution of care to the GFU required organisational changes and hence 
implementation costs (both initial and structural) within the hospital. To collect this 
information, health care providers were interviewed. 
Valuation of the cost items
All costs were calculated (in Euros, price level 2007) according to the CVZ (The Health 
Care Insurance Board) costing guidelines and previous research in the REH.93 Relevant 
items from the CVZ costing guidelines94,95 were updated and used for the calculation of 
patient time costs per hour and travelling costs per kilometre. 
Our cost calculation of hospital costs is based on data from the internal budget al-
location provided by the REH financial administration. This information included loca-
tion costs, costs of medical specialists and other personnel, administrative costs, costs 
of equipment, overhead costs and interest. Only for the costs of non-laser operations 
was the DBC rate (Diagnosis Treatment combination - a fixed reimbursement rate for a 
specific diagnosis related therapy) in 2007 used as estimate of the resource costs.
The direct personnel costs were calculated based on the mean duration for each type 
of visit. However, the indirect personnel and overhead costs were calculated top-down, 
based on the mean duration of a visit in the hospital as a whole. 
The implementation costs, like internal preparatory meetings, visits to another Dutch 
hospital, writing the standard working protocol and the training of the employees of 
the GFU were dominated by personnel input. These costs were added to the costs of 
a GFU visit as implementation costs for the GFU. The initial implementation costs that 
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were only made before starting the GFU were spread over 5 years. The structural costs 
per year were added to the initial implementation costs per year. The implementation 
costs per visit were based on the total number of GFU visits in 2007 (1598 visits) as we 
expect this number of patients to be a representation of the number of patients in the 
near future.
We calculated the patient costs using the information of the patient questionnaires 
combined with the updated time and travelling costs per unit of time and per kilometre. 
The results will be expressed as average costs per patient per study year and average 
costs per patient.
sensitivity / scenario analysis
To determine the influence of uncertainty regarding the duration of visits or tests on 
the costs per patient year, we performed the following uni-variate sensitivity analyses: 
1. We varied the duration of the visits within the range we had measured in our study. 
This resulted in 4 scenarios:
a. We used the minimum duration for all visits;
b.  We used the maximum duration for all visits;
c.  We used the minimum duration of visits to the GFU and the maximum duration for 
the visits to the glaucoma specialist and resident;
d.  We used the maximum duration of visits to the GFU and the minimum duration for 
the visits to the glaucoma specialist and resident.
2. We used the norm duration of the GDx and HFA as used by the financial department, 
instead of the duration of the GDx and HFA measured in our study. 
Furthermore we performed scenario analyses to determine the effects of plausible policy 
changes in the (near) future on the costs. We considered the following scenarios:
3. No optometrists are working in the GFU. This actually happened during the course of 
the study. The direct personnel costs of visits to optometrists were replaced by those 
of the ophthalmic technicians.
4. In the study, the patients in the GFU group visited the glaucoma specialist (or resi-
dent) every third visit, or earlier if necessary. In this scenario, we calculated the visit 
costs if this routine was changed to every fifth visit (or earlier when necessary). In 
case of a non-stable patient, we distinguished two scenarios:
 a.  The patient returned to the GFU as soon as he was judged as stable by the 
glaucoma specialist during a visit.
 b.  The patient only returned to the GFU after he was judged as stable by the 
glaucoma specialist on two consecutive visits.
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uncertainty analysis
We performed a bootstrapping analysis on the costs per patient year and two quality of 
care parameters, to show the degree of uncertainty regarding the results. Since quality 
of care has different dimensions, we decided to use two outcome parameters. One clini-
cal quality parameter: stability according to the practitioner (stability), and one patient 
satisfaction parameter: the overall mark given by the patient. By plotting all bootstrap 
replicates in a so-called cost-effectiveness plane (CE-plane), the uncertainty around 
the point estimates of the costs and effects was displayed. In this analysis individual 
observations of patients were randomly drawn from the distribution of patients in both 
groups in order to calculate the average costs and quality of care per treatment group. 
This was replicated for 2500 times. A CE-plane is an x-y-diagram with the x-axis repre-
senting the difference in quality of care between the GFU and usual care group and the 
y-axis representing the difference in costs. 
statistical analysis
We used Excel for the bootstrapping analysis. SPSS 15.0 was used for all other analyses. 
In normally distributed variables, we performed a t-test for independent samples. If not 
distributed normally, we performed the parametric Mann-Whitney U-test to compare 
the two treatment groups. We used bootstrapping for deriving the 95% confidence in-
tervals around the utilisation and costs because of the non-normal distribution of those 
parameters.
For some visits (29%), information about one or more items related to patient costs 
was missing. The travelling distance could be calculated for every patient, based on the 
Zip code as known in the hospital information system. If appropriate, the remaining 
missing values were replaced by values known from other visits of the same patient. In 
all other cases (9%), the mean value of a comparable group of patients based on gender 
and age was imputed to the missing values.
3.3 resuLTs
Quality of care
The aspects of quality of care measured in our study were: compliance to the protocol, 
patient satisfaction, stability according to the practitioner, mean difference of the IOP, 
results of the examinations and the number of treatment changes. All these aspects of 
the quality of care turned out to be similar for the 2 groups81 and the substitution of care 
to the GFU was successfully implemented. 
1. The GFU employees performed the required tests in at least 98.8% of the visits and 
referred back to the glaucoma specialist in 84.4% of the remarkable cases.
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2. The patient satisfaction was similar in both groups. The overall mark of the patient 
was 8.5 for the GFU group and 8.4 for the usual care group (p=0.147).
3. The percentage of visit that were considered “stable” was 16% in the usual care group 
and 17% in the GFU group (p=0.423)
4. No statistical difference was found between the two groups in the difference of the 
IOP during the study (IOP(≥ 24 months since baseline) – IOP (at baseline)). The average difference in 
IOP OD was -0.2 mmHG in the usual care group and -0.6 mmHG in the GFU treatment 
group (p=0.207). The average difference in IOP OS was – 0.1 mmHg in both groups 
(p=0.915). 
5. The number of treatment changes was 57 (14%) in the GFU group and 63 (15%) in the 
usual care group (p=0.603).
6. Patients as well as GFU employees and glaucoma specialists were pleased with the 
functioning of the GFU. 
Therefore, the quality of care provided in the GFU was concluded to be equal to the care 
provided by the glaucoma specialists for these stable glaucoma patients.
Hospital perspective
The hospital costs covered hospital visits, diagnostic procedures and further treatment, 
but were mainly driven by the costs of the hospital visits to the glaucoma specialist, 
resident or GFU employee (approximately 80%). Table 3.3 shows the duration and com-
position of the unit costs per type of visit. The total annual implementation costs for 
starting up the GFU were €4917 for 1598 GFU visits. The implementation costs of the GFU 
were added to the GFU visits only. 
Table 3.3 shows that despite their longer duration, GFU visits were less expensive 
than those to the glaucoma specialist. In the usual care group, most visits were paid 
to the glaucoma specialist or resident. Patients in the GFU group visited the glaucoma 
specialist every third visit or earlier when a patient was judged not stable. Therefore, the 
costs per visit could vary within one patient and between patients within one treatment 
group. The mean costs per hospital visit including GDx were €83.77 (SD=30.64) in the 
usual care group and €68.34 (SD=15.66) in the GFU group. This difference was statistically 
significant (t-test, p=0.000).
Table 3.4 describes the hospital care use per patient year for the two treatment groups. 
Although the number of visits per patient year was slightly higher in the GFU group (1.65 
vs. 1.57), this difference was not statistically significant. In the GFU group, a significantly 
larger number of GDx images (1.28 vs. 0.77) and auto-refractions (0.20 vs. 0.08) was per-
formed and more time was spent on asking advice (in 24% vs. 10% of the visits). On the 
other hand, glaucoma surgery, laser therapy, medication use and the number of HFA 
tests did not statistically differ between the two groups. 
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Table 3.3. Composition of the unit costs per type of hospital visit in € (2007)
Visit 
glaucoma 
specialist
Visit 
resident
Visit GFu 
optometrist*
Visit GFu 
ToA level 
1 **
Visit GFu 
ToA level 
2***
Costs per visit
Total direct personnel costs 24.36 14.49 19.09 15.05 16.61
Total indirect personnel costs 5.46 5.46 6.59 6.59 6.59
Total overhead costs 29.76 29.76 35.90 35.90 35.90
Implementation costs GFU 0.00 0.00 3.08 3.08 3.08
Total costs excluding Gdx 59.58 49.71 64.66 60.62 62.18
Costs Gdx****
(fraction performed)
25.00 (0.41) 22.25 
(0.36)
3.05 3.05 3.05
Total costs including Gdx 84.58 71.96 67.71 63.67 65.23
Mean visit duration (minutes) 9.06 11.00 20.40 20.40 20.40
* Visit to an optometrist or senior employee 
** Visit to an ophthalmic technician level 1
*** Visit to an ophthalmic technician level 2
**** At the start of the Glaucoma Follow up unit (GFU), a Nerve Fiber Analyser (GDx) was purchased by the 
Rotterdam Eye Hospital. The costs of the GDx performed during GFU visits, consists only of the GDx imaging 
device. In the usual care group, the GDx was performed during an extra visit to the perimetry department. 
In that situation, the costs of a GDx image included personnel and overhead costs as well and were €61.61 
based on a duration of 13.30 minutes.
TOA: ophthalmic technician; GDx: Nerve Fiber analyser.
Table 3.4. Average hospital care use per patient year for the two treatment groups 
 GFu usual care 95%-CI of difference 
between 2 groups
P-value Costs per unit (in €)
Hospital visits 1.65 1.57 -0.13 to +0.31 0.158 see Table 3.3
GDx ECC 1.28 0.77 +0.32 to +0.73 0.000 61.61 
HFA 0.10 0.11 -0.11 to +0.07 0.266 158.44 
Refractive Unit 0.01 0.05 -0.09 to +0.00 0.002 32.43 
Auto-refraction 0.20 0.08 -0.03 to +0.21 0.000 4.64 - 6.59*
Pachymetry 0.02 0.04 -0.07 to +0.03 0.246 23.17
IOP diurnal curve 0.01 0.02 -0.04 to +0.01 0.109 92.66
Laser treatment 0.002 0.007 -0.02 to +0.01 0.267 78.38
Glaucoma surgery 0.002 0.001 -0.01 to +0.01 0.558 1251.70
Asking advice 0.24 0.10 +0.05 to +0.26 0.000 8.19 – 15.86**
Proportion patients using 
medication
0.57 0.59 -0.17 to +0.15 0.614 2.53 – 18.82***
* Depending on health care provider
** Costs per advice, depending on the health care providers involved
*** Costs per month
GFU: Glaucoma Follow-up Unit; CI: confidence interval; GDx ECC: Nerve Fiber Analyser Enhanced Corneal 
Compensation; HFA: Humphrey Field Analyser; IOP: Intra Ocular Pressure.
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Table 3.5. Average costs in Euros per patient year per perspective used for the two treatment groups (SD)
  GFu usual Care P-value
Hospital perspective
     
Hospital visits (including GDx ECC) 111.93 (50.93) 133.17 (50.44) 0.000
Other tests (HFA, refraction, pachymetry, etc.) 20.66 (47.03) 24.18 (48.72) 0.001
Laser treatment related to glaucoma 0.18 (2.54) 0.57 (5.18) 0.258
Glaucoma surgery 2.84 (40.35) 1.72 (34.90) 0.558
Asking advice 3.24 (5.35) 1.78 (5.13) 0.000
Total hospital costs per patient year 138.85 (89.30) 161.43 (86.88) 0.000
Patient perspective      
Patient costs per visit      
Travelling costs of patient and accompaniment 8.26 (11.83) 8.19 (12.10) 0.966
Time costs of patient and accompaniment 40.58 (28.87) 47.51 (34.36) 0.000
Total patient costs per patient per visit 48.83 (33.68) 55.70 (37.88) 0.000
Patient costs per patient year
     
Travelling costs of patient and accompaniment 13.04 (17.16) 12.70 (17.87) 0.488
Time costs of patient and accompaniment 66.62 (50.20) 75.17 (61.37) 0.088
Total patient costs per patient year 79.66 (58.51) 87.87 (68.17) 0.143
Health care perspective      
Hospital costs 138.85 (89.30) 161.43 (86.88) 0.000
Medication costs 91.54 (101.37) 89.82 (100.53) 0.867
Total health care costs per patient year 230.39 (154.57) 251.26 (146.02) 0.004
societal perspective      
Hospital costs 138.85 (89.30) 161.43 (86.88) 0.000
Patient costs 79.66 (58.51) 87.87 (68.15) 0.143
Medication costs 91.54 (101.37) 89.82 (100.53) 0.867
Total societal costs per patient year 310.05 (181.86) 339.13 (180.39) 0.009
SD: Standard Deviation; GFU: Glaucoma Follow-up Unit; GDx ECC: Nerve Fiber Analyser Enhanced Corneal 
Compensation; HFA: Humphrey Field Analyser.
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The hospital care use has been translated into costs per patient year for the two treat-
ment groups in Table 3.5. The total hospital costs were significantly higher for the usual 
care group than for the GFU group, mainly because of the higher hospital visit costs. 
The costs of asking advice were modest, but significantly higher for the GFU group than 
for the usual care group, as was to be expected. The 95% confidence interval for the 
difference in total hospital costs as derived from the bootstrap analysis was €-59 to €-2. 
The probability that the GFU reduces hospital costs is 98%.
The proportion of visits by GFU employees needing advice increased initially from 
15% to 20% in 2006 and then decreased (statistically significant) to 13% in 2007 and 7% 
in 2008. The proportion of visits requiring advice was not affected by the total number 
of visits per patient. 
These findings were confirmed by a logistic regression. The year of the visit was the 
only variable that significantly influenced the probability of asking advice. The other 
variables in the regression analysis were: stable/not stable, visit number, gender, time 
till next visit and age. This indicates that the GFU employees got more experienced over 
time and therefore needed less advice. 
Patient perspective
The patient costs consisted of time and travelling costs of patients and their accompani-
ment. Table 3.5 shows that the patient costs per visit were significantly higher in the 
usual care group, because of higher time costs (€80 vs. €88). This was mainly caused by 
a longer waiting time in the hospital in the usual care group. Patients in the GFU group 
spent, on average, 44.6 minutes in the hospital against 59.4 minutes for the patients in 
usual care group (p=0.000). However, because of a higher number of visits per patient 
year in the GFU arm, the patient costs per patient year were not statistically significantly 
higher anymore. The 95% confidence interval based on the bootstrapping analysis con-
firmed this (€-29 to €12). However, there is still a 78% probability to reduce patient costs. 
Health care perspective
The health care costs consisted of the hospital costs as described above, and medication 
costs. Table 3.5 shows the health care costs per patient year. Because of the comparable 
medication costs and lower hospital costs in the GFU group, the total health care costs 
per patient year were nearly 10% lower for the GFU group (€230.39 vs. €251.26, p=0.04). 
The median cost differ statistically according to the Mann-Whitney U-test, but the con-
fidence interval as provided through bootstrapping does not show a difference in the 
mean costs (€-76 to €21). However, the probability of cost reduction is considerable: 87%.
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societal perspective 
In the societal perspective all costs were taken into account. It consisted of hospital 
costs, medication and patient costs, for 46%, 28% and 26% respectively. The total so-
cietal costs per patient year were almost 10% higher in the usual care group (Table 3.5: 
€339.13 vs. €310.05, p= 0.009). The mean difference in the total societal costs per patient 
year was €-36 (the GFU group was less expensive). The 95% confidence interval based 
on bootstrapping for this difference ranged from €-92 to €23. Thus, though the median 
costs per patient year differs between the two groups, the mean total costs are not 
statistically different. This is because the non-normal distribution of the societal costs. 
However, the probability that the GFU saves societal costs is 84% to 89% (see paragraph 
about the uncertainty analysis below).
sensitivity / scenario analysis
Analysis 1: duration of visit
The mean duration of the visits to the glaucoma specialist was 9 minutes (ranging from 
7 to 11 minutes), to the resident 11 minutes (ranging from 9 to 13 minutes) and to the GFU 
20 minutes (ranging from 16 to 24 minutes).
In the base case – the situation as in our study –, the GFU group was less expensive 
than the usual care group. This conclusion only changed when the duration of a visit 
in the usual care group would be relatively short (7 minutes) and the duration of a visit 
in the GFU group would be relatively long (24 minutes, scenario 1d). In that unlikely 
situation the hospital costs per patient year were 10% higher for the GFU group (see 
Table 3.6). 
Table 3.6. Total average hospital costs per patient year in Euros for all situations in the sensitivity/scenario 
analysis
Hospital costs
GFU Usual care
Base case 138.85 161.43
Scenario 1a 117.79 141.80
Scenario 1b 156.79 179.98
Scenario 1c 117.79 179.98
Scenario 1d 156.79 141.80
Scenario 2 153.78 173.18
Scenario 3 135.16 159.47
GFU: glaucoma follow-up unit
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Analysis 2: duration HFA/GDX
The norm durations of GDx and HFA as used by the financial department, were 15 and 45 
minutes respectively instead of 13.30 and 34.20 minutes. This longer duration of the HFA 
and GDx tests increased the hospital costs per patient year in the GFU group and usual 
care group with €15 and €12 respectively (Table 3.6). 
Analysis 3: no optometrist in GFU
When the direct personnel costs of the optometrist were replaced by those of the oph-
thalmic technicians, the costs in both groups decreased, because incidentally a visit was 
paid to an optometrist in the usual care group as well (Table 3.6). Although the decrease 
in costs per patient year is small, it is almost twice as high in the GFU group (€3.69) as in 
the usual care group (€1.96). Thus, the costs remain lower for the GFU group.
Analysis 4: fewer specialist visits in GFU
a. In this scenario, the total savings were €2193 for five visits of 427 patients. Based on 
a mean number of 1.65 visits per year as measured in this study, the hospital costs 
could be reduced with €1.69 per patient year.
b. In the second scenario, the total savings in visit costs were €1882 for five visits of 427 
patients, thereby reducing the hospital costs in the GFU group with €1.45 per patient 
year (=1%).
uncertainty analysis
From a societal perspective, the incremental cost-effectiveness ratio of the GFU com-
pared with usual care was €-27 per patient per decimal point increase of the patients’ 
overall mark (on a 1-10 scale) per year. The CE-plane with overall mark as outcome 
showed that the majority of bootstrap replications (70%) fell within the lower-right 
quadrant, indicating that the GFU was dominant with lower costs and a higher overall 
mark (Figure 3.1a). 
The incremental cost-effectiveness ratio for the GFU compared with usual care was 
+ €19 per patient per year for one extra percent of visits that were considered to be 
stable by the practitioner. For the CE-plane with “stability” as outcome, the majority of 
bootstrap replications fell within the lower-left quadrant which reflects lower costs and 
fewer stable visits (Figure 3.1b). The probability that the GFU is cost saving is 89% using 
the overall mark and 84% using the “stability” outcome. Against this high probability of 
saving costs, the probability of inferiority of the GFU (being more expensive and less 
effective) is quite small: 2% using the overall mark and 14% using the “stability” outcome. 
Using an acceptable difference of 0.5 point of the overall mark (range 1-10), and of 5% 
difference in the fraction of stable patients, the two groups have an equal quality of care 
in 99.5% and 80.5% of the bootstrap replications respectively. When including replica-
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tions that result in a better quality of life for the GFU, the quality of care is acceptable 
(equal or better) in 100% and in 83.6% of the bootstrap replications. 
3.4 dIsCussIon
Substitution of tasks that require less specialized skills is a possible solution for easing 
the increased workload of ophthalmologists and long waiting lists in ophthalmic care. 
It was hypothesized that task substitution reduces the costs as well. The monitoring of 
most stable glaucoma patients probably does not require specialized skills. In this study, 
we therefore compared the care as usual provided by glaucoma specialists with the care 
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Figure 3.1 Cost-effectiveness plane.
A) yearly incremental costs per patient vs. change in the patients’ overall mark
B) yearly incremental costs per patient vs. change in the percentage of stable visits
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provided by a GFU within the REH staffed by ophthalmic technicians and optometrists 
for stable glaucoma patients. 
We found about 10% lower health care costs per patient year for the GFU group 
compared to the usual care group for three of the four perspectives used: the REH, the 
health care system and the society. Patient costs did not differ between the two treat-
ment groups. 
Scenario and sensitivity analyses confirmed that our results were robust. Only if the 
mean duration of a visit increased in the GFU (with 18% to the maximum duration mea-
sured in this study) and decreased for the glaucoma specialist (with 23% to the minimum 
duration measured in our study, scenario 1d), would the total societal costs not be 
significantly different any longer. However, this situation is not realistic. The bootstrap 
analysis showed that the equivalence of the two groups on quality of care is justified and 
that the GFU is cost saving in 89% of the bootstrap replications when using the overall 
mark as outcome parameter and in 84% of the replications when using the stability of 
the patient according to the practitioner.
We hypothesized that the establishment of the GFU would reduce the waiting list. This 
was confirmed by the increased number of patients (+23%) and patient visits (+16%) per 
year within the study period. The increased number of visits was largely caused by the 
establishment of the GFU, whereas the rise in the number of glaucoma patients was also 
influenced a little by a reduced follow-up interval for some glaucoma patients. However, 
the long term effect on the waiting list seems to be limited. Possible causes are: the 
chronic character of the disease which limits the patient outflow and the substantial 
increase in new glaucoma patients that outweighs the growth in capacity. Further 
research would be necessary to explore the true cause(s). 
The hospital perspective was one of the perspectives used for the cost calculation. 
Although the probability that GFU is cost-effective from this perspective is 94-98%, we 
have to distinguish at least two stakeholders within the hospital; the hospital manage-
ment and the glaucoma specialists. The interests of those two stakeholders are partially 
conflicting due to the current structure of financing care in the Netherlands. The physi-
cian part of the reimbursement is now paid to the specialist although the monitoring is 
partially transferred to the GFU. The distribution of this fee will therefore become subject 
of discussion between glaucoma specialists and the hospital management, especially 
when health care insurers insist on a lower fee in future negotiations, because of the 
lower costs of monitoring glaucoma patients by the GFU.
Our results could not be easily compared with results of other research. Even though 
substituting tasks within the hospital setting is taking place, a full cost calculation of 
this kind of substitution in the ophthalmic care has not been performed yet. In Bristol 
(UK), an economic evaluation alongside an RCT has been performed, comparing costs of 
monitoring stable glaucoma patients by ophthalmologists and community optometrists 
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(outside the hospital).65,79 Contrary to ours, the UK study concluded that the substitution 
of care to community optometrists was not likely to save costs. The main reason for this 
was the larger number of referrals to the ophthalmologist in their study compared to 
ours (19% vs. 6%). An explanation for this difference might be the location of care. Com-
munity optometrists do not have the possibility to consult a specialist for quick advice 
and will therefore refer patients to the hospital relatively more often.
Furthermore, the frequency of visits to the community optometrist in Bristol was 66% 
higher than the visit frequency to the ophthalmologist, compared with a 5% higher 
frequency in our study. This difference is related to a difference in the protocol used. 
In our study, the time to the next visit was copied from the last visit to the glaucoma 
specialist instead of being pre-determined at 6 months. 
A study about the trends in outpatient care provided by physicians and non-physician 
clinicians showed that substitution of care is not always a good strategy for containing 
health care costs.96 The increase in the proportion of patients visiting a non-physician 
clinician is driven by the increase in patients visiting both a non-physician and a physi-
cian clinician. In our study however, the number of extra visits caused by referrals was 
relatively low as stated earlier. 
A possible drawback of our study is the lack of information about disease progres-
sion. The progression rate of glaucoma depends on the intraocular pressure and the 
time to vision loss varies between 3 years for untreated patients with a high intraocular 
pressure to 38 years for well treated patients.77,97 We therefore did not expect to detect 
any significant glaucomatous progression in the 30 month study period in these stable 
patients and performed a cost minimization study. This type of economic evaluation 
assumes an equal outcome for all patients. The results of the RCT81 as well as many other 
studies69,80,82-92 supported this assumption about the equal quality of care to glaucoma 
patients provided by different types of health care providers.
3.5 ConCLusIons
Considering the equal quality of care in both treatment groups, we conclude that 
monitoring of glaucoma patients by the GFU is cost-effective for a subset of glaucoma 
patients, i.e., those that were deemed stable in the Rotterdam Eye Hospital. Implementa-
tion of a similar GFU in other hospitals could therefore be considered.
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suMMAry
Background. Healthcare systems are challenged by a demand that exceeds available re-
sources. One policy to meet this challenge is task substitution/transferring tasks to other 
professions and settings. Our study aimed to explore stakeholders’ perceived feasibility 
of transferring hospital-based monitoring of stable glaucoma patients to primary care 
optometrists.
Methods. A case study was undertaken in the Rotterdam Eye Hospital (REH) using semi-
structured interviews and document reviews. They were inductively analysed using 
three implementation related theoretical perspectives: sociological theories on profes-
sionalism, management theories, and applied political analysis.
Results. Currently it is not feasible to use primary care optometrists as substitutes for 
optometrists and ophthalmic technicians working in a hospital-based glaucoma follow-
up unit (GFU). Respondents’ narratives revealed that: the glaucoma specialists’ sense of 
urgency for task substitution outside the hospital diminished after establishing a GFU 
that satisfied their professionalisation needs; the return on investments were unclear; 
and reluctant key stakeholders with strong power positions blocked implementation. 
The window of opportunity that existed for task substitution in person and setting in 
1999 closed with the institutionalisation of the GFU.
Conclusions. Transferring the monitoring of stable glaucoma patients to primary care 
optometrists in Rotterdam did not seem feasible. The main reasons were the lack of 
agreement on professional boundaries and work domains, the institutionalisation of the 
GFU in the REH, and the absence of an appropriate reimbursement system. Policy mak-
ers considering substituting tasks to other professionals should carefully think about the 
implementation process, especially in a two-step implementation process (substitution 
in person and in setting) such as this case. Involving the substituting professionals early 
on to ensure all stakeholders see the change as a normal step in the professionalisation 
of the substituting professionals is essential, as is implementing the task substitution 
within the window of opportunity.
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4.1 BACKGround
Healthcare systems across many countries face a challenge in responding to growing 
demands for physicians’ and nurses’ care with increasing limitations on human and 
financial resources.60,61 Extrapolations have shown that the number of physicians cannot 
keep pace with the growth in demand caused by ageing populations, enhanced societal 
expectations, and new diagnostic technologies.56-59
One option to cope with workforce shortages is task substitution, which can be de-
fined as devolving clinical responsibilities to lesser or more narrowly-trained health pro-
fessionals with or without supervision.98 Task substitution can be realised with people 
(e.g., a diabetes nurse practitioner substitutes for an internist of the same department), 
settings (e.g., a primary care neurologist substitutes for a hospital-based neurologist), or 
both (e.g., primary care midwives substitute for hospital-based gynaecologists). Research 
has shown that task substitution may improve the quality of care66,67,78,82-86,88-92,99-101 and 
reduce costs because substitutes’ fees are lower.102 Strong evidence for cost savings 
is lacking however, perhaps because physician-substitutes perform additional tasks96 
or are less productive,103 offsetting potential cost savings. Furthermore, the successful 
implementation of task substitution is at least partially influenced by contextual factors, 
such as local stakeholder interests,104-107 power positions,108,109 and the structure of the 
healthcare system, including its financing.110 It therefore seems worthwhile to broaden 
the scope of evaluation and include the professional, organizational, financial, and 
political contexts within which task substitution is implemented.111
We explored a task-substitution project involving glaucoma care at the Rotterdam 
Eye Hospital (REH) in the Netherlands (see Appendix 4.1 for background information). 
Our research question was two-tiered: how do stakeholders perceive the feasibility 
of implementing task substitution of person (from ophthalmologists to allied health 
professionals) and setting (from a hospital to a primary care setting), and what are their 
supporting and opposing arguments?
Historical background
Our case study was not the first initiative of the REH to cooperate with primary care 
optometrists working in optical shops in the Rotterdam area (later united in a Collective 
of Optometrists in Rijnmond Region – OCR). The first initiative, started in 1997, led to the 
Transmural Glaucoma project (TG-project), a preliminary person and setting task sub-
stitution project in 1999. One part of the project consisted of primary care optometrists 
supplementing glaucoma specialists in monitoring glaucoma patients by means of 
GDx-technology (Carl Zeiss Meditec, Dublin, CA, USA), an imaging tool to assess (dam-
age to) the nerve fibre layer. REH glaucoma patients were referred to a local primary care 
optometrist for three additional tests between two visits to the hospital-based glaucoma 
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specialist. It appeared difficult to convince patients to visit a primary care optometrist; 
only twelve of the twenty patients (60%) actually did so.70,71 Nor were glaucoma special-
ists eager to participate because they could have referred more patients.
Given the results, the REH management suspended the project and initiated an inter-
mediate step of task substitution of person only. The REH set up a Glaucoma Follow-up 
Unit (GFU) in the hospital and evaluated its impact through an RCT.72 The GFU was staffed 
by a hospital optometrist and ophthalmic technicians who monitored the glaucoma 
patients according to a working protocol (see Table 2.1). Four years after the successful 
implementation of the GFU,72 REH managers began the step of substituting primary care 
optometrists in optical shops for the GFU, as in the original plan (substitution of person 
and setting).
4.2 MeTHods
An in-depth single case study evaluation was carried out from September 2007 to 
August 2008 using semi-structured face-to-face interviews and a document review to 
explore the feasibility of using primary care optometrists in optical shops as substitutes 
for in-hospital GFU employees.
sampling and recruitment
Semi-structured interviews
We selected 27 participants based on role, profession, and organisation, thereby draw-
ing on three sampling strategies. First, we included all four REH glaucoma specialists, 
five GFU employees, and the responsible hospital managers (CEO, CFO, manager of the 
Eye Care Network, and the advisor concerned with optometry relations). Second, we 
used convenience sampling to identify five primary care optometrists and two repre-
sentatives of the major health insurers in the Rotterdam region. We contacted the Dutch 
Healthcare Authority to identify potential participants. Third, we randomly selected five 
patients who had participated in the GFU study, taking care that the sample included 
patients with only a risk factor for glaucoma as well as stable glaucoma patients and 
employed as well as unemployed patients. One patient was selected because of his 
function as chairman of the Dutch Glaucoma Patient Association. The sample is shown 
in Table 4.1.
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Table 4.1. Interviewed stakeholders
staff rotterdam eye Hospital
Respondent Position Interviewers
1 CEO Rotterdam Eye Hospital ES & TP
2 CFO Rotterdam Eye Hospital KHG & TP
3 Manager of the Eye Care Network KHG & ES
4 Advisor concerned with optometry relations ES
5 Glaucoma specialists, Rotterdam Eye Hospital ES
6 Glaucoma specialists, Rotterdam Eye Hospital ES & TP
7 Glaucoma specialists, Rotterdam Eye Hospital KHG
8 Glaucoma specialists, Rotterdam Eye Hospital KHG
9 Ophthalmic technician, Rotterdam Eye Hospital KHG
10 Optometrist, Rotterdam Eye Hospital ES
11 Ophthalmic technician, Rotterdam Eye Hospital ES
12 Ophthalmic technician, Rotterdam Eye Hospital KHG
13 Ophthalmic technician, Rotterdam Eye Hospital KHG
Primary care optometrists
Respondent Self-employed / optical 
chain
Participant OCR Interviewers
14 Self-employed Yes KHG
15 Self-employed Yes KHG
16 Self-employed Yes ES
17 Optical chain No TP
18 Self-employed Yes TP
19 Optical chain Yes ES
Patients
Respondent Travelling distance to REH 
(in kilometres)
Working status Severity of the disease Interviewers
20 21 Employed Risk factor TP
21 19 Unemployed Glaucoma ES
22* 75 Employed Glaucoma TP
23 14 Employed Risk factor KHG
24 18 Unemployed Suspect KHG
Health insurers / The dutch Healthcare Authority
Respondent Position Interviewers
25 Health insurer (Health insurance only) ES & MK
26 Health insurer (All kinds of insurances) KHG & TP
27 Senior policy advisor of The Dutch Healthcare Authority KHG
* chairman of the Dutch Glaucoma Patient Association; OCR: Collective of Optometrists in the Rijnmond 
region; REH: Rotterdam Eye Hospital.
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Document review
Relevant policy and administrative documents were continually collected during the 
study period (2004 to 2009). Their sources were suggested by participants or found on 
the internet and websites of relevant stakeholders. EvS and KHG selected the documents 
when they considered any part of them relevant to the research question. Selected 
documents included public information, official policy reports, minutes of meetings, 
and working documents.
Procedure
Two researchers conducted the first six interviews together because it allowed them to 
give each other feedback on the interviewing process. The remaining interviews were 
done by one of four researchers (KHG, EvS, TP, MK). We developed a topic list (Appendix 
4.2) based on the research question to guide the interviews, which contained open 
questions that left room for participants to expand and clarify their answers. Moreover, 
they had the opportunity to express their opinions and to share what was important to 
them concerning the feasibility of transferring glaucoma care to primary care optom-
etrists. The interviews took approximately one hour each, were audio recorded, and later 
transcribed verbatim.
Analytic approach
The transcripts of interviews and documents were inductively analysed for the re-
spondents’ views regarding the feasibility of the task substitution. We thereby used an 
analytic approach, drawing on three theoretical perspectives.
First, we used sociological theories on professionalism to explore professionals’ views 
and interprofessional dynamics. Professions are sociologically defined as groups of in-
stitutions that permit the members of an occupation to make a living while controlling 
their own work.112 From such a sociological perspective, implementing task substitution 
is not a technical solution, but rather a social process affecting the professional status 
of those involved.112-116 Key to our analysis was how hospital-based glaucoma specialists, 
primary care optometrists, and GFU employees viewed the feasibility of the desired task 
substitution, and how it related to opportunities for or threats to controlling their work.
Second, we applied management theories to explore managerial rationales and views 
underpinning the desired substitution of tasks. Research shows that evidence-based 
interventions to improve quality of care are not automatically implemented and returns 
on investments or so-called ‘business cases for quality’ are often absent or too small to 
be effective.117 Moreover, an organizational infrastructure should be in place to support 
the innovation. Here, we explored how the respondents viewed the business case for 
the task substitution and whether they thought an appropriate infrastructure was in 
place.
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Third, applied political analysis was used to map the interests and power positions of 
each stakeholder involved.109 Their interests regarding the task substitution (supporting 
or opposing) together with their power positions and willingness to use them structure 
the political feasibility of successful implementation of task substitution.
Ensuring rigour
We used different strategies to monitor and enhance the rigour of data collection, analy-
sis, and validity. First, we validated key findings by data triangulation. Data collected 
from different sources (semi-structured interviews, document analysis, and literature) 
and researchers were compared to verify specific findings. Second, we sought feedback 
from senior and other researchers (peer review; HL, MK, NK), who critically appraised the 
research process and earlier drafts of the article. Third, reflexivity of the main research-
ers (KHG, TP, and EvS) was applied to rule out threats to validity due to reactivity and 
researcher bias.
4.3 resuLTs
Our threefold data analysis showed that it is currently not feasible to implement task 
substitution in this particular case. Respondents’ narratives revealed that the interme-
diate establishment of a suitable hospital setting (the GFU) in 2004 pre-empted the 
original sense of implementation urgency. Nor did the professionals (ophthalmologists 
and GFU employees) consider the shift to shop setting a positive step towards further 
professionalisation. An unclear return on investment did not help matters. Last, the 
power positions of reluctant key stakeholders were strong enough to block the imple-
mentation of task substitution from the hospital to the primary care setting. Table 4.2 
contrasts the initial assumptions of the stakeholders with the perceived feasibility as 
expressed by the participants.
Closed window of opportunity
The analysis from the professionalisation perspective revealed that the window of op-
portunity for task substitution closed with an intermediate step, i.e., establishing the 
GFU. In the late 1990s, waiting lists (demand pressures), new GDx technology, and com-
petition from ophthalmologists working in private clinics all favoured the task substitu-
tion of both person (from ophthalmologists to optometrists) and setting (from hospital 
to primary care). Professional dynamics, however, impeded the twofold implementation 
strategy.
The first step (substitution within the hospital setting – the GFU) eased the pressures on 
the glaucoma specialists, and the GFU employees enjoyed their work. As a consequence, 
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Table 4.2. Stakeholder positions concerning the task substitution of person and setting before and after 
GFU establishment
Theory 1: closed 
window
Theory 2: unclear 
returns on investments
Theory 3: power 
position - level 
interest
Before GFu 
establishment
Glaucoma 
Specialists
High workload, 
increasing demand for 
glaucoma care.
Workload release, 
decreasing the waiting 
list, more challenging 
work.
High power position 
and high interest 
for a successful task 
substitution.
Management REH Increased competition 
on volume.
Increase in volume of 
(new) patients.
Medium power 
position and high 
interest for a successful 
task substitution.
Primary care 
optometrists
Competition with 
optical chains, chance to 
professionalize.
Increase in volume of 
(new) patients.
Low power position 
and high interest 
for a successful task 
substitution.
Patients Were not involved at 
the start.
More flexible 
appointments and more 
time per appointment.
Medium power 
position and medium 
interest for a successful 
task substitution.
Dutch Health Care 
Authority / Health 
insurers
Were not involved at 
the start.
Care would possibly 
become less expensive
High power position 
and unclear interest 
for a successful task 
substitution.
GFU employees Were not involved at 
the start.
Low power position 
and low interest for 
a successful task 
substitution.
After GFu 
establishment§
Glaucoma 
Specialists
Release of workload due 
to GFU.
The establishment of 
the GFU already fulfilled 
their goals.
Reduction of interest 
for a successful task 
substitution.
Management REH Better alternative 
was found through 
cooperation with optical 
chain.
Disappointing increase 
in volume due to 
cooperation with OCR. 
Alternative was found.
Reduction of interest 
for a successful task 
substitution.
Primary care 
optometrists
Cooperation remained 
on the same level.
Increase in new 
patients differed among 
optometrists.
Reduction of chance to 
strengthen relationship 
with glaucoma 
specialists
Patients GFU resulted in more 
time per patient, and 
care in a familiar setting.
Reduction of interest 
for a successful task 
substitution.
Nza / Health 
insurers
Quality of care in GFU 
was good.
No changes in interest 
due to establishment 
of GFU.
GFU employees Improved relationship 
with glaucoma 
specialists and more 
satisfying work.
The consequences of 
starting task substitution 
for the GFU were 
unclear.
Increase of power 
position.
GFU: Glaucoma Follow-up Unit; Nza: Dutch Healthcare Authority; OCR: Collective of Optometrists in the 
Rijnmond region; REH: Rotterdam Eye Hospital.
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the glaucoma specialists and GFU employees no longer supported the final step, which 
was implicitly reflected in the debate on the expertise of primary care optometrists.
Optometrists’ subtle and constructive views confirmed that quality of care was per-
ceived to be the most important factor for the feasibility of the task substitution. All 
six primary care optometrist-interviewees were convinced of their capability to monitor 
stable glaucoma patients (Table 4.3) because during the TG-project and the TOZ-project 
(transmural eye care for all indications) some participating OCR optometrists gained 
experience in screening patients and strengthened their relationships with REH oph-
thalmologists, and they were trained to detect pathological abnormalities of the eye.
Some primary care optometrists indicated, however, that they would like to have more 
routine monitoring of glaucoma patients to bolster their initial education (Table 4.3). In 
response, the REH organised training guided by glaucoma specialists for the optom-
etrists participating in the TG-project. Optometrists interned for several days, studied a 
textbook, and were tested before they could participate. Despite this training, glaucoma 
specialists and GFU employees were, due to their experience during the TG-project in 
the late 1990s, not convinced of the primary care optometrists’ expertise. The glaucoma 
Table 4.3. Quotations ‘closed window of task substitution’
Primary care optometrists
• As an optometrist you have done everything during your training, you have seen all the abnormalities, you 
have read and learned about them, and you graduated. (Respondent 14)
• Considering our experience in the TOZ project (transmural eye care), in my opinion, we are capable of 
providing, without any problems, part of the care for stable glaucoma patients and patients with a risk 
factor for glaucoma. (Respondent 15)
• We don’t see enough glaucoma patients to monitor them. Even though it can occasionally occur, I do think 
that we need to get more practical experience of these patients on a daily basis. If we start monitoring 
patients, we have to know how the eye hospital wants it to be done, how they do it, and what they exactly 
want to know. This can only be achieved through training. By watching glaucoma specialists at work. 
(Respondent 19)
Glaucoma specialists and GFu employees
• To me, the GFU is a good system because I do have some idea of the quality being delivered. And I think 
that is essential to know. I am not in favour of transferring this care to optometrists who work outside of the 
REH, because then I’m not sure what the quality of their care will be. (Glaucoma specialist, respondent 7)
• Unfortunately, we have had quite some bad experiences with a number of primary care optometrists. 
A small number, but quite bad experiences. They were playing at being doctors, without having the 
knowledge. That’s what I’m concerned about. (Glaucoma specialist, respondent 8)
• I still see the quality of care of these optometrists on a weekly basis (TG project), and I think that this group 
is not suitable for monitoring these patients. I still see too many assessments, where they say, there’s 
nothing wrong, and where I think: well there is definitely something wrong. (GFU employee, respondent 9)
GFU: Glaucoma Follow-up Unit; REH: Rotterdam Eye Hospital.
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specialists doubted whether the quality of care delivered by optometrists would be 
comparable to GFU employees despite the additional education. The glaucoma special-
ists were furthermore eager to check the GFU employees’ quality of care in the hospital 
setting and feared losing control over their patients in an outpatient setting (Table 4.3).
Having the GFU staffed by hospital optometrists instead of primary care optometrists 
further reduced the likelihood that the task substitution to primary care optometrists 
would succeed. Besides eliminating the sense of urgency for task substitution of person 
and setting, establishment of the GFU strengthened the bond between the glaucoma 
specialists and GFU employees, closing the window of opportunity for task substitution 
of person and setting.
unclear returns on investments
The stakeholders doubted whether the monitoring of stable glaucoma patients by 
primary care optometrists would still be financially interesting, i.e., the return on invest-
ment was unclear (see Table 4.4). The high workload of the glaucoma specialists, which 
sparked the initiative, was significantly reduced by the establishment of the GFU in 
2004. Increased capacity made it possible to lift the ban on accepting new glaucoma 
patients, which resulted in a 23% increase from 2004 to 2008. Two glaucoma specialists 
indicated that the increase in capacity eliminated the pressure to further pursue task 
substitution. Moreover, one underlying key assumption proved to be untrue. The REH 
management assumed that the task substitution would increase capacity and inflow of 
new patients. But in 2008 the primary care optometrists within REH’s eye care network 
were responsible for only 1% of the new patient inflow. The collective OCR organisation 
was furthermore rudimentary: the optometrists were mostly self-employed, and could 
not be easily approached as a group. For both reasons, the REH started collaborating 
with a large optical chain to ensure a steady inflow of new patients.
This new collaboration put a strain on the REH-OCR collaboration. The optometrists 
had seen the monitoring of glaucoma patients as opportunity to compete with optical 
chains because they could not compete with them on the price of eyewear. On the other 
hand, some primary care optometrists were unsure about the competitive advantage of 
membership in the REH’s eye care network. Despite their belief that monitoring glau-
coma patients would provide work diversity, whether it would result in additional clients 
or income was unclear.
The combination of an unclear effect of eye care network membership with the 
absence of a separate reimbursement tariff for optometric examinations rendered the 
monitoring of glaucoma patients financially unattractive for primary care optometrists.
In the absence of a reimbursement tariff for an optometric examination, most patients 
did not choose primary care, because they would have to pay (directly or indirectly) for 
care that otherwise was reimbursable. Besides, some patients claimed that they relied 
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Table 4.4. Quotations ‘unclear returns on investments’
Glaucoma specialists:
• I: But it is getting busier with glaucoma patients, and you cannot discharge everyone. R: That’s why we 
created this system, the GFU. I: Do you think that is enough? R: I think so. (Respondent 6)
• If the pressure, the number of patients at the clinic increases, and we have to announce waiting lists again 
or limit the number of patients at some point, then it will not be beneficial to the quality of care. Then we’ll 
have to do something like that [task substitution], we’ll have to go down that road. (Respondent 8)
reH Management:
• What we do is, we move the chronic patients. Those patients are not financially attractive, not for the 
partnership either. So to make it financially attractive, we need to see new patients, we must get referrals. 
(Respondent 1)
• Primary care optometrists only send 1% of our referrals. So we need to arrange the other referral channels. 
(Respondent 3)
Primary Care optometrists:
• But when an optical chain joins, it makes us less unique. And as an independent optical shop, we take 
optometry very seriously. (Respondent 16)
• Yes, there are customers who come to our shop, even if I do not know them personally… I have not seen 
them before, but they ask during their visit to the REH where they can buy spectacles, etc. Then they are 
referred to me, which is really great. (Respondent 16)
• I: As regards the fact that you are part of the Eye Care Network, do you use it, put a sign on the door: 
‘Optician, member of the Eye Care Network’? R: Um, good question. Hardly. I: Why not use it? R: Because it 
has no effect. I: How do you deduce that? R: Instinctive, advertising is purely instinctive. (Respondent 18)
• If you ask me what I think needs to be done, then I think health care insurers are keeping out of the way 
and do not take enough action in this matter. I think that when it comes to eye care, the health care insurers 
should accept their responsibility. (Respondent 18)
dutch Healthcare Authority / Health care insurers:
• When it comes under the B segment (tariff becomes negotiable) the health care insurer will say: we no 
longer pay for the part of the DBC delivered by primary care optometrists, because we are already paying 
those optometrists directly. That is a possibility. Then the Dutch Healthcare Authority does not have to set a 
price. (The Dutch Healthcare Authority, respondent 27)
• If the reason for your question is: would we insurers be prepared to contract an optometrist, to agree on a 
tariff and let him be responsible for this care; that is something I would be prepared to consider. But on the 
condition that the quality of care is guaranteed, that the Health Care Inspectorate is confident about it, and 
above all that the referring glaucoma specialists have confidence in it. (Health care insurer, respondent 25)
Patients:
• I think it is a bit more reassuring when you stay under your doctor’s care, of course. A specialist is probably a 
bit more knowledgeable. You’re so used to it. (Respondent 24)
• In some ways, care by a local optometrist might be nicer. The ophthalmologist with his experience and 
knowledge might see certain things very quickly, though. But I have the impression that at the GFU they 
have a bit more time for you, they want to know things exactly and are more precise than the doctor.
But still, if I have the choice between one and the other and they are both of good quality, then I would 
choose the one that doesn’t cost me anything. (Respondent 23)
DBC: Diagnosis Treatment combination; GFU: Glaucoma Follow-up Unit.
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more on the glaucoma specialists than the primary care optometrists. Such consider-
ations outweighed the advantages of the optometrists’ care, such as flexible appoint-
ments and proximity to patients’ homes.
Health insurers could mediate between primary care optometrists and the REH to 
realize shared care and provide an appropriate reimbursement tariff, but were at the 
moment of evaluation in 2008 reluctant to initiate discussions. They claimed, however, 
that if the REH could guarantee the quality of care and if physicians supported the sub-
stitution, they would seriously consider recommending reimbursement of primary care 
optometric examinations to the Dutch Health Care Insurance Board.
The Dutch Healthcare Authority mentioned another problem in this regard: the 
realisation of a tariff for an optometric examination would result in additional costs 
for health insurers and their clients because such tasks (monitoring stable glaucoma 
patients) were also financed for hospital-based glaucoma specialists. This was, however, 
a temporary problem as the reimbursement of glaucoma monitoring by glaucoma spe-
cialists became negotiable in 2009.118
Power positions and level of interest
In Table 4.5 we summarised the stakeholder positions by mapping their willingness to 
participate in the task substitution and their power positions.
The REH management initially wanted to transfer visits of stable glaucoma patients 
to primary care optometrists with the conditional support of the Dutch Healthcare 
Authority, patients, and health insurers. The conditions of the Dutch Healthcare Author-
ity included accessibility and affordability of care (Table 4.6). Although patients saw 
benefits of the task substitution, like faster and more flexible appointments and shorter 
travelling times, they were not likely to visit primary care optometrists if they had to pay 
for care that would have been otherwise reimbursed (Table 4.6). The reimbursement 
could be accelerated by the health insurers, but they stood with the patients, arguing 
that they were only willing to cooperate if glaucoma specialists and the Health Care 
Inspectorate were fully behind the task substitution.
Table 4.5. Summary of the stakeholder positions
stakeholders support / opposition Power-position
REH management Moderate support Medium
Glaucoma specialists Strong opposition High
GFU employees Strong opposition Low
Primary care optometrists Strong support Low
Patients Neutral Medium
Health insurers / Nza Neutral High
GFU: Glaucoma Follow-up Unit; Nza: Dutch Healthcare Authority; REH: Rotterdam Eye Hospital.
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Only one glaucoma specialist preferred the situation of having stable glaucoma pa-
tients monitored by primary care optometrists. The remaining three specialists and most 
GFU employees were not in favour.
The OCR optometrists supported the task substitution of monitoring stable glaucoma 
patients at their shops because the task substitution would improve their professional 
image and strengthen their competitive positions relative to other optometrists. Their 
power position, however, was relatively weak due to the OCR’s low degree of organisa-
tion and the self-employed state of most of their optometrists, unlike, for example, large 
optical chains. The role of the primary care optometrists was therefore relatively passive 
(Table 4.6).
Stakeholders holding strong power positions were glaucoma specialists and health 
insurers. Although the health insurers supported the idea of task substitution, they did 
not intend to initiate discussions about the establishment of tariffs for primary care 
optometrists unless the REH could guarantee quality of care. Besides, insurers believed 
the active support of the glaucoma specialists important, as did most patients. Thus, the 
substitution of person and setting would not succeed in the short term. Even the most 
enthusiastic glaucoma specialist affirmed this (Table 4.6).
Table 4.6. Quotations ‘Power positions and level of interest’
Management reH:
• With respect to glaucoma care, we have started to investigate whether apart of the activities that take place 
here could be substituted to optometrists who are closer to the patient’s home. (Respondent 2)
• I: What is your opinion about substitution of eye care to other professionals?
R: If we did not agree, we would not put so much energy into it. (Respondent 1)
The dutch Healthcare Authority / Health care insurers:
• It looks like it would be more accessible than going to see a doctor. In that respect it seems to be in the 
interests of the patient. It seems like a good development. (The Dutch Healthcare Authority, respondent 27)
Patients:
• Yes, I thought it was safe, so I thought, well, if the doctor says so. I simply trust him, so you go along with it. 
(Respondent 21)
• I think it is a bit more reassuring when you stay under your doctor’s care, of course. A specialist is probably a 
bit more knowledgeable. You’re so used to it. (Respondent 24)
Primary care optometrists:
• Yes, there is a professional group, but I never hear anything about it. A great deal would have to be done 
there. So I’m afraid that that is also a factor. (Respondent 18)
Glaucoma specialists:
• So you need to move forward with small steps, take the lead yourself. Then you have to get clear results 
which you can show, and once you have these, you can gain the trust of others to do it. (Respondent 7)
REH: Rotterdam Eye Hospital.
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4.4 dIsCussIon
Transferring the monitoring of stable glaucoma patients to primary care optometrists did 
not seem feasible in the Rotterdam area in the period 2004 to 2011, despite other studies 
indicating that (primary care) optometrists can provide high-quality care.66,67,72,82-86,88-92,99 
The implementation turned out to be the stumbling block as the involved professionals 
quarrelled over professional boundaries and work domains, they disagreed on the capa-
bilities of primary care optometrists, the assumed returns on investment were unclear 
after all, and power positions favoured the status quo.
The three theoretical perspectives used in our case study align very well with the 
implementation literature that broadly acknowledges that implementation of an innova-
tion can be difficult and a well-designed implementation process is critical.3,110,112,113,119-122
Our results can be explained by classical theories on implementation, financial incen-
tives, and stakeholder interests. From implementation theories, for example, it could be 
expected that ophthalmic examination by primary optometrists would be difficult with-
out reimbursement, because the current situation (no reimbursement) differed from the 
desired situation (with reimbursement).119 A second example is the failure to enhance 
ophthalmologists’ perceived benefit of the innovation by staffing the GFU with primary 
optometrists at the outset, because that would have reduced the uncertainty about the 
future situation, which is very important to let the task substitution succeed.110
This study also taught us two theoretical lessons that might influence the implementa-
tion literature. First, the findings highlighted the merit of connecting the implementation 
literature with sociological theories on professionalism, which is also acknowledged by 
Adler et al. (2009). A key notion for understanding the feasibility of the task substitution 
was recognizing the path dependency of the professionalisation of the occupations 
involved. There was indeed a window of opportunity for the task substitution at the 
outset because ophthalmologists were pressured to make professional relationships 
and domains more fluid. The intermediate step of the GFU fixed the professionalisation 
processes, and the pressures were sufficiently relieved. Thus, being aware of (local) 
professionalisation processes combined with good timing seem crucial for successfully 
transferring tasks from one professional group to another. Combining implementation 
literature with sociological theories on professionalism,112-115 we can say in general that 
it is crucial to involve the substituting professionals early on to ensure that stakeholders 
see the change as a normal step in the professionalisation of the substituting profes-
sionals.
Second, the study underscores the importance of time element; windows of op-
portunity may disappear over time. In Rotterdam, the accumulation of (local) dynamics 
proved the assumed benefits of the task substitution wrong in the end. The assumption 
that cooperation with primary care optometrists would increase the inflow of new pa-
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tients appeared incorrect. Besides, the assumed financial benefits were unclear. Because 
only hospital visits were reimbursed, primary care optometrists had to monitor stable 
glaucoma patients for free, charge patients for the examination, or organise a payment 
by the REH, all of which reduced its benefits. The last possibility would be to create a 
separate tariff for monitoring glaucoma patients by primary care optometrists, but the 
power positions of key stakeholders did not support this. Implementation scientists 
thus should not underestimate (the effect of ) changing aims and interests of the differ-
ent stakeholders over time because they often do change. It is therefore crucial to make 
the right decisions at the right time to obtain the expected result.
4.5 ConCLusIons
National and local factors hamper transferring the responsibility to monitor stable glau-
coma patients from the REH’s GFU to primary care optometrists in an outpatient setting. 
Task substitution in person and in setting is therefore not feasible in the short term in 
the Rotterdam area.
Unlike the primary care optometrists, most hospital-based glaucoma specialists over 
time were unwilling to collaborate in the scheme. Moreover, the REH management’s 
enthusiasm for the task substitution waned when its aim shifted from cooperating with 
primary care optometrists towards increasing the inflow of new patients, as the demand 
could be met with the newly established and successful hospital-based GFU.
Policy makers considering substituting tasks to lesser trained professionals as well as 
substituting the delivery of services from a hospital to a primary care setting should 
carefully think about the implementation process, especially when they decide to imple-
ment task substitution in separate steps. Our case study demonstrates that professional, 
financial, managerial, and political factors all play a role in rendering task substitution 
feasible and that consolidating task substitution within a hospital setting will freeze the 
opportunity to transfer to a primary care setting. Recognizing a restricted window of 
opportunity in the implementation of task substitution is critical.
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APPendICes
Appendix 4.1. Background information about the hospital, glaucoma and GFu 
working procedure and protocol
The Rotterdam Eye Hospital is a Centre of Excellence that provides high level medical, 
paramedical and nursing care, and pays much attention to the transfer of knowledge. 
In 2009, the number of outpatient visits was 138,311 and the number of hospitalisations 
was 1048.
Glaucoma is a group of eye diseases characterised by damage to the optic nerve that 
causes gradual, irreversible visual field loss. It is often related to age and high intraocular 
pressure, and care is currently provided by general ophthalmologists and glaucoma spe-
cialists. It calls for a tailored approach for each individual patient to slow down or halt 
the natural course of the disease. Monitoring patients by optometrists or ophthalmic 
assistants might be sufficient for stable glaucoma patients who are regulated correctly 
by ophthalmologists or patients at risk for glaucoma. 
Those patients were referred to the GFU by their treating ophthalmologist. As long as 
patients were stable according to specific criteria for back referral, they visited the GFU 
twice followed by a visit to the glaucoma specialist or resident. If the patient was not 
stable according to these criteria, the patient was seen by a glaucoma specialist earlier. 
The GFU employees performed the following activities: ask a short history, determine 
the IOP and Snellen visual acuity and make GDx images. In case of moderate to ad-
vanced visual field damage or at doctor’s request, they performed an additional yearly 
HFA (Humphrey Field Analyser, standard 24-2 test algorithm; Carl Zeiss Meditec, Dublin, 
CA, USA).
Appendix 4.2 Topic list
Topic list
a. Introduction
b. Introduction of study, the interviewees and the participant
1. What is your attitude towards task substitution in general and more specifically in 
glaucoma care? 
2. What are, according to you, the advantages and disadvantages of task substitution?
3. How would you define and picture the task substitution in glaucoma care in the ideal 
situation?
4. What basis criteria need to be fulfilled? To what extent have they already been ful-
filled? And if applicable: how can you accomplish that?
5. For what reasons would you (not) cooperate to let primary care optometrists become 
substitutes for glaucoma specialists in monitoring stable glaucoma patients?
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6. What would you (or your organisation) do to make sure that the task substitution 
will (not) be established or to increase or decrease the chance of its successful imple-
mentation?
7. Which adjustments to the current health care system are required to establish the 
proposed task substitution?
 Are there any other issues you would like to discuss?
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suMMAry
Background. As the effectiveness and cost-effectiveness in daily clinical practice be-
comes more important in for example reimbursement decisions, observational studies 
also become increasingly important as these studies better reflect clinical practice in the 
complete patient population than randomised clinical trials. 
Methods. In this observational study, we continually reviewed patient charts to assess 
daily clinical practice, treatment outcome and survival in 160 chronic lymphocytic 
leukaemia patients diagnosed between 1999 and 2003 in 19 Dutch hospitals. We also 
assessed whether daily clinical practice corresponded to the national guideline of 2004.
Results. Of the patients who received treatment (60.6%), 87% received chlorambucil in 
the first line. Fludarabine monotherapy (46%) and FC(R) (16%) were the most applied 
treatments in the second line. After the second treatment line, variation in treatment 
increases exponentially. The five-year overall survival was 89%.
Conclusions. The majority of Dutch CLL patients diagnosed between 1999 and 2003 were 
treated according to the national guideline that was formulated in 2004. However, since 
the management of CLL is heterogenic and has changed rapidly in the last decades, 
guidelines should be updated periodically. 
For a disease like CLL, with a variety of and rapidly changing management strategies, 
capturing accurate and long-term observational data is necessary for quality assess-
ment, but challenging.
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5.1 InTroduCTIon
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in the 
Western world, affecting roughly 3 to 6 people per 100,000 population.123 Incidence 
increases with age, peaks at 60 to 80 years, and affects twice as many males as females.123
Early symptoms of CLL are usually minimal and diagnosis often follows a routine blood 
test that returns a high lymphocyte blood count. As the disease progresses, patients can 
experience fatigue, weight loss, bleeding, and recurrent or persistent infections.124,125
The clinical course of CLL is highly variable.126 Survival from the time of diagnosis 
ranges from several months to 20 or more years, depending on prognostic factors.127,128 
The first prognostic indices including lymphadenopathy, hepatomegaly, splenomegaly, 
anaemia and thrombocytopenia were designed by Rai and Binet126,129 to define disease 
stages. More recently molecular based prognostic markers have been defined like chro-
mosomal abnormalities130 and mutational status of the immunoglobulin genes.131
The CLL management changed in the last decades. At the onset of our study, alkylat-
ing agents (e.g. chlorambucil) and nucleoside analogues (e.g. fludarabine) were the only 
available effective agents for the treatment of CLL. At that time there was no evidence 
claiming that drug combinations were preferable to monotherapy but at the end of our 
study in 2009, multiple studies had shown improvement in progression-free survival 
with fludarabine based combinations.132-135
Observational research is becoming increasingly important, as policy makers are 
interested in disease management and its effectiveness in daily clinical practice for mak-
ing reimbursement decisions. Results of observational studies may differ from results 
of clinical trials, as the latter frequently uses treatment protocols and concerns selected 
groups of patients with accrual depending on referral policies, and strict inclusion and 
exclusion criteria. Observational studies use minimal exclusion criteria leading to a more 
representative reflection of the total patient population. 
As currently no observational study results are available, the aim of this study was 
to (1) obtain information about the management of CLL and its effectiveness in daily 
clinical practice in the Netherlands, (2) calculate actual costs of treatment of CLL, and 
(3) describe the quality of life of CLL patients.136 In this paper, we describe the results 
of the first aim: CLL management in daily clinical practice and its effectiveness. We also 
compared these results with the Dutch guideline formulated in 2004.137
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5.2 MATerIALs And MeTHods
Patient selection
Four university hospitals and 15 general hospitals in the Netherlands invited their CLL pa-
tients to participate in our observational study when they presented in clinical practice 
in 2004 and 2005. Any patient 18 years or older diagnosed with CLL between June 1999 
and June 2003 could enter the study if he or she did not suffer from any other serious 
disease or previous malignancy, had a complete patient file, and gave informed consent. 
Patients who developed a non-CLL related malignancy were censored at the time of 
diagnosis of the second malignancy. The medical ethics committee of the Erasmus MC 
concluded that our study was exempted from the legal WMO criteria for scientific medi-
cal studies in humans due to its observational nature, and that there were no objections 
against conducting the study.
data collection 
Patient files and hospital databases were continually reviewed to assess (in- and out-
patient) CLL treatment strategies from diagnosis till the end of the study. Patients were 
followed for at least five years for a sufficiently long observation time, since for a signifi-
cant number of CLL patients, active treatment was not indicated directly after diagnosis. 
Data were collected and entered in an internet database by trained study nurses under 
the supervision of the treating haematologists in 16 of the 19 centres. In the remaining 
three hospitals the data were collected by scientific personnel. In case of missing data 
on treatment outcome, treating haematologists were consulted to ensure a complete 
data set. Some patients had been partially treated in three hospitals outside the 19 
participating centres; study personnel visited these hospitals to collect relevant data. 
data monitoring
For quality assurance, the data entered in the database were checked with the patient 
files and hospital databases continually. Basic characteristics (e.g., age, Binet stage at 
diagnosis and WHO score) and medical consumption related to the chemo(-immuno)
therapy administration were checked for all patients. Other information (e.g. monitoring 
visits, adverse events, diagnostic procedures) was checked in over 75% of the patients.
Therapy description and outcomes
CLL management was reported for the first, second, and third or later treatment lines 
separately. The mean number of cycles has been calculated for each type of treatment 
separately, and information about the dose was reported for therapies used in 20 or 
more patients. A cycle of chlorambucil was defined as a period of treatment without 
breaks longer than one month.
Management of chronic lymphocytic leukaemia 87
Our main outcomes were 1) treatment outcome expressed as overall response (complete 
or partial response) and 2) time to next treatment: the time from the start of treatment 
until the start of the next treatment. Time to progression could not be measured appro-
priately, because of differences in hospitals’ definitions of disease progression. Due to the 
variety in treatments, the treatment outcome has been presented per treatment group 
and was reported only for those treatment groups with 5 or more patients. The following 
treatment groups were used: chlorambucil (with or without prednisone), fludarabine 
monotherapy, fludarabine combinations, therapies including a monoclonal antibody, 
and other therapies. Other outcomes were overall and disease-specific survival, and the 
number of and reasons for hospitalisation. 
statistical analysis
CLL management was reported per treatment line. Survival rates were estimated using 
Kaplan Meier curves drawn in SPSS. A valid statistical comparison of different therapies 
per treatment line was not possible because patient sub-groups were too small.
5.3 resuLTs
Patients
Informed consent for participation was given by 173 patients. Of these, 13 patients (6%) 
were excluded from the analysis: eight did not meet the inclusion criteria, one patient 
file was not available, and one patient withdrew himself from the study. Additionally, 
one hospital discontinued participation during follow-up for technical reasons, resulting 
in the exclusion of three patients for incomplete data. 
Table 5.1 shows that the majority of the patients was male (62.5%) with a mean age 
of 61.6 years (SD=10.2). The average age of the female patients was 66.3 (SD=10.7). The 
mean follow-up duration was 6.4 years (range=1.9-9.4, SD=1.4).
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Therapies per line
The treatment sequences informed us about the daily clinical practice in the period 
1999–2009 for patients diagnosed between mid-1999 and mid-2003. The treatment se-
quence is presented schematically in Figure 5.1. Table 5.2 presents the number of cycles 
per line, time to next treatment and overall response rates per treatment group. Figure 
5.2 shows the response rates for the treatment groups that contained 5 or more patients.
Table 5.1. Patients’ characteristics at diagnosis 
Participating patients (n=160)
Hospital of inclusion:
University
General
28 (17.5%)
132 (82.5%)
Age at diagnosis: Mean (SD)
                               Median
                               Range
63.4 (10.6)
63
30-86
Gender (% male) 62.5
Patients (%) with first or second degree relatives with leukaemia or 
lymphoma 
8.1
Binet Stage (%):
A
A progressive
B
C
Unknown
71.3
1.9
15.0
11.3
0.6
% of patients with ≥1 extra nodal sites 88.1
B-symptoms (yes %) 12.5
Involvement of spleen (yes %) 27.5
WHO-performance score (%):
0
1
2
78.1
19.4
0.6
WHO: World Health Organization
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Watch and wait
During follow-up, 63 patients (39%) remained in ‘watchful waiting’ after diagnosis. One 
of these patients died during the study from a non-CLL related cause after 50.1 months 
of follow-up. The remaining 62 patients had an average follow-up period of 81.7 months 
(SD=13.8). The mean time between outpatient visits during the watchful waiting period 
was 3.1 months.
Table 5.2. Mean number of cycles and time to next treatment per treatment line
Line number Treatment category n Mean number 
of cycles (sd)
Time to next 
treatment
in days (sd)
overall 
response (%)
1 (n=97) Chlorambucil 84 2.4 (1.8) 1088 (831) 53.2
Fludarabine monotherapy 2 5.0 (4.2) Not presented Not presented
Fludarabine combination 2 4.0 (2.8) Not presented Not presented
Therapy including monoclonal 
antibodies
1 14.0 (n.a.) Not presented Not presented
Other therapies 8 7.3 (3.2) 857 (570) 1.0
2 (n=57) Chlorambucil 3 3.3 (2.3) Not presented Not presented
Fludarabine monotherapy 26 4.2 (2.6) 555 (530) 44.0
Fludarabine combination 4 4.0 (2.4) Not presented Not presented
Therapy including monoclonal 
antibodies
12 5.4 (2.6) 562 (393) 72.7
Other therapies 12 5.3 (2.1) 507 (309) 75.0
3 (n=39) Chlorambucil 7 1.6 (0.8) 424 (314) 16.7
Fludarabine monotherapy 7 5.0 (1.2) 522 (365) 85.7
Fludarabine combination 6 3.3 (1.8) 292 (184) 50.0
Therapy including monoclonal 
antibodies
7 5.4 (2.4) 341 (225) 85.7
Other therapies 12 5.3 (2.1) 294 (248) 50.0
>3 (n=50)
Line 4: 28;
Line 5: 11;
Line 6: 9;
Line 7: 2.
Chlorambucil 2 1.0 (0.0) Not presented Not presented
Fludarabine monotherapy 7 2.9 (2.1) 255 (209) 66.7
Fludarabine combination 4 3.0 (0.8) Not presented Not presented
Therapy including monoclonal 
antibodies
19 4.0 (3.1) 181 (153) 56.3
Other therapies 18 2.1 (1.7) 232 (350) 52.9
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First treatment line
Of the 97 patients (61%) who started treatment, 34 patients (35%) started with an active 
treatment within 28 days of their diagnosis. The remaining 63 patients started on aver-
age after 30.5 months of watchful waiting (median=24.3; range=1.2-93.9; SD=23.4). 
In the first treatment line most patients were treated with chlorambucil (n=84; 87%). 
They received on average 2.4 cycles during an average period of 23.4 months. Treatment 
schemes varied: 78% received low dose chlorambucil continuously, 14% high dose in 
cycles, and 8% an intermediate scheme. In 56% of the patients, the daily dose varied 
from 0.5 mg to 6.0 mg. Compared to those treated with alternative therapies, patients 
receiving chlorambucil were on average older (63.4 vs. 58.8 years at diagnosis) and less 
frequently diagnosed with a Binet C stage (14.3% vs. 33.3%). Half of the patients (n=42) 
responded to chlorambucil, 3 of whom developed toxicity. Five additional patients 
(6%) had a toxic reaction to chlorambucil (response information not available). Eleven 
patients (13%) had no response, and 26 patients (31%) experienced progression during 
treatment. The mean time to next treatment for all patients receiving chlorambucil was 
35.7 months.
The 13 patients (13%) who received another type of treatment, had a lower mean time 
to next treatment of 26.3 months but a higher mean overall response of 100% than 
patients who received chlorambucil. They and received the following therapies: cyclo-
phosphamide, vincristine, and prednisone (CVP, 6.2%), rituximab-CVP (R-CVP, 1.0%), 
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Figure 5.2 Overall response per treatment line per treatment group that included 5 or more patients.
92 Chapter 5
fludarabine (2.1%), fludarabine and cyclophosphamide (FC, 2.1%), cyclophosphamide 
(1.0%) and treatment for a transformation (1.0%). The mean number of cycles was 8 for 
CVP, 14 for R-CVP, 5 for fludarabine, 4 for FC, 1 for cyclophosphamide and 9 for the treat-
ment for a transformation.
second treatment line 
Table 5.2 shows that 57 patients (36%) required a second treatment line. Almost 50% 
of these patients (n=26), received fludarabine monotherapy. They received on average 
4.2 cycles and their time to next treatment was 18.2 months. Nine of the eleven patients 
(82%) who completed their fludarabine treatment responded. Their mean dose was 
37mg/m2 per day during 6.6 cycles (range: 25 to 40mg/m2). The 15 patients who did not 
complete treatment received 2.3 cycles on average with a mean dose of 30mg/m2 per 
day. Two patients completed treatment early due to good response. The other patients 
ended treatment because of toxicity (6), anaemia (2), malaise (1), progression during 
treatment (2) or no response (2).
Alternative therapies and their average number of cycles in the second treatment line 
were: CVP (n=9; 5.8 cycles), fludarabine and rituximab with or without cyclophospha-
mide (FCR, n=5; 6.2 cycles), R-CVP (n=4; 4.3 cycles), FC (n=4; 4.0 cycles), chlorambucil 
(n=3; 3.3 cycles), rituximab (n=2; 4.0 cycles), cyclophosphamide, adriamycine, vincristine, 
and prednisone (CHOP, n=1; 4.0 cycles), rituximab combined with CHOP (R-CHOP, n=1; 
9.0 cycles), cyclophosphamide, vinblastine, prednisone, and procarbazine (CVPP, n=1; 
6.0 cycles) and a treatment for transformation (R-CHOP; n=1; 2.0 cycles).
Third and subsequent treatment lines
Table 5.2 shows the treatment outcomes per treatment group of the 39 patients (24%) 
who received three or more treatment lines. These lines included a variety of therapies 
for a small number of patients each. Table 5.2 presents the mean number of cycles per 
treatment category.
All patients in the treatment group ‘fludarabine combinations’ (6 in the third line and 
4 in later lines) received FC in 3.2 cycles on average. The group of therapies including 
monoclonal antibodies comprised patients who received rituximab monotherapy (n=8; 
3.8 cycles), R-CVP (n=6; 5.2 cycles), alemtuzumab monotherapy (n=4; 6.5 cycles), FCR 
(n=4; 3.8 cycles), R-CHOP (n=2; 4.0 cycles), FC combined with alemtuzumab (FCA, n=3; 
1.0 cycle) and one treatment with fludarabine combined with rituximab (FR; 3.0 cycles). 
The other chemotherapies were: CVP (n=13; 4.7 cycles), conditioning therapy (n=6; 1.0 
cycle), CHOP (n=4; 5.0 cycles), treatment for transformation (n=4; 2.3 cycles), cyclophos-
phamide + prednisone (n=1; 1.0 cycle), vincristine (n=3; 6.0 cycles), daunorubicin and 
cytarabine (n=1; 1.0 cycle) and dexamethasone + cytarabine + cisplatin (n=1; 1.0 cycle). 
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stem cell transplantations
A total of six patients were hospitalised for 17.5 days (range=8-25, SD=8.07) for alloge-
neic stem cell transplantation and conditioning chemotherapy. Conditioning chemo-
therapies were fludarabine, fludarabine combined with busulfan, FC, FC combined with 
methotrexate, cyclophosphamide and radiotherapy, and antithymocyte globulin with 
fludarabine and total body irradiation. Of the six patients, two achieved complete remis-
sion and three partial remission.
Transformations 
A transformation of the CLL into an aggressive lymphoma occurred in seven patients 
(4.3%). In two patients the transformation was non-CLL-related and they were therefore 
censored at the time of transformation. The CLL of the five other patients transformed 
into diffuse large B-cell lymphoma. Four of these patients (80%) died during follow-up. 
One received two therapies for transformation during the second and third treatment 
line. 
Hospital admissions
Table 5.3 presents the number of hospitalisations per patient and per patient year by 
cause. Within the mean study period of 6.4 years, 84 patients (48.6%) were hospitalised 
731 times for reasons other than chemo(-immuno)therapy or stem cell transplantation. 
The two most common reasons were blood transfusions (66.4%) and fever/ infection/ 
pneumonia (22.3%). 
survival
Figure 5.3 displays the overall survival. The two- and five-year overall survival was 100% 
and 89%, respectively. A total of 39 patients (24.4%) died during follow-up: 29 deaths 
were CLL-related, 8 were non-CLL related, and in two patients cause of death was un-
known. In general, the prognosis was better for patients with a Binet A stage than for 
patients with a Binet B or C stage. 
The two-year CLL-specific survival was 100% and the five-year CLL specific survival was 
91% (data not shown).
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Table 5.3. Reasons of hospitalisations
reason of 
hospitalisation
number of 
patients
number of 
hospitali-
sations
Mean number of 
hospitalisations for all 
patients (n=160)
Mean number of 
hospitalisations per 
patient year
Blood transfusion 54 470 2.94 0.46
Fever/ Infection/ 
Pneumonia
47 158 0.99 0.15
Administration 
medication (excl. 
chemotherapy)
5 23 0.14 0.02
Malaise 15 15 0.09 0.01
Diagnostic procedures 13 15 0.09 0.01
Abdominal pain/ 
Constipation
8 11 0.07 0.01
Hemolysis/ ITP/ 
Pancytopenia
5 6 0.04 0.01
Heart problems 2 4 0.03 0.00
Graft versus Host disease 2 2 0.01 0.00
Dermatologic problems 2 2 0.01 0.00
Progression CLL 2 2 0.01 0.00
Thrombosis 1 2 0.01 0.00
Other reasons 14 18 0.11 0.02
Unknown 3 3 0.02 0.00
CLL: chronic lymphocytic leukaemia; ITP: immune thrombocytopenic purpura.
Figure 5.3 Kaplan Meier Curve for overall survival per Binet stage at diagnosis.
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Guidelines in the netherlands
At the start of the study there were no general guidelines available for the manage-
ment of CLL patients. In the Netherlands the protocols of a few large academic hospitals 
were leading in the management of CLL. For many years chlorambucil has been the 
most important therapeutic drug for previously untreated CLL. With the introduction of 
fludarabine as a first-line treatment138 a higher response rate was observed, but no pro-
longed overall survival when compared to chlorambucil as primary treatment. For this 
reason, in combination with the lower costs, chlorambucil was the treatment of choice 
for CLL patients in the Netherlands at the time of the present study. This contrasts with 
the management in the United States of America, where the higher response rate was 
reason enough to replace chlorambucil with fludarabine. 
The first guideline for CLL from the Dutch-Belgian Cooperative Group for Haemato 
Oncology for Adults and the Dutch Institute for Healthcare Improvement CBO pub-
lished in 2004 summarised the existing local protocols and current practices 137. It 
advised chlorambucil as first-line treatment and fludarabine as second-line treatment 
in chlorambucil-resistant patients. The guideline advised against the use of total body 
irradiation as upfront treatment and against the use of interferon-α.137
With the introduction of FC and the monoclonal antibodies alemtuzumab and ritux-
imab, more powerful treatment options came available in 2004. Although not proven 
to prolong survival at that time, these therapeutic modalities have been increasingly 
used as first- or second-line therapies in the last years of our study. More recent results 
show that alemtuzumab monotherapy and FCR improve the progression-free survival 
and that FCR improves the overall survival as well.139,140
daily clinical practice versus guideline 
Of the 97 CLL patients requiring treatment, 84 patients (87%) received chlorambucil, 
which corresponded with the guideline. Fludarabine was administered to 24 of the 48 
patients (50%) who required treatment after they had received chlorambucil. Of the re-
maining 24 patients, 8 (33%) received a treatment combination containing fludarabine. 
As recommended in the guideline, none of the patients received total body irradiation as 
primary treatment nor did they receive interferon-α during their total follow-up period. 
Recommendations in the Dutch guideline focused on the first treatment line, and the 
second treatment line of chlorambucil-resistant patients. Although the guideline did 
not exist at the time of the diagnosis of our patients, if we look at those 145 lines (97+48) 
in particular received by 97 patients, 74% of the lines administered to 62% of the patients 
complied with the guideline. 
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5.4 dIsCussIon
In this evaluation of daily clinical practice in the Netherlands, first line treatment reflected 
the guideline as formulated in 2004137 in the 87% of the patients who received chlo-
rambucil. However, our study also illustrated the wide variety of applied chemotherapy 
regimens and the frequent deviations from the guideline. As an example, 46% of the 
chlorambucil-resistant patients were treated with a combination treatment instead of 
fludarabine monotherapy as advised by the guideline. This was probably due to the re-
lease of evidence of the favourable result of combination therapies on progression-free 
survival132-135 during our study, and can therefore be justified.
To obtain information on disease management and effectiveness in daily clinical prac-
tice, observational research is required. And although this type of research has its merits, 
it also has challenges. Dynamics in daily clinical practice due to continuous changes in 
insight and knowledge during the study could mean that study results are not up-to-
date in the end. During our study period monoclonal antibodies like alemtuzumab and 
rituximab were introduced, and cytogenetic analysis to determine the most appropriate 
treatment became available. Another challenge relates to the comparison of treatment 
outcomes. CLL patients often receive multiple treatment lines, the outcome of which 
is influenced by the outcome of the preceding therapies. Consequently, the treatment 
history would have to be taken into account when comparing alternative strategies per 
treatment line. To achieve this, large numbers of patients are required. In combination 
with the relatively low incidence of CLL, treatment variation among physicians and 
patient (risk) groups, and rapid development of new therapies, it is clear that compar-
ing alternative therapies in observational research is challenging. Considering the 
importance of observational research for health care policy, however, finding solutions 
is imperative. Towards this, long-term continuous registration has been started to keep 
records of daily clinical practice for all CLL patients in the Netherlands. Alternatively, a 
disease model could be developed to predict the impact of changes in the management 
on survival, quality of life and costs. Our study provides real world information which 
can be used for the development of such a model. 
Although we prospectively collected the data during the last four years of follow-
up, we had to collect data retrospectively for patients already diagnosed at the time 
of enrolment. Retrospective data collection complicates an objective measurement of 
treatment outcomes. Not all hospitals and specialists use the same response criteria and 
their assessments are not always reported in the patient files, which is why we could 
only report on overall response rates and survival. 
The second limitation is that our study population may not be representative for all 
CLL patients in the Netherlands. Patients with a low disease activity who were monitored 
by their general practitioner were not included, as patients were asked for participation 
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by haematologists. The percentage of patients that did not require active treatment may 
therefore have been somewhat underestimated. 
Such patients, however, would be referred to the haematologist or hospital when 
they needed active treatment, and thus our description of the CLL management is 
probably representative for the population that requires treatment. We could determine 
compliance with the guideline in daily clinical practice management. Seeing whether 
the updated national CLL guidelines of 2011141 are reflected in the treatment of recently 
diagnosed patients would, however, be interesting. 
Overall, the 2004 guideline recommendations are in line with daily clinical practice for 
most patients. Because of rapid developments in management strategies, however, con-
tinual assessment of the appropriateness of the guidelines is necessary. To accomplish 
this, observational research is worthwhile, but also very challenging in case of chronic 
diseases with rapidly changing management strategies. 
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suMMAry
We performed a comprehensive cost calculation identifying the main cost drivers of 
treatment of chronic lymphocytic leukaemia in daily practice. In our observational 
study 160 patient charts were reviewed repeatedly to assess the treatment strategies 
from diagnosis till the study end. Ninety-seven patients (61%) received ≥1 treatment 
lines during an average follow-up time of 6.4 years. The average total costs per patient 
were €41,417 (€539 per month). The costs varied considerably between treatment 
groups and between treatment lines. Although patients were treated with expensive 
chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than 
administration of chemo(immuno-)therapy. 
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6.1 InTroduCTIon 
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia occurring 
in the Western world, affecting 3 to 6 people per 100,000 population,142-144 but literature 
on its economic burden is scarce. Health care is under increasing pressure and cost-
effectiveness data are urgently needed. That is especially true in countries like the Neth-
erlands where expensive drugs are to be evaluated during the first years of temporary 
admittance in order to get unconditioned reimbursement. 
Reviewing the existing literature on cost of CLL published between 1990 and July 
2013, we identified 3 publications that presented an overview of the longitudinal (di-
rect) medical costs of CLL treatment.145-147 In these studies, administrative claim data 
were used to compare costs of CLL patients with those of patients without cancer to 
identify the main cost drivers. Administrative claim data give a quite complete overview 
of all medical costs of large patient populations in a short time frame from a third party 
payers perspective. They have however also drawbacks. Data from health insurers are 
not recorded to calculate the actual costs and moreover, these data are susceptible 
to upcoding in countries with casemix systems (like the USA, Germany and the Neth-
erlands). Upcoding occurs when patients are miscoded or misclassified and leads to 
higher reimbursements for services provided, and therefore to higher health costs.148,149 
Besides, cost information subdivided by type of treatment or disease stage is often not 
available in these datasets.
In this observational study, we followed Dutch CLL patients for several years to get an 
overview of the management of CLL in clinical practice. A comprehensive cost calcula-
tion was performed to produce a transparent overview of different cost categories in 
order to identify the main cost drivers during the complete course of CLL treatment. 
To evaluate most CLL related costs, we followed the patients for 6.4 years on average. 
This long follow-up period was deemed necessary due to the chronic character of CLL 
in the majority of patients. Although treatment strategies for CLL, and therefore costs, 
are evolving over time, our calculations seem to remain relevant for two reasons. Due to 
the long follow up period, nearly all currently available treatments are included in our 
analysis. Besides, and more importantly, in contrast to the currently available data, we 
also reported costs per treatment line and per type of treatment.
6.2 PATIenTs And MeTHods
study design
An observational study design was chosen to calculate the costs of CLL, to reflect daily 
clinical practise. 
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Inclusion and exclusion criteria
In 2004 and 2005, 19 hospitals in the Netherlands invited CLL patients for participation 
in the study. Patients aged 18 years or older diagnosed with CLL between June 1999 and 
June 2003 could enter the study if they did not suffer from another active malignant 
disease or another serious previous malignancy, had a complete patient record, and 
gave written informed consent. Patients who developed a non-CLL related malignancy 
were censored at the time of that diagnosis.
data collection and monitoring
Patient charts were reviewed repeatedly to assess the treatment strategies for CLL in 
daily practice from diagnosis till the end of the study. All CLL-related medical resources 
consumed within the hospital or in the outpatient setting (i.e. medication prescribed by 
a haematologist) were derived from patient charts and hospital databases by trained 
research nurses under supervision of the treating haematologists or by scientific per-
sonnel. To ensure a complete data set, treating haematologists were asked to provide 
any missing information. 
Data were entered in an electronic data file which was accessible through the Internet, 
and checked yearly for quality assessment. Baseline characteristics (e.g. age, Binet stage, 
and WHO score) and resources related to the chemo(immuno-)therapy administration 
were obtained for all patients. The remaining information about e.g. outpatient / day 
ward visits, adverse events, and diagnostic procedures (X thorax, CT scans) was obtained 
for all patients and checked in over 75% of them.
Cost calculations
Total costs for individual patients were calculated by multiplying the resource use and 
unit costs. The analysis was based on the resource use of all patients including patients 
still treated at the end of data collection. Costs were based on the year 2012 (when nec-
essary adjusted using general price index figures from the CBS Statistics Netherlands). 
The unit costs for hospital days, outpatient visits, and day care treatment include 
direct and indirect labour costs, hotel and nutritional costs, overhead and capital costs 
and were derived from different resources using a micro costing method.150-152 These 
unit costs were calculated for university and general hospitals separately. 
For the calculation of laboratory costs, we recorded the number of days per treatment 
line on which laboratory tests were performed. In general we assumed that one blood 
sample was taken per day, during hospitalisations we assumed two blood samples per 
day. The unit costs of laboratory tests per withdrawal were based on our data in a cohort 
of multiple myeloma patients.153 
Costs of diagnostic procedures were based on national tariffs derived from the Dutch 
Healthcare Authority (NZa) which are assumed to reflect the actual costs reasonably.154 
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For the costs of allogeneic stem cell transplantation (AlloSCT) we combined our data 
with results of an earlier study,150 as not all components of SCT could be identified in the 
patient file. We distinguished AlloSCT from related donors and from matched unrelated 
donors. The donor costs for unrelated donor transplants were based on published costs 
of stem cell transplantation in the Netherlands.150
Costs of medication were acquired from the national pharmaceutical formulary 
drafted by the Dutch Healthcare Insurance Board.155 Wasting was taken into account for 
the cost calculation of intravenous medication. 
6.3 resuLTs
Patient characteristics
Informed consent for participation was given by 173 patients. Of these patients, 13 
patients (6%) were excluded from the analysis. Eight patients did not meet the inclu-
sion criteria; one patient chart was missing; and one patient withdrew himself from the 
study. Additionally, one university hospital refused further participation during follow-
up, resulting in three patients with incomplete follow-up data. 
Table 6.1 presents patients’ characteristics at diagnosis of the 160 evaluable patients. 
The majority of the patients were male (62.5%). Male patients had a mean age at 
diagnosis of 61.6 years (median=63, SD=10.2). The average age at diagnosis of female 
patients was 66.3 years (median=69.5, SD=10.7). The mean follow-up duration was 6.4 
years (median=6.4 years, range=1.9-9.4, SD=1.4). Furthermore, Table 6.1 presents the 
characteristics of patients who remained in the wait and see stage (n=63) and of patients 
who were solely treated with chlorambucil monotherapy (n=36). These patients were 
significantly older than the average age of the other patients (64.3 and 66.2 years vs. 60.7 
years) and were diagnosed more often with Binet A stage disease.
unit costs and resource use
Table 6.2 presents the unit costs and the average resource use per patient during the 
study period for all types of hospital visits, (diagnostic) tests, and treatment regimens.
Patients visited the internal/haematology outpatient clinic on average 5.6 times per 
year, and other departments 0.2 times a year (outpatient visits). Additionally, they had 
on average 0.2 telephone contacts per year. The therapy costs are the highest in the 
allogeneic transplantations and the monoclonal antibody containing regimens like 
rituximab monotherapy, FCR (fludarabine, cyclophosphamide, and rituximab), and FCA 
(fludarabine, cyclophosphamide, and alemtuzumab).
Appendix 6.1 describes the unit costs of AlloSCT in more detail, resulting in a unit price 
of €55,966 for an AlloSCT of a related donor and €111,913 for an AlloSCT of an unrelated 
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Table 6.1. Patients’ characteristics at diagnosis 
All patients 
(n=160)
Patients without 
treatment (n=63)
Patients treated 
with CLB only 
(n=36)
Other patients 
(n=61)
Age at diagnosis: 
 Mean (SD)
 Median
 Range
63.4 (10.6)
63
30-86
64.3 (9.4)
64
34-83
66.2 (11.9)
67
30-86
60.7
61
38-85
Gender (% male) 62.5 57.1 55.6 72.1
Patients (%) with first or second degree 
relatives with leukaemia or lymphoma 
8.1 6.3 8.3 9.8
Binet Stage (%):
 A
 A progressive
 B
 C
71.9
1.9
15.0
11.3
95.2
0
1.6
3.2
72.2
0
16.6
11.1
47.5
4.9
27. 9
19.7
B-symptoms (yes %) 12.5 6.3 11.1 19.7
Involvement of spleen (yes %) 27.5 11.1 38.9 37.7
WHO-performance score (%):
 0
 1
 2
 4
 n.a.
78.1
19.4
0.6
1.3
0.6
84.1
15.9
0
0
0
75.0
22.2
0
2.8
0
73.8
21.3
1.6
1.6
1.6
N.a.: not available; CLB: chlorambucil; WHO: World Health Organization.
Table 6.2. Unit costs and average resource use per patient for the complete study duration of on average 
6.4 years (in €, year 2012)
unit
unit costs Average resource use
General hospital
University 
hospital 
Hospital visits
Inpatient hospital day 441 749 17.30
Outpatient visit 95 156 37.85
Visit to nurse (practitioner) 58 58 0.15
Telephone contact 14 14 1.52
Day care visit 194 336 7.91
ICU per day 2137 2137 0.41
Emergency room visit 227 227 0.23
Inpatient hospital isolation day n.a. 980 0.66
Revalidation clinic 392 392 Not separately reported
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Table 6.2. Unit costs and average resource use per patient for the complete study duration of on average 
6.4 years (in €, year 2012) (continued)
unit
unit costs Average resource use
General hospital
University 
hospital 
diagnostic tests
Laboratory test (per withdrawal) 58 58 83.23
X-ray 57 57 Not separately reported
CT scan 260 260 Not separately reported
Echo (ultrasound) 95 95 Not separately reported
Haemoculture 35 35 Not separately reported
Other culture 22 22 Not separately reported
Puncture bone marrow and cytology 
testing
69 69 Not separately reported
Blood: erythrocytes 221 221 Not separately reported
Blood: thrombocytes 534 534 Not separately reported
ECG 21 21 Not separately reported
Bone biopsy 227 227 Not separately reported
Immunophenotyping 279 279 Not separately reported
Bone marrow biopsy 326 326 Not separately reported
Therapy costs
Chlorambucil 198 per cycle 2.3 cycles*
Fludarabine (oral/i.v.) 1134 per cycle 4.1 cycles
Fludarabine, cyclophosphamide (FC) 911 per cycle 3.5 cycles
FC plus Rituximab (FCR) 3131 per cycle 4.9 cycles
Other rituximab combination 2454 per cycle 5.6 cycles
Rituximab monotherapy 3350 per cycle 3.8 cycles
Alemtuzumab monotherapy 2119 per cycle 6.5 cycles
Induction therapy 2068 per cycle 4.1 cycles
Transformation therapy 2022 per cycle 3.3 cycles
FC + Alemtuzumab (FCA) 2957 per cycle 1.0 cycles
Other chemotherapy 132 per cycle 5.4 cycles
SCT of related donor 
(excluding laboratory costs)**
55,966 per procedure 0.03 procedures
SCT of unrelated donor 
(excluding laboratory costs)**
111,913 per procedure 0.01 procedures
* In the treatment with chlorambucil, treatment periods were considered to be two separate lines when the 
period between them was more than 365 days. 
** See Appendix 6.1 for more details. 
ECG: Electrocardiography; ICU: intensive care unit; SCT: stem cell transplantation.
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donor. The components marked with *** were directly derived from our study and are 
the average of 5 transplantations of a related donor and one transplantation with an 
unrelated donor. The other components could not be extracted from the patient files in 
most cases. To calculate the costs of these components, we used the data from another 
study.150 
Costs and cost categories
Table 6.3 shows how the total costs related to (the treatment of ) CLL of €41,417 per 
patient for the average total follow-up period of 6.4 years break down into different cost 
categories. The following categories were distinguished: monitoring visits (day ward or 
outpatient visits), chemo(immuno-)therapy in in- or outpatient setting including stem 
Table 6.3. Breakdown of the total direct medical costs related to chronic lymphocytic leukaemia
Totals (n = 160)
Total costs (SD) 41,417 (65,983)
Treatment line duration in months (SD) 76.9 (18)
Total monthly costs 539
Monitoring visits  43.1%
Laboratory tests 11.7%
Outpatient visits 9.6%
Day ward visits 1.1%
Procedures 10.7%
Medication (in periods without treatment) 9.9%
Chemo(immuno-)therapy 28.1%
Chemo(immuno-)therapeutics 13.9%
Administration of therapy (day ward/outpatient) 3.5%
Blood products 1.3%
Procedures 3.9%
(Prophylactic) medication (during treatment periods) 3.9%
Inpatient days (stem cell transplantation) 1.6%
Hospitalisation due to other reasons 28.8%
Inpatient days (normal care) 18.5%
Inpatient days (intensive care unit) 2.1%
Other contacts (outpatient visits, ICC, dietician) 0.7%
Emergency room visit 0.1%
Procedures 6.2%
Medication 1.3%
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cell transplantation, hospitalisation due to other causes than administration of therapy. 
Stem cell transplantation counted for 5.9% of all costs (€2444).
The main cost driver was inpatient days/day ward treatment (23% of the total costs), 
followed by costs of chemo(immuno-)therapy (13.9% of the total costs). Patients were 
hospitalised most frequently for a blood transfusion, pneumonia, other infections, or 
fever of unknown origin.
The majority of the costs were made during the monitoring visits (43% of the total 
costs, but this also includes outpatient medication and procedures over the complete 
course of CLL (including during treatment periods). 
Table 6.4 presents the costs differentiated per treatment line and per treatment group. 
In most treatment lines the main cost driver was inpatient days. Only in the wait and see 
stage, the outpatient visits (and procedures, not presented) were the main cost driver. 
When looking at the different types of treatments, costs were mainly driven by 
inpatient days as well. Only in the 38 patients (24%) who received the following treat-
ments, chemo(immuno-)therapy was the main cost driver: FCR, rituximab monotherapy, 
therapy for a (Richter’s) transformation, induction therapy preceding AlloSCT, or condi-
tioning therapy plus AlloSCT. In patients who received other rituximab combinations or 
alemtuzumab monotherapy the costs of chemo(immuno-)therapy did not exceed the 
total costs made during the monitoring visits, but did exceed the costs of the outpatient 
visits.
 The mean monthly costs of €539, ranged from €116 to €5,801 per patient when differ-
entiated per treatment line and from €116 to €22,132 when differentiated per treatment 
group. Although the latter maximum is not representative as it concerned one patient 
who died within a month after treatment, the exclusion of this patient still resulted in a 
very broad range of the monthly costs per treatment group (€116 to €7,932) indicating 
that costs in CLL treatment vary enormously. 
The mean total costs per treatment line increased by the number of lines up to the 
fifth line. The costs in the sixth and seventh line were lower, but as only very few patients 
had that advanced disease nothing can be said about the trend in costs in these lines.
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6.4 dIsCussIon
We presented a detailed cost analysis for CLL outlining the costs of CLL in daily practice 
as realistic as possible by choosing for an observational design. Our patient characteris-
tics seem to be reasonably representative for the entire Dutch CLL population since the 
percentage of men and the average age at diagnosis agree reasonably well with those 
of the national registration of CLL and indolent lymphomas (62% vs. 56% males and 63 
vs. 66 years of age).29 The slightly lower mean age at diagnosis may be caused by the 
tendency of haematologists not to bother older patients with the study. The distribution 
of the disease stages, however, also corresponds with the published distribution in the 
Netherlands: Binet stage A: 74% vs. 60%, Binet stage B: 15% vs. 30% and Binet stage C: 
11% vs. 10%.21 
Our AlloSCT costs, were quite comparable with those from a recent study in multiple 
myeloma, leukaemia and lymphoma patients. After correction for differences in cost 
calculation methodology (exclusion of the laboratory costs and costs during the first 
year of follow-up), the costs were €55,966 vs. €53,420 for an AlloSCT of a related donor 
and €111,913 vs. €94,450 for an unrelated donor AlloSCT (price year 2012).156
Costs of CLL vary greatly over the course of the disease and per treatment type. For 
most treatment choices, costs were mainly driven by inpatient hospital days. This finding 
is consistent with the conclusions of previous publications of costs of CLL by Lafeuille146 
and Blankart147 who conclude that -in contrary to the study of Stephens et al.43- the main 
cost drivers were not the costs of chemotherapy, bone marrow or stem cell transplanta-
tion but the usage of physicians146 and inpatient care.146,147 
In treatment lines with newer combination regimens, including immunotherapy (i.e. 
FCR, rituximab monotherapy or AlloSCT), however, chemo(immuno-)therapy proved to 
be the main cost driver. It may be expected that the cost of CLL will further increase in the 
future as recently diagnosed patients are treated more frequently with these expensive 
treatments, which will also increase the share of therapy costs on the total costs. Devel-
opment of other new treatment modalities that improves the overall survival compared 
with a wait and see approach will even further increase the share of therapy costs. 
Previous publications focus either on one treatment or diagnostic technology within 
the course of CLL, or use administrative data from health insurers to calculate the cost 
of illness of CLL. Compared to the latter studies, the monthly direct medical costs in our 
study are significantly lower.
The first possible explanation for this difference is the phenomenon of upcoding 
which may occur when using data from health insurers. Upcoding leads to higher health 
costs because of miscoded or misclassified patients.148,149
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The second explanation for the changing costs of immuno- or chemotherapy is pro-
vided by Reis et al.145 Their study included all costs during one year, but was prevalence-
based instead of incidence-based. A prevalence based study does not necessarily reflect 
the mean costs per year over the complete course of the disease and may lead to an 
under or overestimation of costs. 
A third explanation is the difference in prices between countries. This may apply to 
the study of Lafeuille146 since the medical costs in the USA are known to be much higher 
than those in the Netherlands.157 
But also within a given country, costs increase over time due to changes in manage-
ment and the development and implementation of (more expensive) novel therapies. 
This can be well demonstrated by comparing the two German studies.145,147 The treat-
ment costs reported in 2013 by Blankart et al had doubled when compared to those 
reported in 2006 by Reis et al.145 That is the reason why we reported the price of che-
motherapeutics separately enabling readers to easily adjust the disease management 
strategy and unit prices.
The possibility in these observational data to adjust the cost calculation according to 
differences in disease management and unit costs makes a cost calculation based on pa-
tient record data valuable for modelling studies that are used for economic evaluations. 
However, using observational data has limitations as well. Observational studies opti-
mally reflect the situation in clinical practice when patients are followed from diagnosis 
till their cure or death. During our study 39 patients died (24%). In the remaining patients 
the costs made due to CLL are not complete as their treatment continued. Because the 
costs per treatment line vary enormously, the estimation of costs for these survivors 
cannot be done easily, but require modelling. The results of our study may however be 
used as source for the model’s input parameters due to the relatively long follow-up 
period and the report of the results per treatment line and type of treatment. 
A second limitation is the underrepresentation of patients with a low disease activity 
who were referred back to their general practitioner. Due to our inclusion strategy, these 
patients were probably missed. This may have led to an overestimation of the costs of 
CLL per patient and of CLL overall. On the other hand, as already described, the costs of 
CLL are likely to increase in the future when new (more) expensive treatment options 
will be applied more frequently in clinical practice. 
In conclusion, cost of illness of CLL varied greatly over the course of the disease and 
was driven mainly by hospital admissions and hospital visits when considering the com-
plete course of the disease. During treatment lines of FCR, rituximab and AlloSCT, costs 
of chemo(immuno-)therapy were the main cost driver. In this era of high health care 
costs, it is important to know how the costs of CLL are structured. That information is 
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valuable especially when the economic impact of changes in the current (international) 
guidelines – based on the quick developments in the management of CLL – is high.
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APPendIx
Appendix 6.1. Costs of Allogeneic Stem Cell Transplantation (excluding laboratory costs)
sCT of related donor sCT of unrelated donor
HLA typing patient 1,385 1,385
HLA typing donor 3,971* 58,276**
Stem cell harvesting 1,637 n.a.
Stem cell selection 6,301 6,301
Donor Lymphocyte Infusion 1,388 4,667
Personnel cost 16,025 16,025
Conditioning therapy 3,555*** 3,555***
Prophylactic medication 1,478*** 1,478***
Blood transfusions 985*** 985***
Diagnostic procedures 1,869*** 1,869***
Inpatient stay 17,316*** 17,316***
Other contacts during stem cell trans-plantation 
(day ward, outpatient visits)
57*** 57***
Total costs 55,966 111,913
* On average HLA-typings of four relatives were performed in order to choose one donor
** Including stem cell harvesting, transport and medication of Europdonor
*** Mean costs of all allogeneic stem cell transplantations (5 related, 1 unrelated) based on the data col-
lected during our study
HLA: human leukocyte antigen; SCT: stem cell transplantation.
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suMMAry
Purpose. To describe the health related quality of life (HRQoL) of an unselected popula-
tion of patients with chronic lymphocytic leukaemia (CLL) including untreated patients.
Methods. HRQoL was measured by the EORTC QLQ-C30 including the CLL16 module, 
EQ-5D, and VAS in an observational study over multiple years. All HRQoL measurements 
per patient were connected and analysed using area under the curve analysis over the 
entire study duration. The total patient group was compared with the general popula-
tion, and three groups of CLL patients were described separately, i.e. patients without 
any active treatment (“watch and wait”), chlorambucil treatment only, and patients with 
other treatment(s). 
Results. HRQoL in the total group of CLL patients was compromised when compared 
with age- and gender-matched norm scores of the general population. CLL patients 
scored statistically worse on the VAS and utility score of the EQ-5D5, all functioning scales 
of the EORTC-QLQ-C30, and the symptoms of fatigue, dyspnoea, sleeping disturbance, 
appetite loss, and financial difficulties.
In untreated patients, the HRQoL was slightly reduced. In all treatment stages, HRQoL 
was compromised considerably. Patients treated with chlorambucil only, scored worse 
on the EORTC-QLQ-C30 than patients who were treated with other treatments with re-
gard to emotional functioning, cognitive functioning, bruises, uncomfortable stomach, 
and apathy. 
Conclusions. CLL patients differ most from the general population on role functioning, 
fatigue, concerns about future health, and having not enough energy. Once treatment 
is indicated, HRQoL becomes considerably compromised. This applies to all treatments, 
including chlorambucil, which is considered to be a mild treatment. 
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7.1 InTroduCTIon 
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia occurring 
in the Western world, affecting around 3 to 6 people per 100,000 persons.143,144,158 Early 
symptoms of CLL are minimal and diagnosis often follows the incidental finding of a 
high lymphocyte blood count or lymph node swelling. Unlike most types of cancer, the 
majority of CLL patients will not be treated immediately after diagnosis but will be moni-
tored through a ‘watch and wait’ approach.159 Only upon disease progression and/or the 
development of CLL-related symptoms such as fatigue, weight loss, malaise, bleeding, 
and recurrent or persistent infections,124,125 treatment is indicated.
Disease-related symptoms, toxic effects of therapy, and the awareness of living with an 
incurable disease31 can have a profound impact on health related quality of life (HRQoL). 
Despite these effects, little is known about the HRQoL of patients living with CLL.31,35,160 
Currently, nearly all available information is obtained during clinical trials which also 
studied the influence of treatment with chemotherapy on HRQoL.132,161-163 However, the 
generalisability of these studies is limited because these studies only enrol patients in 
need of treatment. In addition, they use strict inclusion and strict exclusion criteria, e.g. 
often excluding patients over the age of 65. 
The measurement of HRQoL in clinical trials which enrol mostly younger patients in 
need of treatment is valuable for comparison of treatments with regard to their effect 
on HRQoL and the course of these effects over time, i.e. from the start of treatment 
till the start of next treatment. From the available studies, we know that the HRQoL of 
patients during and after treatment with fludarabine plus cyclophosphamide (FC) does 
not differ from that of patients treated with fludarabine monotherapy on global health 
score, physical and emotional functioning and fatigue. Patients treated with FC score 
worse on nausea and vomiting during treatment, and better (but not significantly bet-
ter) after treatment than patients treated with fludarabine monotherapy.132,161 However, 
these clinical trials do not allow a conclusion with regard to the HRQoL in patients who 
are not in need of treatment yet.
That information would be valuable since one-third of all CLL patients,164 will not 
progress to treatment even over decades. Current study provides an indication of the 
type of symptoms treatment naïve patients experience and the limitations in daily 
functioning that occur. The comparison of the HRQoL in untreated patients versus those 
who just started treatment might give some indication of the impact of starting first line 
treatment on HRQoL. When the HRQoL of untreated patients is already severely compro-
mised, the impact of expected side effects during treatment on HRQoL is not likely to 
have a decisive role in the decision whether to start treatment. In the opposite situation, 
the expected impact of starting treatment on HRQoL should be seriously considered in 
the decision whether to start treatment or not.
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None of the available studies that address HRQoL in the whole CLL population,36-38 mea-
sured the HRQoL over a period longer than 1 year. In order to fill this gap, we conducted 
a longitudinal, multicentre observational study including a HRQoL study. 
7.2 PATIenTs And MeTHods
Inclusion and exclusion criteria
Nineteen hospitals in the Netherlands invited patients with CLL for participation in an 
observational study addressing the management of CLL, costs, and HRQoL.165 Patients 
aged 18 years or older diagnosed with CLL could enter the study if they did not suffer 
from another serious malignant disease or previous malignancy, had a complete record, 
and gave informed consent. Patients who developed a non-CLL related malignancy 
were censored at the time of its diagnosis. 
Quality of life
Patients who participated in the HRQoL study received a HRQoL questionnaire at the 
start, halfway through, and at the end of therapy from their treating specialists. Addi-
tional questionnaires were sent every 6 months in the periods without treatment to get 
information about the HRQoL in the period before treatment and between treatments. 
Since chlorambucil was frequently administered continuously for a long and not pre-
determined period of time, we choose to send questionnaires during this treatment 
every 6 months as well, to get more information about the HRQoL during the whole 
period of treatment. 
The instruments employed in the HRQoL assessment were the EORTC QLQ-C30 with 
the accompanying CLL specific module166 and a modified version of the EQ-5D in which 
5 response levels replaced the original 3 levels167 as suggested and investigated by Kind 
and Macran.168
eorTC QLQ-C30
The EORTC QLQ-C30, has been developed by the European Organisation for Research 
and Treatment of Cancer (EORTC) Quality of Life Study Group to assess the HRQoL of pa-
tients with cancer.166 The core instrument includes 30 questions covering many HRQoL 
issues related to cancer patients in general and can be supplemented by a diagnosis-
specific module.169 
The questionnaire EORTC QLQ-C30 incorporates five functional scales, three symptom 
scales, a global quality of life scale (2 items), and six single items. The functional scales 
are physical functioning, role functioning, emotional functioning, cognitive functioning, 
and social functioning. The symptom scales are fatigue, nausea and vomiting, and pain. 
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Dyspnoea (shortness of breath), sleeping (disturbance), appetite loss, constipation, 
diarrhoea, and financial difficulties are the six single items. According to the EORTC scor-
ing manual, scores were linearly transformed to a 0–100 scale.170 A higher score on the 
functional scales and global quality of life scales meant better functioning and quality of 
life, whereas a higher score on the symptom scales meant more complaints. Differences 
in scale scores of 10 points or more were considered clinically meaningful.171 
In this study the core questionnaire EORTC QLQ-C30 was supplemented by the CLL 
specific module.171 The module is used to describe aspects of CLL that are not included 
in the core questionnaire and provides information about several domains. There are 
three multi-item scales, i.e. fatigue, treatment side effects and disease symptoms, infec-
tions, and two single item scales on social activities and future health worries. However 
the module is not yet officially published, and the score on the scales cannot be calcu-
lated,172 the average score - ranging from 1 (not at all) to 4 (very much) - on the items can 
be described.
Modified version of the eQ-5d
The EQ-5D measures the general HRQoL and is therefore not influenced by CLL only. 
At the time of start of the study, a 5-level EQ-5D had been developed since the original 
3 level EQ-5D was not sensitive enough for smaller changes in HRQoL. Since patients 
with CLL in general experience a high level of HRQoL,36 at least until they reach the 
advanced stages, it was hypothesised that this expanded 5-level classification might 
provide a more sensitive measure of change in health status than the original 3 level 
EQ-5D (EQ-5D3). 
The modified version of the EQ-5D (EQ-5D5)168 comprised the same two items as the 
EQ-5D3: a visual analogue scale (VAS) providing a single overall summary score of HRQoL 
and descriptive classification with five dimensions (mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression). However, the descriptive classification of the EQ-
5D5 contained five levels, rather than the standard 3 levels. The two additional levels 
were unlabelled.168 It can be seen as the predecessor of the labeled 5-level version of the 
EQ-5D,173 which did not exist at the start of our study yet.
The responses on the descriptive classification can be translated to a utility score, 
which is a value that reflect an individual’s preference for a certain health outcome with 
zero reflecting states of health equivalent to death and one reflecting perfect health. 
Utility values for the EQ-5D5 states have never been determined, as this instrument has 
been replaced by a 5-level labelled version. We calculated utility values following the 
suggestion of the creator of the EQ-5D5.168 The known utility values for the levels 1, 2 and 
3 of the EQ-5D3 were used for the levels 1, 3 and 5 of the EQ-5D5 and the additional 2 levels 
were generated assuming the midpoint value between the standard 2 tariff values using 
an adaptation of the Dutch 3 level tariff.174 
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statistical analysis
The HRQoL of a CLL patient over time was calculated by connecting all measurements 
per patient using area under the curve analysis over the entire study duration. To enable 
the comparison of patients, we presented area under the curve values corrected for the 
follow-up duration per patient. For each patient, an individual norm score was derived 
from age- and gender-matched scores of the general population on the EQ-5D175 and 
EORTC QLQ-C30.176 Both studies used a panel consisting of more than 2000 Dutch 
households, representative of the Dutch-speaking non-institutionalised population in 
the Netherlands.175,176
Patient scores were compared with norm scores using t-test or nonparametric test 
for related samples (significant when p < 0.05). Patient scores of three patient groups 
(patients without any active treatment, patients treated with chlorambucil only, and 
other patients) were compared using the Kruskal Wallis test.
Subsequently, we chose to focus on the HRQoL during two treatment phases. First, we 
focused on the questionnaires completed during the watch and wait phase since data 
on this subject is scarce, and second on the questionnaires filled in during chlorambucil 
treatment because this was the most frequently administered treatment in our study. 
The results of both phases were described in a separate section and compared using 
Kruskal Wallis test or t-test depending on the variable distribution.
7.3 resuLTs
Patient characteristics
Informed consent for participation was given by 173 CLL patients. Of these patients, 13 
patients (6%) were excluded from the analysis for the following reasons: eight patients 
did not meet the inclusion criteria after all; one patient chart was missing; and one 
patient withdrew himself from the study. Additionally, one hospital dropped out of the 
study, leaving three patients with incomplete follow-up data. 
Of the 160 evaluable patients, 144 patients (90%) participated in the HRQoL study. For 
25 patients we did not have information during the complete follow-up duration of the 
study (see Figure 7.1). Table 7.1 presents patient characteristics of these 144 patients 
as a whole and per patient group: patients who did not receive any active treatment 
during the study period, patients who only received chlorambucil and patients with 
other or more treatments. It also presents the characteristics of the patients who did not 
participate in the HRQol part of the study. 
The mean age at diagnosis of all patients was 62.6 years (SD=10.5) of whom the 
majority were male (63%). On average, male patients were younger at diagnosis (60.8 
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years, SD=10.1) than female patients (65.5 year, SD=10.5). Age at diagnosis did not differ 
significantly between the patient groups. 
From diagnosis until the end of the HRQoL study, 85 patients received active treat-
ment (59%). Seventy-three patients started treatment before the start of the HRQoL 
study and 12 patients started their first line treatment during the study period. Eighty-
five percent of all patients who received active treatment, were treated initially with 
chlorambucil with or without prednisone. Other initial treatments were: chlorambucil-
vincristine-prednisone (CVP) (7%), fludarabine (2%), fludarabine-cyclophosphamide (FC, 
2%), rituximab plus CVP (R-CVP, 1%), cyclophosphamide (1%) and cyclophosphamide-
doxorubicin-teniposide-prednisone with bleomycin-vincristine + radiotherapy (1%). 
Fifty-three patients also received subsequent line(s) of treatment. Second line treatment 
was fludarabine monotherapy in most patients (23 patients, 43%). Other second line 
treatments were: CVP (17%), FC (8%), FCR (8%), R-CVP (8%), chlorambucil plus predni-
sone (6%), rituximab (4%), R-CHOP (4%), CVPP (2%) and fludarabine-rituximab (FR, 2%).
Patients were diagnosed for on average 3.9 years at the time of their first question-
naire. Their last questionnaire was on average completed 2.6 years later, at 6.5 years 
since diagnosis. The mean number of questionnaires was 5.7 per patient and 127 patients 
 
Enrolled in HRQoL study 
(n=144) 
 
Not willing to participate 
in HRQoL study 
(n=16) 
Enrolled in main study 
(n=160) 
Lost to follow-up (n=25):  
 Completing questionnaire was too exhausting (2),  
 Misunderstanding of research method by treating 
haematologist (1) 
 Deceased (22) 
  
  
 
Analysed (n=144): 
 Excluded from analysis (n=0)  
 
Figure 7.1 Patient flow chart.
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(88.2%) completed 3 or more questionnaires. For 25 patients we did not have informa-
tion during the complete follow-up duration of the study (see Figure 7.1).
Quality of life during total study
Table 7.2 summarizes the results on all instruments used for the total CLL population 
and for the three patient groups that were described before. 
Taken into account the total group of CLL patients, the score on both the EQ-5D and 
the VAS was lower than the norm score corrected for age and gender.175,176 This also ap-
plies for the subgroups of patients treated with chlorambucil only or with more /other 
Table 7.1. Patient characteristics
All 
participants 
(n=144)
Patients 
without 
any active 
treatment 
(n=59)
Patients 
treated with 
CLB only 
(n=28)
Other 
patients 
(n=57)
Non-
participants in 
HRQoL study 
(n=16)
Age at diagnosis: 
 Mean (SD)
 Median
 Range
62.6 (10.5)
63
30-86
64.1 (9.3)
64
34-82
63.6 (12.1)
66
30-86
60.5 (10.6)
61
38-85
71.0 (8.6)
69
56-84
Gender (% male) 62.5 59.3 50.0 71.9 62.5
Patients (%) with first or second 
degree relatives with leukaemia 
or lymphoma 
9.0 6.8 10.7 10.5 0.0
Binet Stage (%):
 A
 A progressive
 B
 C
70.8
2.1
16.0
11.1
94.9
0
1.7
3.4
67.9
0
21.4
10.7
47.4
5.3
28.1
19.3
81.2
6.3
12.5
B-symptoms (yes %) 12.5 5.1 10.7 21.1 13.3
Involvement of spleen (yes %) 27.8 10.2 42.9 38.6 26.7
Co-morbidities (yes %) 27.8 20.3 39.3 29.8 43.7
WHO-performance score (%):
 0
 1
 2
 n.a.
78.5
19.4
0
2.1
84.7
15.3
0
0
71.4
25.0
0
3.6
75.4
21.1
0
3.5
75.0
18.8
6.3
0
N.a.: not available; CLB: chlorambucil; HRQoL: health related quality of life; WHO: World Health Organiza-
tion.
Quality of life in CLL patients 123
Table 7.2. Average patient and norm scores on EQ-5D5, EORTC QLQ-C30 and EORTC QLQ-CLL16 (SD) of the 
total CLL population, and the three patient groups
Total group of CLL patients Patient groups 
Total group 
(n=144)
Age-and gender 
matched norm 
score 
Patients without 
any active 
treatment (n=59)
Patients with 
(watch & wait +) 
chlorambucil only 
(n=28)
Other patients 
(n=57)
eQ-5d5
Utility 0.85 (0.1)† 0.89 (0.0) 0.89 (0.1) 0.82 (0.2)* 0.85 (0.1)†
VAS 73.5 (12.9)‡ 83.1 (3.7) 77.6 (12.8)† 71.3 (12.0)‡ 70.3 (12.4)‡
eorTC-QLQ-C30 – functioning scales
Physical functioning 79.15 (18.1)‡ 87.18 (5.9) 83.95 (16.2) 75.89 (22.3)* 75.79 (17.8)‡
Role functioning 75.44 (22.9)‡ 86.57 (4.2) 81.99 (20.9) 71.30 (23.9)† 70.68 (24.8)‡
Emotional functioning 85.31 (15.3)‡ 89.89 (2.0) 87.29 (13.4) 77.52 (18.3)† 87.09 (16.3)
Cognitive functioning 84.98 (16.1)‡ 90.81 (2.9) 85.59 (16.3)* 76.50 (18.2)‡ 88.53 (16.6)
Social functioning 85.61 (18.3)‡ 93.44 (2.4) 90.60 (14.5) 82.76 (22.0)* 81.85 (21.5)‡
Global health 75.36 (13.8) 77.06 (2.7) 78.68 (13.1) 73.86 (14.7) 72.66 (14.8)*
eorTC-QLQ-C30 – symptoms
Fatigue 31. 17 (21.0)‡ 17.51 (3.8) 24.96 (21.4)† 36.48 (21.1)‡ 34.97 (20.6)‡
Nausea vomiting 3.77 (7.7) 2.50 (1.8) 2.31 (5.0) 5.96 (9.9) 4.20 (9.3)
Pain 15.06 (17.9) 17.26 (5.6) 14.48 (18.2) 19.58 (23.0) 13.45 (15.6)
Dyspnoea 18.15 (21.7)‡ 9.30 (3.1) 12.12 (17.9) 19.02 (21.4)* 23.96 (23.0)‡
Sleeping 22.07 (23.6)‡ 15.18 (4.9) 20.86 (25.0) 28.85 (20.9)† 20.00 (25.4)
Appetite loss 8.36 (15.8)‡ 3.48 (1.7) 3.94 (9.6) 16.92 (24.9)* 8.73 (13.9)†
Constipation 4.77 (10.5) 5.98 (2.9) 4.41 (9.6) 4.87 (9.9) 5.09 (12.3)
Diarrhoea 4.75 (9.8) 3.96 (0.9) 4.52 (11.2) 5.76 (11.3) 4.50 (7.1)
Financial difficulties 5.78 (13.8)* 3.33 (1.35) 4.77 (11.5) 5.38 (16.5) 7.03 (20.1)
eorTC-QLQ-CLL16
Weight loss 1.15 (0.5) n.a. 1.06 (0.4) 1.34 (0.6) 1.15 (0.6)
Dry mouth 1.38 (0.8) n.a. 1.35 (0.7) 1.61 (0.9) 1.31 (0.7)
Bruises 1.06 (0.5) n.a. 1.05 (0.4) 1.24 (0.7) 0.98 (0.4)
Uncomfortable stomach 1.27 (0.7) n.a. 1.24 (0.6) 1.49 (0.7) 1.20 (0.6)
Changes in temperature 1.14 (0.6) n.a. 1.03 (0.4) 1.30 (0.7) 1.17 (0.7)
Night sweats 1.55 (0.9) n.a. 1.42 (0.8) 1.76 (0.9) 1.58 (0.9)
Feeling sick or unwell 0.78 (0.5) n.a. 0.68 (0.4) 0.99 (0.7) 0.79 (0.5)
Feeling apathetic 1.41 (0.7) n.a. 1.30 (0.7) 1.71 (0.7) 1.37 (0.7)
Not enough energy 1.49 (0.8) n.a. 1.36 (0.7) 1.79 (0.8) 1.47 (0.8)
Planning activities 1.45 (0.8) n.a. 1.29 (0.7) 1.73 (0.9) 1.46 (0.8)
Future health concern 1.62 (0.8) n.a. 1.50 (0.8) 1.93 (1.0) 1.59 (0.9)
Respiratory infection 1.42 (0.8) n.a. 1.26 (0.5) 1.42 (0.7) 1.58 (0.9)
Other infection 1.26 (0.6) n.a. 1.19 (0.6) 1.25 (0.6) 1.33 (0.8)
Repeated use antibiotics 1.26 (0.7) n.a. 1.10 (0.5) 1.17 (0.5) 1.48 (0.9)
Worries for infection risk 1.32 (0.7) n.a. 1.10 (0.5) 1.47 (0.8) 1.48 (0.8)
Patient scores were based on an Area Under the Curve analysis. CLL: chronic lymphocytic leukaemia; n.a.: 
not available.
*P < 0.05, † p < 0.01, ‡ p < 0.001 for comparisons with age- and gender-matched norm scores
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treatments than chlorambucil. Patients who received no active treatment at all, scored 
lower on the VAS than the general population, but not on the utility score of the EQ-5D5. 
The patients’ mean score and the mean norm scores per EORTC QLQ-C30 item/scale are 
also shown in Table 7.2. It identifies the significant differences of p<0.05 from the norm 
score. Statistically significant differences are however, not always clinically meaningful. 
Meaningful differences (of more than 10 points171) between the norm score and patients’ 
score were observed for role functioning and fatigue in the total group of CLL patients. 
This was also applicable to the subgroups of patients treated with chlorambucil only or 
with more / other treatments than chlorambucil. Other differences were observed for 
emotional and cognitive functioning, appetite loss, and sleeping in patients who only 
received chlorambucil and for physical and social functioning, and dyspnoea in patients 
who received more or other treatments than chlorambucil. None of the significant differ-
ences for patients who did not receive any active treatment were clinically meaningful.
When looking at the total population of CLL patients that reported “a little”, “quite a 
bit”, or “very much” problems on the EORTC QLQ-CLL16 questionnaire, most patients 
reported problems on future health concern (62% of the questionnaires), feeling to have 
not enough energy (50%), and having night sweats (48%). For all patient groups, most 
problems were reported on future health concern and night sweats. The subgroup with 
patients who were treated with more or different therapies than chlorambucil also re-
ported many problems with respiratory infections and worries about getting infections. 
The subgroup with patients who only received chlorambucil had the highest (worst) 
total mean score over all items.
Figure 7.2 shows that on almost all single-items and scales, the group without any ac-
tive treatment (watch and wait approach only), scored best of all patient groups. Patients 
who were treated with chlorambucil only scored worse on HRQoL than patients who 
were treated with more or different treatments with regard to emotional functioning, 
cognitive functioning, bruises, uncomfortable stomach, and apathy (data not shown). 
Being currently treated or not did influence the HRQoL. The 41 patients who filled in 
questionnaires during treatment and before/after treatment had a significantly lower 
utility score during treatment (data not shown). This pattern was also observed in the 
total study sample as presented elsewhere when the data was analysed per treatment 
line.136
 In the total population of CLL patients, scores on the VAS and EQ-5D5 differed signifi-
cantly between the categories of WHO performance status and the presence/absence of 
co-morbidities (See Appendix 7.1). 
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Figure 7.2 Norm scores and patient scores on the EORTC QLQ-C30 and EQ-5D5.
Patient scores on the EORTC QLQ-C30 and EQ-5D5 are reported for the general population (norm score),175,176 
the total CLL group and for the three patient groups separately. The norm scores present the mean norm 
score of all CLL patients in our study. Patient scores were based on an Area Under the Curve analysis.
Upper figure: results of the functioning scales of the EORTC QLQ-C30 and the EQ-5D. The higher the score, 
the higher the quality of life (range 0-100). 
Lower figure: results of the symptom scales of the EORTC QLQ-C30. The higher the score, the lower the 
quality of life (range 0-100).
CLB: chlorambucil
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Quality of life during watch and wait phase and during treatment with 
chlorambucil vs. general population
HRQoL results during the watch and wait phase are based on all questionnaires com-
pleted before the start of active treatment. This covers not only patients who did not 
receive any active treatment at all, but also the patients who received a treatment after 
being in the watch and wait phase. During the watch and wait phase, HRQoL can be 
compromised due to the illness and its related insecurity as well as by other causes like 
comorbidities or life events. 
The HRQoL during treatment with chlorambucil covers only those questionnaires 
which were filled in during active treatment with chlorambucil.
Both patients in the watch and wait phase and those during treatment with chloram-
bucil scored lower on the VAS than the general population corrected for age and gender 
distribution (Table 7.3). The difference in utility was only significant for patients treated 
with chlorambucil (0.81 vs. 0.90). 
Supplemental Table 7.1 shows that scores on the EQ-5D5 were significantly different 
between the categories of gender, age at diagnosis, WHO performance status, and the 
presence/absence of co-morbidities for patients during the watch and wait phase. Dur-
ing treatment with chlorambucil, none of the collected patient characteristics influenced 
the score on the EQ-5D and VAS significantly (e.g. males vs. females). 
When comparing the individual patient scores on the EORTC QLQ-C30 with the indi-
vidual age and gender adjusted norms scores, the patients’ scores were meaningfully 
different from the norm score on emotional and role functioning and on sleeping and 
dyspnoea during treatment with chlorambucil. Differences were also found for physical, 
cognitive, and social functioning and sleeping scales but although statistically signifi-
cant, they were not clinically meaningful. In the watch and wait phase, differences from 
the norm score for cognitive, role and physical functioning, fatigue and sleeping were 
statistically significant, but not clinically meaningful. 
With regard to the items of EORTC QLQ-CLL16 module, patients in the watch and wait 
phase suffered most from worries about their future health (55% of the questionnaires), 
night sweats (44%), and having not enough energy (40%). Patients during treatment 
with chlorambucil suffered most from worries about their future health (78% of the 
questionnaires), having not enough energy (61%) and infection risk (56%).
With regard to the items of EORTC QLQ-CLL16 module, patients in the watch and wait 
phase suffered most from worries about their future health (55% of the questionnaires), 
night sweats (44%), and having not enough energy (40%). Patients during treatment 
with chlorambucil suffered most from worries about their future health (78% of the 
questionnaires), having not enough energy (61%) and infection risk (56%).
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Table 7.3. Average patient and norm scores on EQ-5D5 and EORTC QLQ-C30 (SD) during watch and wait 
phase and during treatment with chlorambucil
During 
watch & 
wait phase 
(n=71)
Norm 
score 
watch & 
wait phase
p-value During 
treatment 
with CLB 
(n=42)
Norm score 
during 
treatment with 
CLB 
p-value ***
eQ-5d5
Utility 0.88 (0.1) 0.89 (0.0) 0. 052 0.81 (0.2)** 0.90 (0.0) 0.003
VAS 77.4 (12.4) 82.8 (3.9) 0.000 69.1 (14.5)** 82.7 (3.7) 0.000
eorTC-QLQ-C30 – functioning 
scales
Physical functioning 83.2 (15.9) 86.8 (6.1) 0.030 79.0 (18.2) 86.2 (5.3) 0.011
Role functioning 79.8 (21.2) 86.3 (4.4) 0.009 73.3 (22.5) 85.5 (3.5) 0.001
Emotional functioning 86.6 (13.7) 89.7 (2.1) 0.055 78.0 (18.0)** 89.7 (2.1) 0.000
Cognitive functioning 85.2 (16.9) 90.9 (2.9) 0.038 82.6 (19.3) 90.2 (3.0) 0.011
Social functioning 89.9 (15.0) 93.3 (2.5) 0.051 83.5 (20.0)* 92.7 (2.2) 0.004
Global health 78.0 (13.6) 76.9 (2.8) 0.474 72.9 (15.4) 76.4 (2.1) 0.147
eorTC-QLQ-C30 – symptoms  
Fatigue 25.5 (20.5) 17.7 (4.0) 0.002 22.99 (17.8)* 18.6 (3.1) 0.000
Nausea vomiting 2.9 (5.9) 2.7 (1.9) 0.766 4.49 (15.6) 2.6 (1.8) 0.435
Pain 15.5 (17.6) 17.8 (5.9) 0.254 15.38 (18.3) 18.4 (4.9) 0.279
Dyspnoea 12.1 (18.6) 9.4 (3.2) 0.225 24.28 (26.1)** 9.6 (3.0) 0.001
Sleeping 21.6 (24.6) 15.6 (5.1) 0.032 26.75 (26.3) 16.1 (4.7) 0.012
Appetite loss 5.5 (12.4) 3.6 (1.7) 0.191 9.98 (21.9) 3.7 (1.6) 0.067
Constipation 4.3 (9.4) 6.2 (3.0) 0.085 3.48 (8.6) 6.5 (2.7) 0.025
Diarrhoea 4.4 (10.3) 3.9 (1.0) 0.720 3.62 (8.6) 4.2 (0.8) 0.686
Financial difficulties 5.6 (14.0) 3.4 (1.4) 0.195 5.00 (16.7) 3.5 (1.5) 0.561
eorTC-QLQ-CLL16
Weight loss 1.2 (0.3) n.a. 1.48 (0.3)* n.a.
Dry mouth 1.5 (0.7) n.a. 1.70 (0.7) n.a.
Bruises 1.1 (0.3) n.a. 1.20 (0.3) n.a.
Uncomfortable stomach 1.4 (0.5) n.a. 1.53 (0.6) n.a.
Changes in temperature 1.1 (0.3) n.a. 1.43 (0.3)** n.a.
Night sweats 1.7 (0.7) n.a. 1.95 (0.7) n.a.
Feeling sick or unwell 1.3 (0.4) n.a. 1.45 (0.4) n.a.
Feeling apathetic 1.5 (0.5) n.a. 1.79 (0.6)** n.a.
Not enough energy 1.5 (0.6) n.a. 1.88 (0.6)* n.a.
Planning activities 1.4 (0.6) n.a. 1.74 (0.6) n.a.
Future health concern 1.7 (0.7) n.a. 2.10 (0.7) n.a.
Respiratory infection 1.4 (0.5) n.a. 1.78 (0.5)* n.a.
Other infection 1.3 (0.5) n.a. 1.38 (0.5) n.a.
Repeated use antibiotics 1.3 (0.5) n.a. 1.40 (0.5) n.a.
Worries for infection risk 1.3 (0.4) n.a. 1.78 (0.4)** n.a.
Patient scores were based on an Area Under the Curve analysis. N.a.: not available.
* a significant difference between the watch and wait phase and treatment with chlorambucil (p-value <0.05) 
** a significant difference between the watch and wait phase and treatment with chlorambucil (p-value < 0.01)
*** A value in italics indicates a significant difference between the patient score and norm score (p value < 0.05)
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Quality of life during watch and wait phase versus during treatment with 
chlorambucil
Patient characteristics of the patients who completed questionnaires during the watch 
and wait phase were comparable with those of the patients who completed question-
naires during treatment with chlorambucil. Age at diagnosis was 68.7 vs. 67.2 years 
(p=0.426), WHO performance status was 0 in 83.1% vs. 82.9% of the patients (p=0.981) 
and co-morbidity was present in 26.8% vs. 37.2% of the patients (p=0.195) respectively. 
The HRQoL was significantly worse during treatment with chlorambucil than during 
the watch and wait phase for the following outcomes: utility, VAS, emotional function-
ing, social functioning, fatigue, dyspnoea, losing weight, changes in temperature, feel-
ing apathetic, lack of energy, respiratory infections, and risk of infections. 
Norm scores were available for the EQ-5D175,176 and the EORTC QLQ-C30.176 The mean 
difference between the patients’ score and the norm score for that patient was signifi-
cantly higher during treatment with chlorambucil than during the watch and wait phase 
for the following scales and items: emotional functioning (p=0.004), fatigue (p=0.021), 
dyspnoea (p=0.003), VAS (p=0.002) and utility (p=0.004). 
7.4 dIsCussIon
This longitudinal observational study showed that the HRQoL in CLL patients is com-
promised when compared with age- and gender-matched norm scores of the general 
population. Patients with CLL differed from the general population on the VAS and util-
ity score of the EQ-5D5, all functioning scales of the EORTC QLQ-C30, and the symptoms 
of fatigue, dyspnoea, sleeping, appetite loss, and financial difficulties.
The HRQoL in untreated CLL patients is already compromised with regard to physical, 
role and cognitive functioning, VAS score, fatigue and sleeping. During treatment with 
the most frequently administered therapy in our study (chlorambucil), patients also 
had dyspnoea and constipation and were compromised in their emotional and social 
functioning. Although, we are aware that treatment is initiated only when there is a 
treatment indication and clinical benefits are to be expected, we conclude that starting 
treatment will probably further reduce the already slightly compromised HRQoL during 
the watch and wait phase - at least temporarily. That applies to the relatively mild agent 
chlorambucil, and that decrease might be even bigger for the more effective, but also 
more intensive therapies that are (coming) available. The expected impact of starting 
treatment on HRQoL should therefore be considered in the decision whether to start 
treatment.
It is remarkable that the HRQoL is already compromised in untreated patients since 
in general treatment is started when the patients experience B-symptoms or disease 
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progression. None of the three previous studies that reported the HRQoL in CLL patients 
in a non-trial setting, reported the scale scores of HRQoL in untreated patients. We are 
therefore not able to compare our results in untreated patients with other studies. 
When looking at the total group of CLL patients, our results compare very well with 
those of Holzner et al.,37 who found a lower HRQoL in CLL patients compared with the 
age- and gender-matched healthy population on 8 of the 15 items/scales of the EORTC 
QLQ-C30 at baseline. We came to the same conclusion, but we found more statistically 
significant differences (10 of 15 items/scales) compared with the general population. 
However, our patient scores on the EORTC QLQ-C30 were better than those reported by 
Holzner et al.37 This is probably due to the lower age of the patients in our study, and the 
earlier disease stage at diagnosis. 
A recent article by Pashos et al.38 reported the baseline results of the HRQoL study 
using the Brief Fatigue Inventory, EQ-5D, and Functional Assessment of Cancer Therapy-
Leukemia. Our results on the EQ-5D5 are comparable to those reported by Pashos et al.38 
In the study by Shanafelt et al.,36 CLL patients scored worse than the general popula-
tion on the emotional scale of the FACT-G questionnaire only. Just like the results of 
the study by Shanafelt et al., we found a significant difference from the norm score on 
emotional functioning for the total group of CLL patients, but in contrary to their study, 
we found many other differences as well. 
Fatigue is one of the most frequently reported symptoms among patients with CLL. 
Our study showed that even untreated patients report significantly more symptoms of 
fatigue than the general population, and during or after treatment the symptoms were 
worse. It is a common symptom even many years after diagnosis. More attention should 
be given to this symptom during and after treatment, but also during the watch and 
wait phase. Interventions may help to reduce fatigue, but since the precise underlying 
pathophysiology is largely unknown,177 further studies are necessary.
Limitations of the study
Since new treatments tend to prolong the overall survival of CLL patients,139 the quality 
of life during and after treatment becomes more important. Although our study pro-
vides insight into the problems that patients with CLL are likely to have, the relatively 
small number of patients did not allow for comparisons between therapies. This would 
be very informative for clinicians, but to enable these comparisons in a real world set-
ting, many patients need to be enrolled, given the high number of available treatments. 
Due to a low incidence rate of CLL, this would require a long inclusion period, or an 
international approach. Changes in management of CLL over time makes it difficult to 
interpret results of a study with a long inclusion period and an international study also 
carries difficulties to the interpretation of the results. Fortunately, the HRQoL results of 
clinical trials can provide important information on this issue. 
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A second limitation of our study was that due to the observational character of the 
study, we were dependent on the health practitioners involved in the study for the 
timely administration of questionnaires, specifically the questionnaire at the start 
of a new treatment. Despite our efforts to remind them, they forgot to hand over the 
questionnaire to the patients before the start of the treatment in the majority of the 
patients who started a new treatment during our study period. We did not have suf-
ficient information about the HRQoL at the start of treatment to compare the HRQoL 
before and after treatment.
Another limitation is the uncertainty around the utility scores of the EQ-5D5 instru-
ment. To decrease this uncertainty, we also calculated the mean utility over the study 
period using two other methods to generate utility values. The first additional method 
used a predictive model which was developed in multiple myeloma and validated in 
non-Hodgkin lymphoma patients. The predicted values appeared to follow a similar pat-
tern to the observed EQ-5D values.178 The second additional method used the “crosswalk” 
obtained from an international study of the EuroQol group that administered both the 
3-level and 5-level versions of the EQ-5D (see their website: www.euroqol.org). 
The mean utility score of the midpoint estimation and the two additional methods 
for the total CLL group – based on only those questionnaires without missing values 
necessary to derive all three estimations- give the following utility scores: 0.854, 0.847, 
and 0.844. Since these three methods give quite similar results, we can conclude that 
our calculation is quite reliable. 
Since HRQoL is influenced by the WHO performance status and the presence of co-
morbidities, they are potential confounders in our study. We were not able to correct for 
these potential confounders due to the heterogeneity in treatment patterns resulting 
in too small patient groups to apply for example propensity score matching. These 
patient characteristics were, however, not statistically different for the patients with 
measurement during the watch and wait phase versus those with measurements during 
treatment with chlorambucil.
Generalisability
The patient characteristics in our study seem to be reasonably representative for the 
entire Dutch CLL population since the distribution of gender and the average age at di-
agnosis agree reasonably well with those of the national registration of CLL and indolent 
lymphomas (63% vs. 56% males and 63 vs. 66 years of age).179 The slightly lower mean 
age at diagnosis may be caused by the tendency of haematologists not to bother older 
patients with the study, or the higher refusal rate to participate by the older patients. 
The distribution of the disease stages, however, also corresponds with the published 
distribution in The Netherlands: Binet stage A: 71% vs. 60%, Binet stage B: 16% vs. 30%, 
and Binet stage C: 11% vs. 10%.21
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In contrast to most RCTs, we also included patients with severe co-morbidity. Co-
morbidity (severe heart failure, severe pulmonary disease, severe neurologic disease, 
severe metabolic disease, inadequate liver function, inadequate renal function, or other 
co-morbidity) was present in 28% of the patients. RCTs which aim to study the efficacy 
of treatments and their influence on HRQoL, often exclude these patients. The outcome 
of treatments in daily practice could therefore differ from the results found in the RCT. 
We showed that HRQoL is indeed negatively influenced by having co-morbidities and 
the WHO stage at diagnosis. In our study, the patient group “chlorambucil only” had 
the highest percentage of patients with co-morbidity. This may explain the relatively 
worse HRQoL of the patients in this group compared with the patients receiving other 
treatments. 
The percentage of patients with comorbidities was even higher in the group with non-
participants. They were also significantly older at diagnosis than participants. This might 
be related to their choice not to participate in the quality of life study. The percentage of 
patients willing to participate in the HRQoL study was, however, very high (90%) so that 
we do not expect that inclusion of these patients would significantly affect the results. 
Since the group of patients with co-morbidity is growing steadily due to an ageing 
population and an improved overall survival, future research should also focus on the ef-
fectiveness of treatments in these patients and the effect of treatments on their HRQoL.
Conclusion
We concluded that chronic lymphocytic leukaemia has a profound impact on HRQoL. The 
HRQoL in CLL patients is compromised when compared with age- and gender-matched 
norm scores of the general population. Patients with CLL differ most from the general 
population with regard to the level of role functioning, symptoms of fatigue, concerns 
about future health, and lacking energy. For patients in the watch and wait phase, the 
impact of their disease was limited, but larger than generally assumed. Especially with 
regard to symptoms of sleeping problems and fatigue more attention should be given 
to these patients. Once treatment was indicated, HRQoL became considerably compro-
mised. This applied to all treatments, including chlorambucil, which is considered to be 
a mild treatment. The impact of starting a treatment on the HRQoL should therefore be 
weighted in the decision whether to start therapy, especially since more effective, but 
also more intensive therapies are coming available.
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Appendix 7.1. Utility and VAS scores per category of the included patient characteristics
During Watch and wait 
phase (N=71)
During treatment with 
Chlorambucil (N=42)
Total group of patients 
(N=144)
Utility (SD) VAS (SD) Utility (SD) VAS (SD) Utility (SD) VAS (SD)
Total score 0.88 (0.13) 77.37 (12.4) 0.81 (19.3) 69.1 (14.5) 0.85 (0.14) 73.5 (12.9)
Gender (p-value) p=0.025 p=0.132 p=0.595 p=0.843 p=0.068 p=0.102
Male 0.91 (0.12) 79.26 (12.1) 0.79 (0.23) 69.5 (16.5) 0.88 (0.13) 75.1 (12.9)
Female 0.84 (0.14) 74.77 (12.4) 0.82 (0.13) 68.6 (12.3) 0.82 (0.14) 70.9 (12.7)
Ageclass (p-value) p=0.046 p=0.290 p=0.242 p=0.836 p=0.721 p=0.888
<59 0.91 78.76 (12.6) 0.83 (0.15) 71.2 (10.0) 0.88 (0.10) 74.1 (12.2)
60-69 0.91 (0.10) 79.66 (11.1) 0.78 (0.10) 67.5 (12.1) 0.86 (0.14) 73.7 (13.5)
>69 0.81 74.22 (13.0) 0.79 (0.29) 67.6 (20.2) 0.83 (0.17) 72.7 (13.4)
WHo status at 
diagnosis (p-value)
p=0.021 p=0.004 p=0.730 p=0.826 p=0.041 p=0.146
WHO 0 0.90 (0.12) 79.22 (11.4) 0.81 (0.20) 69.8 (15.8) 0.87 (0.13) 74.8 (12.8)
WHO 1 0.80 (0.17) 68.24 (13.5) 0.78 (0.17) 68.4 (16.4) 0.81 (0.15) 70.6 (11.9)
WHO not known - - 0.73 (0.24)* 59.5 (13.4)* 0.68 (0.19) 56.2 (13.7)
Binet stage at 
diagnosis (p-value)
p=0.259 p=0.742 p=0.795 p=0.789 p=0.375 p=0.265
Stage A 0.88 (0.13) 77.58 (12.5) 0.79 (0.23) 67.2 (17.6) 0.87 (0.14) 75.1 (13.2)
Stage A pr. - - 0.90 (n.a.)* 75.0 (n.a.)* 0.87 (0.06) 70.1 (15.1)
Stage B 1.00 (0.00)* 71.20 (10.4)* 0.81 (0.15) 72.0 (11.3) 0.82 (0.15) 68.1 (11.9)
Stage C 0.86 (0.20)* 76.23 (15.0)* 0.84 (0.06) 69.5 (2.5) 0.85 (0.10) 72.4 (10.7)
B-symptoms at 
diagnosis (p-value)
p=0.551 p=0.543 p=0.302 p=0.333 p=0.447 p=0.276
No 0.88 (0.13) 77.18 (12.2) 0.79 (0.21) 68.1 (15.2) 0.86 (0.14) 73.9 (12.8)
Yes 0.93 (0.11) 81.67 (18.6) 0.87 (0.08) 74.0 (9.7) 0.84 (0.12) 71.0 (13.5)
Involvement 
spleen (p-value)
p=0.391 p=0.551 p=0.070 p=0.495 p=0.876 p=0.068
No 0.88 (0.14) 77.72 (12.9) 0.74 (0.26) 67.0 (17.4) 0.86 (0.15) 74.9 (13.0)
Yes 0.92 (0.08) 75.18 (8.7) 0.86 (0.08) 70.1 (10.5) 0.85 (0.11) 69.6 (11.8)
Unknown - - 0.90 (n.a.)* 91.6 (n.a.)* 0.89 (n.a.)* 90.8 (n.a.)*
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Appendix 7.1. Utility and VAS scores per category of the included patient characteristics (continued)
During Watch and wait 
phase (N=71)
During treatment with 
Chlorambucil (N=42)
Total group of patients 
(N=144)
Utility (SD) VAS (SD) Utility (SD) VAS (SD) Utility (SD) VAS (SD)
Total score 0.88 (0.13) 77.37 (12.4) 0.81 (19.3) 69.1 (14.5) 0.85 (0.14) 73.5 (12.9)
Involvement bone 
marrow (p-value)
p=0.320 p=0.357 p=0.371 p=0.741 p=0.148 p=0.322
No 0.85 (0.15) 79.88 (12.5) 0.65 (0.44) 65.3 (29.2) 0.82 (0.18) 76.8 (14.2)
Yes 0.89 (0.13) 76.61 (12.3) 0.85 (0.11) 69.5 (8.6) 0.88 (0.11) 73.9 (11.7)
Unknown 0.89 (0.10) 76.38 (13.2) 0.79 (0.16) 70.1 (15.8) 0.81 (0.16) 69.2 (15.5)
Co-morbidities 
(p-value)
p=0.028 p=0.041 p=0.702 p=0.719 p=0.024 p=0.026
No 0.90 (0.11) 79.18 (12.1) 0.81 (0.14) 69.7 (11.2) 0.88 (0.12) 74.8 (13.2)
Yes 0.81 (0.17) 72.41 (12.0) 0.79 (0.27) 68.0 (19.3) 0.81 (0.17) 70.3 (11.6)
education after 16 
years (p-value)
p=0.069 p=0.807 p=0.197 p=0.143 p=0.077 p=0.031
No 0.82 (0.19) 76.67 (12.1) 0.76 (0.26) 65.03 (17.9) 0.81 (0.18) 69.29 (13.8)
Yes 0.90 (0.11) 77.57 (12.7) 0.84 (0.12) 71.70 (11.5) 0.87 (0.12) 74.79 (12.5)
N.A. 0.93 (0.04) 77.26 (12.4) 0.92 (0.04) 77.92 (11.0)
smoking status at 
diagnosis (p-value)
p=0.482 p=0.423 p=0.494 p=0.885 p=0.305 p=0.434
Current smoker 0.91 (0.13) 79.37 (14.0) 0.82 (0.07) 69.59 (12.2) 0.89 (0.14) 75.99 (11.8)
Ex smoker 0.89 (0.12) 78.65 (12.2) 0.75 (0.26) 68.63 (17.3) 0.85 (0.14) 73.62 (13.7)
Non smoker 0.85 (0.15) 74.96 (12.4) 0.86 (0.10) 69.44 (11.1) 0.85 (0.14) 72.03 (12.7)
N.A. 0.92 (0.03) 75.86 (10.5) 0.93 (0.04) 76.44 (9.45)
* Less than 3 patients within the subgroup. P-values indicate statistical significance between the categories 
of the patient characteristics (e.g. between age classes). WHO: World Health Organization
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8.1 BACKGround
Health care innovations can be used to respond to the challenge presented by the 
growing demand for health care. Such innovations can contribute to making health care 
more convenient, more effective and to reducing costs. This would make more health 
care available with the same resources and thus continuing to be accessible to everyone.
Three types of health care innovations can be defined.3 The first are changes to the 
way consumers purchase and use health care. The second uses technology to develop 
new products and treatments to improve health care. The third generates new business 
models, such as integration of health care organisations.
This thesis compares the cost implications and consequences of two health care inno-
vations, using different types of economic evaluation and different data sources in two 
diseases. The first innovation is an example of a new business model in glaucoma care, 
in which some tasks undertaken by glaucoma specialists are carried out by optometrists 
and ophthalmic technicians. The second innovation is a new treatment option (technol-
ogy) for chronic lymphocytic leukaemia (CLL): fludarabine.
8.2 GLAuCoMA
Currently, glaucoma is mainly managed by glaucoma specialists. The sustainability of 
this practice is questionable because the rapidly growing demand for glaucoma care 
cannot be met by the current number of glaucoma specialists (in training). In a subgroup 
of patients (those deemed stable and those at risk of developing glaucoma), glaucoma 
care could well be provided by optometrists or ophthalmic technicians. 
In this subgroup of patients, care by glaucoma specialists was compared with the care 
by a Glaucoma Follow-up Unit (GFU) in the Rotterdam Eye Hospital (REH) that is staffed 
by ophthalmic technicians and optometrists. The proposition was that task substitution 
would be a solution to the increasing workload of ophthalmologists and long waiting 
lists for ophthalmic care, would result in the same quality of care and would reduce 
costs.
The GFU staff adhered to their work protocol for almost all patients, patient sat-
isfaction in both treatment groups was comparable and the difference in intraocular 
pressure (IOP) over time did not differ statistically between the two treatment groups. 
The average time spent per patient per year, and the increased number of patients and 
patient visits confirmed our hypothesis that the GFU reduced the waiting list (Chapter 2). 
Health care costs were about 10% lower for the GFU group compared to the usual 
care group (Chapter 3). The bootstrap analysis showed that the equivalence of the two 
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groups on quality of care is justified and that the GFU is cost saving from a societal 
perspective in 84% to 89% of the bootstrap replications.
However, despite the evidence indicating that (primary care) optometrists can provide 
high-quality care, this health care innovation could not be transferred to primary care 
optometrists in the Rotterdam area in the period 2004 to 2011 (see Chapter 4). Imple-
mentation was the stumbling block, because glaucoma specialists disagreed with the 
primary optometrists about professional boundaries and work domains. They disagreed 
on the capabilities of primary care optometrists, and the assumed returns on investment 
were unclear. Power positions favoured the status quo, because the establishment of the 
GFU in the hospital sufficiently relieved the workload of glaucoma specialists. This situ-
ation might have been different if the primary care optometrists had been involved in 
the first step of the task substitution, the establishment of the GFU. Then all stakeholders 
could have seen the second step (transfer to the primary care setting) as a progressive 
step in the professionalisation of the primary care optometrists.
8.3 CHronIC LyMPHoCyTIC LeuKAeMIA 
Management of chronic lymphocytic leukaemia (CLL) has changed in the last few 
decades. At the start of our study in 2003, multiple studies showed that fludarabine 
mono-therapy, which was given market authorisation in the European Union in 1994, 
was more effective than chlorambucil.180,181 However, there were still no studies on its 
cost-effectiveness in daily clinical practice. 
The observational study in patients with CLL showed little treatment variation in 
the first treatment line, but variation increased exponentially with the second and 
later treatment lines. The cost of CLL varied greatly over the course of the disease and 
per treatment type. Although patients were treated with expensive chemo(immuno-)
therapy, costs were mainly driven by hospital admissions and hospital visits in most 
treatment choices. Chemo(immuno-)therapy was the main cost driver during treatment 
lines of ‘rituximab’, ‘therapy for a (Richter’s) transformation’, ’induction therapy preceding 
allogeneic stem cell transplantation’ and ‘fludarabine plus cyclophosphamide and ritux-
imab’. The cost of CLL may be expected to rise further as more patients receive expensive 
treatments, which will also increase the proportion of therapy costs of the total costs. 
Although the two- and five-year overall survival was good (100% and 89%, respective-
ly), CLL had a profound impact on health related quality of life (HRQoL) of the patients. 
The HRQoL in CLL patients was compromised compared to age- and gender-matched 
norm scores of the general population. For patients in the watch and wait phase, the 
impact of their disease was limited, but larger than generally assumed. Once treatment 
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was indicated, HRQoL was considerably compromised. This applied to all treatments, 
including chlorambucil, which is considered to be a mild treatment. 
8.4 oVerALL ToPICs
difficulties in implementing innovations in health care
In health technology assessment (HTA), economic evaluation is used to provide informa-
tion about the relative cost-effectiveness of a health care innovation compared to usual 
care or another relevant alternative. Although a favourable outcome may be sufficient to 
obtain or maintain reimbursement, it does not necessarily mean successful implementa-
tion and uptake in daily practice.
As shown in Chapter 4, implementation of the hospital-based GFU, an effective and 
cost saving innovation, was not feasible in a primary care setting. Glaucoma special-
ists were unwilling to refer stable glaucoma patients to primary care optometrists, yet 
the intermediate step to transfer the monitoring task in the hospital was a workable 
compromise that sufficiently relieved their workload.
In case of the introduction of a new drug, the implementation process may appear 
easier, but in practice, it often takes a long time before effective medications are used as 
frequently as expected based on the results of the clinical trials.182,183
The question is why implementation of health care innovations is so difficult. The first 
reason can be found in the differences in the agendas of stakeholders involved. Even an 
innovation that has been proven to be effective and efficient is only quickly adopted 
when the majority of the powerful stakeholders benefit from its implementation. These 
benefits may be financially, but also benefits in terms of technical advances, status or 
ease can facilitate the implementation. 
The chance of successful implementation may be affected by the payment scheme to 
health care practitioners. In the case of the shared glaucoma care, glaucoma specialists 
were paid a fixed amount per glaucoma patient. Thus, there was no incentive to refer 
stable and ‘easy’ patients to other health care professionals, because they would be left 
to treat the more severe patients while not receiving more payment to do so. However, 
primary care optometrists welcomed glaucoma patients, because monitoring these 
patients was expected to generate additional income. The fact that no reimbursement 
protocol for monitoring stable glaucoma patients (in a primary care setting) was in place 
led some primary care optometrists to doubt the feasibility and financial benefits of 
shared glaucoma care. These reservations by glaucoma specialists and some optom-
etrists hampered implementation of shared glaucoma care in the primary care setting. 
In line with this, the insurer responsible for purchasing most of the health care did not 
always see the link between reduction in labour costs and the additional cost of the new 
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care. This is more obvious in preventive care, because the health gains and possible cost 
reduction occur later than the investment in the innovation. 
Furthermore, patients are generally committed to the opinion of their treating 
physician, which empowers the physician as a stakeholder in a health care innovation. 
Often, patients have limited information about the relevant and best alternatives from 
sources other than their own physician. In the last decade, health care insurers have en-
deavoured to become an independent information source, but as yet are little used by 
patients for this purpose. The success of an innovation relies on the health care provider 
and innovations need to appeal to physicians, who are in a position to recommend care 
products to their patients.
In addition to recommending new care to their patients, physicians must be con-
vinced that the new care does not threaten their power position. Thus, a key factor in 
implementing new care is structured and long-term dialogue between physicians and 
the party that threaten their power position because fear for the unknown is the great-
est of all fears.184 
There is also a limited time frame for implementation. If adoption of an innovation 
starts too early, the supporting infrastructure may not yet be in place, while starting 
late reduces the competitive advantage. Equivalent or even better alternatives may be 
developed in the meantime, or the sense of urgency for change has disappeared.
The value of mixed method research in HTA
As stated above, users of a health care innovation need to be convinced of the value. 
An economic evaluation can contribute to convincing them of the effectiveness and 
cost-effectiveness of the health care innovation. 
Most economic evaluations are conducted for pharmaceuticals because a require-
ment for a significant part of the new pharmaceutical products is to demonstrate its 
cost-effectiveness to obtain and/or maintain reimbursement. In these evaluations, the 
relationship between the administration of a medicine in a trial setting and its effect on 
the outcome measures is in general quite clear. The evaluations and the interpretation 
of the results are thus rather straightforward.
As described in Chapters 5 to 7, calculation of the cost-effectiveness of a new treat-
ment option is more problematic in a real world setting, especially for a disease with 
large treatment variation and rapidly changing management strategies, such as CLL. 
Disease management changes with the introduction of each new treatment option. 
Existing treatments are prescribed for fewer or other patients, also affecting the effec-
tiveness and marginal cost-effectiveness of that treatment option. This dynamic process 
impedes calculation of the cost-effectiveness, and may make the results of a multi-year 
observational study out dated before the analysis is performed. However, it can provide 
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information about trends in management of a disease in clinical practice and budget 
impact.
CLL patients often receive multiple treatment lines, the outcome of which is influenced 
by the outcome of the preceding therapies. Consequently, treatment history has to be 
taken into account in comparing alternative strategies per treatment line. This requires 
large numbers of patients. Comparing alternative therapies in observational studies is 
challenging in CLL, which has a relatively low incidence. A solution might be long-term 
continuous registration or development of a disease model. 
Interpretation of the results of an economic evaluation is even more difficult if the 
effects of a health care innovation cannot be seen directly. The results may be partially 
influenced by contextual factors, such as stakeholder interest,104-107 power positions,108,109 
and the structure of the health care system, including its financing,110 as discussed in the 
organisational intervention (see Chapters 2 to 4). 
Quantitative measurement of these factors is difficult. Real insight into the cost-effec-
tiveness of a health care programme, organisational change or implementation method 
can be obtained only by supplementing the economic evaluation with a qualitative 
study of these less tangible factors, using a mixed methods approach.
As shown in Chapter 4, although the quality of care of an innovation (for instance, a 
hospital-based GFU) was equal to that of the usual care and provided a cost saving from 
a societal perspective in 84% to 89% of the bootstrap replications, the glaucoma special-
ists were not willing to refer patients to a GFU-like construction in primary care. They 
argued that the capabilities of primary care optometrists were insufficient. The primary 
care optometrists disagreed, and believed they were capable – in some cases after a 
short period of training – of monitoring these stable glaucoma patients. The return on 
investment for the primary care optometrists and the REH were unclear and reluctant 
key stakeholders with strong power positions blocked implementation. In addition, the 
glaucoma specialists’ sense of urgency for task substitution outside the hospital dimin-
ished after a hospital-based GFU was established that satisfied their professionalisation 
needs. The window of opportunity for task substitution in person and setting in 1999 
closed with the institutionalisation of the GFU.
The combination of qualitative research and a quantitative economic evaluation yields 
valuable information (see Chapter 4). The question is whether this is a coincidence, or 
whether this benefit can be expected in many HTA analyses. To answer this question, the 
potential value of qualitative research in the observational study described in Chapters 
5 to 7 was explored.
In an observational study, a qualitative approach might contribute to identifying pos-
sible confounding by indication, which occurs frequently in observational studies (see 
Section 8.4.3). By asking physicians to explain treatment choices made in the recent past, 
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insight can be obtained in the presence of confounding by indication, and more easily 
taken into account in the analysis. 
Interviews may also reveal the role of high treatment costs, or other potential prescrip-
tion barriers in treatment decisions. The combination of quantitative and qualitative 
research methods has already been shown to be valuable in oncology.185
Furthermore, qualitative research can give insight into the difference between the 
expected and observed place of the new treatment for a specific group of patients, 
when carried out at the start of the observational study. The latter happens regularly in 
modelling HTA studies in the form of an expert panel.
The value of qualitative research in addition to the economic evaluation depends on 
the situation and is influenced by the data source for the economic evaluation. 
The values and pitfalls of observational research
An economic evaluation can be based on different types of data sources. It can be 
performed alongside a (randomised) clinical trial, or based on observational data (real 
world practice). The third option is to use published data on clinical trials or observa-
tional studies. 
An economic evaluation piggy-backed on a randomised clinical trial was considered 
to be the preferred method because randomisation ensures a good internal validity. 
Randomisation spreads patients evenly over the treatments when sufficient patients 
are included, and when patients are treated precisely according treatment protocol. 
However, this method has some drawbacks. Firstly, a randomised controlled trial often 
compares the new treatment with only one relevant alternative. Secondly, a trial does 
not always provide all information required for a complete economic evaluation. Thirdly, 
often a trial protocol does not reflect the treatment in daily clinical practice, which leads 
to a limited external validity. 
Due to the lack of strict inclusion and exclusion criteria in clinical practice, more and/
or other patients are treated with the new treatment than in a clinical trial. Furthermore, 
the dose, treatment duration, and follow-up intensity can differ considerably from that 
of the trial protocol. For these reasons, the treatment effect and costs and thus also the 
cost-effectiveness of the new treatment in daily practice can differ considerably from its 
cost-effectiveness in the trial. 
Use of observational data overcomes the problem of limited external validity, because 
it can provide an indication of differences in management patterns and clinical effec-
tiveness between patients in clinical trials and those in clinical practice. This is essential 
information in calculating marginal cost-effectiveness which reflects results in clinical 
practice. Moreover, information about management in daily clinical practice can be 
used by medical practitioners to reflect on their own treatment choices. 
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However, observational data also have methodological challenges. The first chal-
lenge that impedes comparison of treatments in clinical practice is the variation with 
regard to the type of treatment, dose, treatment duration and sequence of subsequent 
treatments. This variation is useful because it enables comparison of the new treatment 
with several alternatives, as an extensive economic evaluation aims to do. However, this 
requires a large number of participating patients, which is not always feasible, as shown 
in Chapter 5.
The second methodological challenge is the correlation between aspects that affect 
the choice of treatment (patient characteristics such as age, disease symptoms, physical 
condition, and patient preferences regarding route of administration) and the expected 
treatment effect. This correlation, also referred to as confounding by indication, might 
lead to an uneven spread of patients over the treatments.
Confounding by indication can be identified using qualitative research and corrected 
for using statistical methods such as multivariable regression modelling, propensity 
score matching, and data synthesis. Multivariable regression models require information 
on patient and disease characteristics such as disease classification that is not always 
available in a retrospective observational study. Propensity score matching requires 
larger numbers of patients, because all subgroups distinguished need sufficient patients. 
The extent to which this correction can be made depends on the heterogeneity of the 
study population with regard to treatment variation and sequence, the natural course 
of disease and the number of patients. This method is less attractive for comparison of 
multiple treatment options.
When statistical methods to correct for confounders cannot be applied, the solution 
might be data synthesis to model incremental outcomes, combining efficacy data from 
a randomised clinical trial and effectiveness data from daily clinical practice might be 
a solution. Development of the model requires data from reliable studies in a relevant 
group of patients to provide reliable outcomes. However, availability of these data 
can be problematic for several reasons. A first reason is publication bias. Studies with 
disappointing results have less chance of being published, and this can lead to a biased 
picture. A second reason is that when the model is to provide information about the 
cost-effectiveness of a new treatment in daily clinical practice, the input parameters 
should also be based on observational studies or patient registrations. These sources 
are subject to the same problems as described above.185
The role of economic evaluation in clinical guidelines for Chronic Lymphocytic 
Leukaemia
Recommendations on CLL diagnosis and treatment in the Netherlands by the Dutch-
Belgian Cooperative Group for Haemato Oncology for Adults (HOVON) are based on the 
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recommendations of the International Workshop on Chronic Lymphocytic Leukemia 
(IWCLL) for the management of CLL in clinical trials and general practice in 2008.186
Many new treatment options for CLL, such as idelalisib, ofatumumab and ibrutinib, 
have become available in the last few decades, which are in general more expensive 
than the older treatments. However, the role of economic considerations is currently 
not explicit in the CLL guidelines. The development of innovative but expensive treat-
ment options will probably continue in the near future. As is common in oncology, these 
expensive drugs are often combined putting further pressure to incorporate economic 
considerations in the clinical CLL guidelines. Whether this is necessary, depends on the 
structure and main cost drivers in the CLL treatment. 
In the period 1999 to 2008, the cost of CLL was mainly driven by the cost of outpatient 
visits and hospital admissions (see Chapter 6). The cost of hospital admissions could be 
reduced if treatments become available that do not require hospitalisation and/or result 
in fewer adverse events related to treatment. 
In treatment lines with some newer combination regimens, the cost of chemo(immuno)-
therapy has been the main cost driver. Since currently more CLL patients receive these 
treatment options, the proportion of therapy costs of the total costs will increase. The 
proportion of treatment costs will further increase with the development of other new 
treatment modalities that improve overall survival compared with a wait and see ap-
proach. Thus, it might become inevitable to reflect on the marginal cost-effectiveness in 
addition to the clinical effectiveness of treatment options.
The Dutch Government seems to have difficulties in denying reimbursement of very 
expensive treatments, such as aglicosidase alfa for Pompe’s disease and agalsidase alfa 
or agalsidase bèta for Fabry’s disease.187 In these cases, the medical profession could play 
a role in the decision making process by incorporating considerations on the economic 
consequences of treatment choices when updating clinical guidelines. HTA analysis as 
part of this reflection is challenging when disease management is continually changed 
by successive introduction of new treatment options. The marginal cost-effectiveness 
is difficult to calculate because the most appropriate comparator is changing rapidly. 
Results of an observational study over multiple years are likely to be out dated by the 
time the analysis is performed.
The update of the CLL guideline should give attention to the following considerations 
with regard to the HRQoL. Based on the findings set out in Chapter 7, more attention 
needs to be given to sleep problems and fatigue since this affects all CLL patients, 
including treatment naïve patients when compared to the general population of the 
same age. 
Furthermore, the study showed that HRQoL is significantly reduced after the start of 
treatment compared to treatment naive CLL patients, also for the relatively mild treat-
ment with chlorambucil. It should be stressed that the negative impact of starting a 
General discussion 145
treatment on patient HRQoL should be weighted in the decision when to start therapy, 
especially as more effective but also more intensive therapies are coming available.
8.5 LIMITATIons And suGGesTIons For FurTHer reseArCH
The main limitation of the economic evaluation alongside the RCT in shared glaucoma 
care is the relatively short period of follow-up, which was up to 44 months. The progres-
sion rate of glaucoma depends on the intraocular pressure and the time to vision loss 
varies between 3 years for untreated patients with a high intraocular pressure to 38 years 
for well-treated patients.77,97 For this reason, we could not use glaucomatous progres-
sion as an appropriate outcome measure. Our alternative outcome measure, the mean 
difference in intraocular pressure over the study period, did not differ between the usual 
care group and GFU group. Further research into the effect of shared on glaucomatous 
progression would be valuable, because the safety of a shared care scheme should be 
equal to the care by glaucoma specialists on this measure as well.
A second limitation is the study design for the GFU group with every third visit to the 
glaucoma specialist. This study design was chosen for clinical reasons, but may have 
introduced bias with regard to patient satisfaction. Patients might have been satisfied 
with the GFU because they knew that they would visit a glaucoma specialist after two 
visits to the GFU. Moreover, the GFU had more time available for each patient, which 
might have contributed to the higher satisfaction.76 Whether this bias affects patient 
satisfaction should be subject of further research. 
The main limitation of the study in CLL patients was data collection on resource use 
and effectiveness based on retrospective chart review. Although this method provided 
detailed information about the treatment type, dose, duration and sequence, the reason 
for the choice of one treatment over another was not clear. Moreover, the difference 
between partial and complete response could not be traced in a significant number of 
the patients (Chapter 5).
A second limitation of this study was the dependency on the health practitioners for 
the timely administration of questionnaires, specifically the questionnaire at the start of 
a new treatment. Despite our efforts to remind the health practitioners, patients often 
did not receive the questionnaire before the start of the treatment. Thus, HRQoL before 
and after treatment could not be effectively compared. 
HRQoL was shown to be negatively influenced by having co-morbidities and a high 
WHO stage at diagnosis. In our study, the treatment group ‘chlorambucil only’ had the 
highest percentage of patients with co-morbidity. This may explain the relatively lower 
HRQoL of patients in this group compared with the patients receiving other treatments. 
Since the patient group with co-morbidities is increasing steadily due to an ageing 
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population and an improved overall survival, future research needs to focus on the ef-
fectiveness of treatments in these patients and the effect of treatments on their HRQoL.
A third limitation is the limited follow-up duration of the observational study. Obser-
vational studies optimally reflect the situation in clinical practice when patients are fol-
lowed from diagnosis until cure or death. In the case of an incurable disease with a long 
overall survival for all or a proportion of patients (such as CLL), it is both expensive and 
time consuming to collect these data. In the CLL study, complete data were collected for 
39 patients (24%) who died during the study period. The CLL-related costs for survivors 
could not be estimated easily because the costs per treatment line varied enormously.
This challenge and the difficulties in comparing treatments may be solved using in-
formation from the observational study on the management, treatment cost and treat-
ment effects in clinical practice as input to a mathematical model, when other relevant 
sources of information are available. 
8.6 Lessons LeArned 
First and foremost, a HTA is very challenging in a real world setting in which the disease 
management strategy is rapidly changing because of the introduction of new treat-
ment options. In such a dynamic process, the most appropriate comparator is changing 
rapidly. This impedes calculation of the marginal cost-effectiveness because the new 
treatment option has to be compared with multiple (older and newer) treatments to 
ensure the results are not outdated. This will often result in an insufficient number of 
comparable patients per treatment option. 
Secondly, mixed methods research appeared to be valuable in the glaucoma 
study. Chances of implementation of an organisational innovation and thus the cost-
effectiveness and budget impact on a macro level are partially influenced by contextual 
factors, such as local stakeholder interests, and the structure of the healthcare system. 
This makes it worthwhile to broaden the scope of evaluation to include these contexts 
in the analysis. 
The first lesson from this study is that policy makers considering substituting tasks 
to lesser trained professionals and transferring services from a hospital to a primary 
care setting need to consider carefully the implementation process, especially when 
deciding to implement task substitution in separate steps. An intermediate step might 
diminish the sense of urgency for task substitution if it satisfies the professionalisation 
needs of the professionals involved. Recognising a restricted window of opportunity in 
the implementation of task substitution is thus critical.
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The second lesson from this mixed methods study is that it is crucial to involve the 
substituting professionals early to ensure that all stakeholders see the change as a 
normal step in the professionalisation of the substituting professionals.
Third, the combination of methods is also expected to be valuable in the HTA of drugs. 
Like the implementation of an organisational innovation, the uptake of a new drug de-
pends on contextual factors, such as the criteria for reimbursement, the division of the 
hospital budget for expensive drugs over all departments, the opinion of the treating 
specialist and patient preferences. The addition of qualitative research methods to an 
HTA analysis to reveal the influence of stakeholder interests, power positions and the 
financial structure of the health care system might result in a more accurate calculation 
of the marginal cost-effectiveness of a new medicine.
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suMMAry 
This thesis addresses the costs and effects of health innovations in two diseases: glau-
coma and chronic lymphatic leukaemia. 
Glaucoma is a group of eye conditions characterised by damage to the optic nerve, 
which may lead to blank spots in the patient’s peripheral (side) vision and eventually 
lead to blindness if left untreated. Increased intraocular pressure is an important risk fac-
tor for the development of glaucoma. Glaucoma treatment aims to lower the intraocular 
pressure. This can be achieved by medication (eye drops), laser treatment or surgery. 
When the treatment in patients with glaucoma has been effective, and the progression 
of the disease has come to a halt, patients are considered to be “stable glaucoma pa-
tients”. These patients and those with a risk factor for developing glaucoma are currently 
treated by glaucoma specialists, although lower educated staff such as optometrists or 
ophthalmic technicians are also capable of monitoring these patients. 
Because of the high workload of the glaucoma specialists, the Rotterdam Eye Hospital 
(REH) attempted to refer stable glaucoma patients and patients with a risk factor for 
developing glaucoma to community optometrists for some of their regular glaucoma 
follow-up visits. It turned out that this attempt was not successful, because it took more 
time and effort of the glaucoma specialists to convince patients to visit the primary op-
tometrist, and not all glaucoma specialists were willing to do that. The REH then decided 
to set up a Glaucoma Follow-up Unit (GFU) within the hospital staffed by an optometrist 
and ophthalmic technicians. Care provided by the GFU has been compared with the care 
as usual by glaucoma specialists and residents in a randomised controlled trial. 
In the GFU group, every patient visited the GFU twice, followed by a visit to a glaucoma 
specialist. If necessary, the patient was seen by a glaucoma specialist earlier. Medical 
resource use and clinical outcomes were reported for the 815 participating patients 
with glaucoma or a risk factor for developing glaucoma. After every visit to the REH, the 
patients completed a questionnaire about their satisfaction with the received care, time 
and travelling costs of themselves and their accompaniment (if applicable). 
Chapter two describes the quality of care delivered by the GFU and glaucoma special-
ists. GFU employees closely followed the working protocol regarding the measurement 
of intraocular pressure, visual acuity and GDx images. They performed fewer Humphrey 
Field Analyser assessments than prescribed by the protocol, but more than in the Usual 
Care group. Only in a small minority of patients requiring back-referral was the protocol 
disregarded, notably when criteria were only slightly exceeded. The clinical effective-
ness, measured as the change in intraocular pressure over time, was equal for the two 
treatment groups and the overall mark for the GFU was slightly higher than that of the 
152 Chapter 9
glaucoma specialists. The GFU functioned well, patients were satisfied and no differ-
ences in clinical effectiveness could be observed.
Chapter three compared the costs of the GFU group with those of the Usual Care 
group. The GFU was about 10% less expensive than usual care for 3 of the 4 perspectives 
used: the REH, the health care system, and societal perspective. Patient costs did not 
differ between the two patient groups. Bootstrap analysis showed that the overall mark 
given by the patient, as well as the percentage of ‘stable’ patients was equal and that the 
GFU was cost saving in 84 to 89% of the bootstrap replications. Scenario- and sensitivity 
analyses confirmed that the results were robust. Only in unlikely situation that the dura-
tion of a visit to the GFU would have been underestimated ánd the duration of a visit 
to a glaucoma specialist would have been overestimated, was the GFU not cost saving 
any longer. 
After having obtained the results of the randomised clinical trial, all glaucoma special-
ists working in the REH as well as the GFU employees and the responsible hospital man-
agers were interviewed to reassess the feasibility to transfer stable glaucoma patients 
to community optometrists. We also interviewed a sample of other stakeholders such 
as patients, community optometrists, the Dutch Healthcare Authority and healthcare 
insurers using semi-structured interviews. Chapter four describes the results of this 
case study using three implementation related theoretical perspectives: sociological 
theory of professionalism, management theory and applied political analysis. At that 
moment, task substitution by community optometrists turned out to be impossible, 
because of the following reasons: the establishment of the hospital-based GFU dimin-
ished the originally felt sense of urgency for task substitution; the returns on invest-
ments were unclear; and the glaucoma specialists and GFU employees did not expect 
that the task substitution would improve the professionalism of these optometrists. 
Finally, the power position of the stakeholders who did not support the task substitution 
was strong enough to block the implementation. The ‘window of opportunity’ closed 
with the establishment of the GFU. For this reason, it is necessary that policy makers 
considering substituting tasks to lesser trained professionals and transferring services 
from a hospital to a primary care setting consider the implementation process carefully, 
especially when deciding to implement it in separate steps.
Chronic Lymphatic Leukaemia (CLL) is the most prevalent type of leukaemia among 
adults in western countries. Early symptoms of CLL are often minimal and the diagnosis 
often follows a routine blood test that returns a high lymphocyte blood count. 
Since randomised studies failed to a significant difference in survival between early 
versus deferred treatment of patients with asymptomatic, low risk CLL, the majority of 
CLL patients are not treated immediately after diagnosis. They will first be monitored 
through a watch and wait approach. Treatment is indicated only upon disease progres-
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sion and/or the development of CLL related symptoms. It aims to control the disease 
and its symptoms. Treatment options are (a combination of ) chemotherapy, radiation 
therapy, immunotherapy, and bone marrow transplantation.  
In the past decades, the number of treatment options for CLL has increased rapidly. 
Since health care is under increasing pressure, cost-effectiveness data of new versus 
existing treatment options are urgently needed. That is especially true in countries like 
the Netherlands where expensive drugs are to be evaluated during the first years of tem-
porary admittance in order to obtain unconditional reimbursement. In an observational 
study, we followed Dutch CLL patients for 6.4 years on average to get an overview of the 
management of CLL and the patients’ quality of life in clinical practice. 
Chapter five describes little treatment variation in the first treatment line. After the 
second treatment line, variation in treatment increases exponentially. A large propor-
tion of patients (39%) did not receive active treatment for their disease. Twenty five 
percent received one active treatment, 12% received two active treatments and 24% 
received three or more treatments. The two- and five-years survival was 100% and 89% 
respectively and the CLL specific survival was 91% after five years.
 A comprehensive cost calculation was performed to produce a transparent overview 
of the different cost categories. Chapter six presents the most important cost catego-
ries per treatment line and per type of treatment. The average total CLL related costs 
per patient were €41,417 (€539 per month) and varied considerably between treatment 
groups. The costs increased by the number of treatment lines. Although patients were 
treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient 
days for other reasons than administration of chemo(immuno-)therapy, such as the 
administration of blood products.
Information about the longitudinal quality of life of an unselected group of CLL 
patients over time was collected during the same study. Chapter seven describes the 
health related quality of life which was measured over multiple years by the EuroQol-5D, 
Visual Analogue Scale (VAS) and the European Organisation for Research and Treatment 
of Cancer (EORTC) QLQ-C30 including the CLL16 module. Patients received the question-
naires every 6 months in periods without active treatment, as well as at the start in the 
middle and at the end of each treatment line.  All HRQoL measurements per patient 
were connected and analysed using area under the curve analysis over the entire study 
duration. 
The total patient group was compared with age- and gender-matched norm scores 
of the general population. CLL patients scored statistically worse on the VAS and utility 
score of the EQ-5D5, all functioning scales of the EORTC-QLQ-C30, and the symptoms 
of fatigue, dyspnoea, sleeping disturbance, appetite loss, and financial difficulties. 
The results were described separately for CLL patients without any active treatment, 
for patients with chlorambucil treatment only, and patients with other treatment(s). 
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In untreated patients, the HRQoL was slightly reduced. In all treatment stages, HRQoL 
was compromised considerably. Patients treated with chlorambucil only scored worse 
on the EORTC-QLQ-C30 than patients who were treated with other treatments. This dif-
ference can probably be explained by the relatively high percentage of patients with 
co-morbidity in the group of CLL patients treated with chlorambucil only. 
The studies described in this thesis show that health technology assessment in daily 
clinical practice is challenging when disease management of the disease of interest is 
continually changed by successive introduction of new treatment options (Chapter 
eight). In such a dynamic process, the most appropriate comparator is changing rapidly. 
This impedes calculation of the marginal cost-effectiveness because the new treatment 
option has to be compared with multiple (older and newer) treatments to ensure the 
results are not outdated. This will often result in an insufficient number of comparable 
patients per treatment option for a reliable comparison.
The glaucoma study shows the value of mixed methods research in HTA analyses. 
Chances of implementation of an organisational innovation and thus the cost-effective-
ness and budget impact on a macro level are partially influenced by contextual factors, 
such as local stakeholder interests, and the structure of the healthcare system. 
This study teaches us that policy makers considering substituting tasks to lesser 
trained professionals and transferring services from a hospital to a primary care setting 
need to consider carefully the implementation process, especially when deciding to 
implement task substitution in separate steps. An intermediate step might diminish 
the sense of urgency for task substitution if it satisfies the professionalisation needs 
of the professionals involved. Recognising a restricted window of opportunity in the 
implementation of task substitution is thus critical.
The second lesson is that it is crucial to involve the substituting professionals (in this 
case the community optometrists) early to ensure that all stakeholders see the change 
as a normal step in the professionalisation of the substituting professionals.
Third, the combination of methods is also expected to be valuable in the HTA of 
drugs. Like the implementation of an organisational innovation, the uptake of a new 
drug depends on contextual factors, such as the criteria for reimbursement, the divi-
sion of the hospital budget for expensive drugs over all departments, the opinion of 
the treating specialist and patient preferences. The addition of qualitative research 
methods to an HTA analysis might result in a more accurate calculation of the marginal 
cost-effectiveness of a new medicine.
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Dit proefschrift behandelt de kosten en effecten van gezondheidszorg innovaties bin-
nen twee ziektegebieden: glaucoom en chronisch lymfatische leukemie.
Glaucoom is een verzamelnaam voor een groep oogaandoeningen die gekenmerkt wordt 
door schade aan de oogzenuw en daarmee samenhangende uitval in het gezichtsveld. 
Een verhoogde oogdruk is een belangrijke risicofactor voor het ontstaan van glaucoom. 
De behandeling richt zich daarom op het verlagen van de oogdruk, wat mogelijk is door 
middel van medicatie, laserbehandeling of een operatie. Wanneer de oogdruk goed kan 
worden gereguleerd is er sprake van stabiele ziekte. Patiënten die stabiel glaucoom heb-
ben of een risicofactor hebben voor het ontwikkelen van glaucoom worden nu veelal 
behandeld door glaucoom specialisten, terwijl dit ook door lager opgeleid personeel 
zoals optometristen of technisch oogheelkundig assistenten kan worden gedaan. De 
hoge werkdruk van glaucoom specialisten heeft ertoe geleid dat in Het Oogziekenhuis 
Rotterdam is getracht stabiele glaucoompatiënten en patiënten met een risicofactor 
voor het ontwikkelen van glaucoom te verwijzen naar eerstelijns optometristen. Toen 
dit niet bleek te lukken, omdat het glaucoom specialisten veel tijd kostte om patiënten 
ervan te overtuigen dat de optometristen deze zorg evengoed konden leveren en niet 
alle glaucoom specialisten hiertoe bereid waren, is er besloten een glaucoompost op te 
richten binnen het ziekenhuis. De glaucoompost werd bemand door een ziekenhuis-
optometrist en technisch oogheelkundig assistenten.
Met behulp van een gerandomiseerd onderzoek is de zorg die werd geleverd door 
de glaucoompost vergeleken met de gebruikelijke zorg door glaucoom specialisten of 
arts assistenten. Daarbij brachten patiënten die in de arm glaucoompost zaten, twee 
bezoeken aan de glaucoompost en daarna één bezoek aan de glaucoom specialist. 
Wanneer daar aanleiding toe was, werd de patiënt eerder door een glaucoom specialist 
gezien. Bij 815 patiënten met stabiel glaucoom of een risicofactor voor het ontwikkelen 
van glaucoom werd het zorggebruik en de uitkomst ervan vastgelegd. Daarnaast wer-
den alle deelnemende patiënten gevraagd om bij ieder bezoek aan Het Oogziekenhuis 
Rotterdam een vragenlijst in te vullen over hun tevredenheid over de geleverde zorg, en 
de gemaakte reis- en tijdkosten door de patiënt en eventuele begeleiders. 
Hoofdstuk twee beschrijft de kwaliteit van de geleverde zorg door de glaucoompost 
en glaucoom specialisten. Medewerkers van de glaucoompost bleken het opgestelde 
protocol nauwgezet te volgen voor het meten van de oogdruk, gezichtsscherpte en 
GDx metingen. Humphey Field Analyser beoordelingen werden minder vaak uitgevoerd 
dan voorgeschreven door het protocol, maar vaker dan in de arm ‘glaucoom specialist’. 
In een klein deel van de patiënten dat de glaucoompost had moeten terugverwijzen 
naar de glaucoom specialist, gebeurde dat niet. Bij deze patiënten was de overschrijding 
156 Chapter 9
van de norm die was beschreven in het protocol echter beperkt. De uitkomst van de 
zorg, gemeten als de verandering in oogdruk over de duur van de studie, bleek niet 
te verschillen tussen de twee armen en patiënten gaven een iets hoger rapportcijfer 
aan de medewerkers van de glaucoompost dan aan de glaucoom specialisten. De 
glaucoompost bleek goed en naar tevredenheid van de patiënten te functioneren en 
er konden geen verschillen worden waargenomen in de klinische uitkomst van de zorg.
Hoofdstuk drie vergeleek de kosten van de glaucoompost met die van de glaucoom 
specialisten. De kosten van de glaucoompost waren ongeveer 10% lager dan die van de 
gebruikelijke zorg voor 3 van de 4 gebruikte perspectieven: Het Oogziekenhuis Rotter-
dam, het zorgsysteem en de maatschappij. De kosten voor de patiënt verschilden niet 
tussen de twee groepen patiënten. Bootstrap analyses toonden aan dat zowel het rap-
portcijfer gegeven door de patiënt als het percentage patiënten dat werd beoordeeld als 
‘stabiel’ in de twee armen gelijkwaardig was en dat de glaucoompost kostenbesparend 
was in 84 tot 89% van de bootstrap herhalingen. Scenario- en sensitiviteitsanalyses be-
vestigden dat de resultaten robuust waren. Alleen in het onwaarschijnlijke geval dat de 
gemiddelde duur van een bezoek aan de glaucoompost zou zijn onderschat én de duur 
van een bezoek aan de glaucoom specialist zou zijn overschat, zou de glaucoompost 
niet langer kostenbesparend zijn.
Om na te gaan of de betrokkenen het haalbaar achtten om alsnog, na het uitvoeren 
van het gerandomiseerde onderzoek en het daaruit verkregen bewijs, een deel van de 
glaucoom patiënten over te dragen aan de eerstelijns optometristen, is er een case-
studie uitgevoerd. Met alle betrokkenen vanuit Het Oogziekenhuis Rotterdam en een 
gerichte steekproef van externe betrokkenen werd een semigestructureerd interview 
gehouden. Hoofdstuk vier beschrijft de resultaten hiervan in het licht van drie imple-
mentatie gerelateerde theoretische perspectieven: sociologische theorie over profes-
sionalisme, management theorie en toegepaste politieke analyse. Hieruit bleek dat het 
op dat moment niet mogelijk was om de zorg te verplaatsen naar de eerste lijn. Dit 
kwam enerzijds door de oprichting van de glaucoompost binnen het ziekenhuis, die de 
oorspronkelijke gevoelde noodzaak tot verandering sterk verminderde en anderzijds 
doordat de opbrengsten van de investering onduidelijk waren. Daarnaast zagen de 
glaucoom specialisten en glaucoompost medewerkers de verplaatsing van de zorg naar 
de optiekzaken niet als een positieve ontwikkeling richting verdere professionalisering 
van de eerstelijns optometristen. Tenslotte bleek de machtspositie van de betrokken 
partijen die niet achter de verplaatsing van de zorg stonden sterk genoeg om deze 
tegen te houden. De ‘window of opportunity’ voor de verplaatsing van zorg naar de 
eerste lijn verdween door de oprichting van de glaucoompost binnen het ziekenhuis. 
Om die reden is het essentieel dat het ontwerp van het implementatie proces goed is 
doordacht, zeker wanneer beleidsmakers overwegen om taaksubstitutie stapsgewijs te 
implementeren. 
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Chronische Lymfatische Leukemie (CLL) is de meest voorkomende vorm van leukemie 
onder volwassenen in westerse landen. Vroege symptomen van CLL zijn echter meestal 
minimaal en diagnose volgt vaak na een routine bloedonderzoek, waarbij een te hoge 
waarde voor lymfocyten wordt gevonden. 
Aangezien gerandomiseerde studies aantonen dat vroegtijdige behandeling niet 
leidt tot een betere overleving dan uitgestelde behandeling van patiënten met asymp-
tomatisch, laag risico CLL, worden de meeste CLL patiënten niet onmiddellijk na het 
stellen van de diagnose behandeld. Bij hen wordt eerst alleen de ziektevoortgang goed 
gemonitord door middel van lichamelijk en bloedonderzoek. Bij ziekte progressie of 
de ontwikkeling van CLL gerelateerde symptomen wordt een behandeling in de vorm 
chemotherapie, radiotherapie, immunotherapie, beenmergtransplantatie of een com-
binatie daarvan gestart met het doel om de ziekte en de symptomen onder controle 
houden. 
In de afgelopen decennia is het aantal behandelopties voor CLL snel toegenomen. 
Aangezien de gezondheidszorg onder toenemende druk staat, is informatie over de 
kosteneffectiviteit van nieuwe versus bestaande behandelingsmogelijkheden dringend 
nodig. Dat is vooral het geval in landen als Nederland, waar het gebruik (de kosten) en de 
effectiviteit van dure medicijnen tijdens de eerste jaren van de tijdelijke toelating wor-
den geëvalueerd om definitieve vergoeding te kunnen verkrijgen. In een observationele 
studie, werden 160 CLL patiënten gedurende gemiddeld 6,4 jaar gevolgd om inzicht 
te krijgen in de behandeling van CLL in Nederland en de kwaliteit van leven van CLL 
patiënten in de dagelijkse praktijk. In Hoofdstuk vijf wordt beschreven dat de behande-
ling van CLL sterk varieert, met name na de tweede behandellijn. Een groot deel van de 
patiënten (39%) ontving geen enkele actieve behandeling voor de ziekte. Vijfentwintig 
procent ontving 1 actieve behandeling, 12% ontving 2 actieve behandelingen en 24% 
ontving drie of meer behandelingen. De twee- en vijfjaars overleving was respectievelijk 
100% en 89% en de CLL-specifieke overleving was 91% na 5 jaar.
Een uitgebreide kostenberekening werd uitgevoerd om een transparant overzicht te 
verkrijgen van de omvang van de verschillende kostencategorieën. Per behandellijn en 
per type behandeling zijn de belangrijkste kostencategorieën beschreven in Hoofdstuk 
zes. De totale gemiddelde kosten gerelateerd aan CLL bedroegen €41.417 per patiënt 
(€539 per maand) en varieerden sterk per type behandeling. Bovendien namen de kosten 
toe met iedere behandellijn. Ondanks dat de behandeling met (dure) chemo(immuno-)
therapie was meegenomen in de kostenberekening, kwamen de meeste kosten voort 
uit de opnamedagen voor een andere reden dan de toediening van chemo(immuno-)
therapie, zoals de toediening van bloedproducten. 
In hetzelfde onderzoek is informatie verkregen over de longitudinale kwaliteit van le-
ven van een ongeselecteerde populatie van CLL-patiënten. Hoofdstuk zeven beschrijft 
de kwaliteit van leven die gedurende meerdere jaren werd gemeten door middel van 
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een samengestelde vragenlijst bestaande uit de EuroQol-5D, Visual Analogue Scale (VAS) 
en de European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 
inclusief de CLL16 module. Patiënten ontvingen de vragenlijsten iedere 6 maanden in 
periodes zonder behandeling en daarnaast bij de start, halverwege en aan het einde van 
iedere behandellijn. De uitkomsten per patiënt over de tijd zijn met elkaar verbonden en 
uitgedrukt als het oppervlakte onder de curve.
De totale groep CLL patiënten is vergeleken met de voor geslacht en leeftijd gewogen 
norm scores voor de algehele bevolking. CLL patiënten scoorden slechter op de VAS en 
de utiliteitsscore van de EQ-5D, alle functionele schalen van de EORTC-QLQ-C30 en de 
volgende symptomen: vermoeidheid, kortademigheid, moeite met slapen, gebrek aan 
eetlust, en financiële moeilijkheden. De resultaten zijn apart beschreven voor patiën-
ten die nog geen actieve behandeling hadden ontvangen, voor patiënten die alleen 
met chloorambucil waren behandeld en patiënten die waren behandeld met andere 
of meerdere behandelingen. Voor patiënten die nog niet waren behandeld bleek de 
kwaliteit van leven enigszins beperkt te zijn. In andere fases van de behandeling was die 
beperking aanzienlijk. Patiënten die waren behandeld met alleen chloorambucil, een 
relatief milde behandeling, bleken nog iets slechter te scoren dan patiënten die meer 
of andere behandelingen hadden gekregen. Waarschijnlijk is dit verschil voor een deel 
te verklaren doordat de groep patiënten die alleen met chloorambucil was behandeld 
vaker last had van comorbiditeiten dan de groep die meer of andere behandelingen 
hadden gekregen. 
Uit de onderzoeken beschreven in dit proefschrift blijkt dat health technology assess-
ment in de dagelijkse klinische praktijk een uitdaging vormt wanneer het een tech-
nologie betreft voor een aandoening met een snel veranderende behandelingsstrat-
egie doordat er in een korte tijd veel nieuwe behandeling beschikbaar (zijn ge)komen 
(Hoofdstuk acht). In een dergelijke dynamische omgeving, wisselt de behandeling 
waarmee de interventie zou moeten worden vergeleken ook snel. Dit bemoeilijkt de 
berekening van de marginale kosteneffectiviteit, omdat de interventie met meerdere 
(oudere en nieuwere) behandelingen moet worden vergeleken om ervoor te zorgen 
dat de resultaten in achterhaald zullen zijn. Het gebruik van meerdere behandelingen 
maakt het vaak lastiger om genoeg vergelijkbare patiënten per groep te vinden voor 
een betrouwbare vergelijking. 
Daarnaast blijkt uit de glaucoom studie, dat mixed methods onderzoek waardevol is 
in HTA onderzoek. Kans op implementatie van een organisatorische innovatie en daar-
mee zijn relatieve kosteneffectiviteit en budget impact op macro niveau worden mede 
bepaald door omgevingsfactoren, zoals de belangen van stakeholders, en de structuur 
van het gezondheidszorgsysteem. 
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Dit onderzoek leert dat beleidsmakers die overwegen taken te verschuiven naar min-
der hoog opgeleid personeel, en van een ziekenhuisomgeving naar de eerste lijn, het 
implementatie proces zorgvuldig moeten vormgeven, zeker wanneer de verplaatsing 
van zorg in meerdere stappen plaats vindt. Een tussenstap kan de gevoelde noodzaak 
voor verandering wegnemen, als deze tussenstap voldoet in de behoeften op het profes-
sionele vlak. De ‘window for opportunity’ is daarom beperkt. Het hebben van aandacht 
voor dit feit is cruciaal. Daarnaast bleek het essentieel om de beoogde zorgverleners (in 
dit geval de eerstelijns optometristen) al vroeg in het proces van verplaatsing van zorg 
te betrekken, zodat alle stakeholders de verandering zouden zien als een normale stap 
in de professionalisering van de optometristen. 
Mixed methods onderzoek is wellicht ook waardevol in de HTA van geneesmiddelen. 
Net als bij de implementatie van een organisatorische innovatie, hangt het gebruik van 
het nieuwe geneesmiddel namelijk af van omgevingsfactoren, zoals de vergoedingscri-
teria, de verdeling van het ziekenhuisbudget voor dure geneesmiddelen over de ver-
schillende afdelingen, de mening van de behandelend specialist en patiëntvoorkeuren. 
De toevoeging van kwalitatief onderzoek aan de HTA analyse, kan de berekening van 
de marginale kosteneffectiviteit van een nieuw geneesmiddel daarom betrouwbaarder 
maken.
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Het einde van mijn avontuur dat promoveren heet, is in zicht. Dit avontuur heeft hoogte 
en dieptepunten gekend, en een eindsprint waarin ik veel avonden en weekenden heb 
doorgewerkt. Maar  nu is het boekje klaar! Deze afronding was niet mogelijk geweest 
zonder de hulp, steun, bijdrage en ideeën van vele anderen, waarvoor veel dank! Het is 
onmogelijk om iedereen hiervoor persoonlijk te bedanken, maar toch wil ik een aantal 
mensen bij naam noemen.
Ten eerste dank aan alle patiënten en deelnemers van de studies die in dit proefschrift 
beschreven staan. Zonder hun toestemming voor deelname en alle ingevulde vragenli-
jsten had dit proefschrift niet tot stand kunnen komen. 
Mijn scriptiebegeleider en later collega bij het iMTA, Michel van Agthoven. Beste Michel, 
ik ben erg blij dat mijn sollicitatiebrief naar de functie van student-assistent van slechts 
één zin je niet afschrok. Ik ben je heel dankbaar dat je me twee keer naar het iMTA 
hebt gehaald. De eerste keer was dat als student-assistent voor de HOVON-24 studie, 
waarvoor we samen het hele land zijn doorgereisd en hoge stapels dossiers hebben 
doorgenomen. De tweede keer als onderzoeker voor de observationele kosten-effectiv-
iteitsstudie naar chronische lymfatische leukemie. Ik had toen niet kunnen denken dat 
dit de start was van mijn proefschrift. 
Mijn promotor, Carin Uyl-de Groot. Beste Carin, wat fijn dat je de begeleiding van het 
onderzoek overnam na het vertrek van Michel bij het iMTA. Bedankt voor het vertrouwen 
dat je me gaf om het onderzoek af te ronden en voor onze samenwerking in de latere 
studies naar chronische lymfatische leukemie, borstkanker en de ziekte van Hodgkin. 
Goede herinneringen heb ik ook aan onze deelname aan de Academische Jaarprijs, waar 
we toch zeker niet slecht hebben gepresteerd.
Mijn copromotor, Marc Koopmanschap. Beste Marc, ik wil je graag bedanken voor je hulp 
bij het glaucoom onderzoek, de vele levendige discussies die we hebben gevoerd en de 
prachtige fluitconcerten die je weggaf op de gang. Het feit dat onze karakters op som-
mige punten sterk verschillen, maakte voor mij onze samenwerking altijd erg bijzonder 
en inspirerend.
Graag wil ik de leden van de kleine en grote promotiecommissie bedanken voor het 
beoordelen van dit proefschrift, en voor de mogelijkheid dit werk met hen te bediscus-
siëren.
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De meeste hoofdstukken van dit proefschrift zijn geschreven met de hulp van de be-
trokken artsen en collega-wetenschappers. Ik ben de co-auteurs van de verschillende 
hoofdstukken erg dankbaar voor hun bijdrage hieraan. Ron Schaafsma en Hans Lemij wil 
ik daarbij in het bijzonder noemen, omdat ik altijd bij hen terecht kon met mijn klinische 
vragen.
Veel dank ben ik verschuldigd aan de collega’s en student-assistenten die hebben gehol-
pen bij het dossieronderzoek. Aat, Clazien, Esther en Gerson, ik wil jullie graag bedanken 
voor alle hulp bij het verzamelen van data in ziekenhuizen en de gezellige ritjes die we 
daarvoor hebben gemaakt door heel Nederland, van Delfzijl tot Heerlen. Ook dank ik 
(research) verpleegkundigen in de ziekenhuizen voor hun hulp bij het verkrijgen van 
de dossiers, het beschikbaar stellen van protocollen en het beantwoorden van vragen. 
Het schrijven van een proefschrift wordt een stuk plezieriger wanneer je dit kunt delen 
met fijne collega’s. Ik wil daarom graag alle collega’s bij het iMTA en iBMG heel graag 
bedanken voor hun directe of indirecte bijdrage aan dit proefschrift. Eén collega wil ik 
in het bijzonder bedanken: Martine, mijn kamergenoot van mijn eerste tot de laatste 
dag bij het iMTA. Beste Martine, op de eerste dag voelde ik me meteen ‘thuis’ en dat 
is niet veranderd. Ik wil je graag bedanken voor je steun en gezelligheid in voor- en 
tegenspoed. We hebben samen gelachen en gehuild, gemopperd en gevierd. De twee 
perioden waarin we allebei tegelijk zwanger waren, waren daarin toch wel het meest 
bijzonder. Ik ben erg blij dat je mijn paranimf wilt zijn. 
Voor mijn laatste projecten, die niet in dit proefschrift zijn verwerkt, heb ik heel plezierig 
samengewerkt met collega’s waar ik nog niet eerder zo nauw mee samenwerkte. Mai-
wenn en Elly, jullie begeleiding was zeer leerzaam voor me. Maiwenn, dat je technisch 
zeer kundig bent wist ik al, maar ik werd diep geraakt door je oprechte interesse en 
aandacht. Bedankt daarvoor. Elly, het schrijven van wervende teksten was nog nooit 
zo leuk en makkelijk ‘naast’ jou. Een woord van dank wil ik ook laten uitgaan naar mijn 
nieuwe collega’s Giel en Amber. Heel hartelijk dank voor jullie vertrouwen in me en jullie 
inzet om me de mogelijkheid te geven het retinopathie project af te ronden.
Manon, toen ik je vroeg mijn paranimf te zijn gaf je aan je vereerd te voelen. Dat is 
geheel wederzijds. Het is fijn om je zus dichtbij te hebben op zo’n moment. Je steun 
doet me goed. 
Anouk, onze vriendschap gaat heel wat jaren terug. Ondanks onze drukke agenda’s 
waardoor we elkaar niet zo vaak meer zien, is ieder contact wel heel vertrouwd en erg 
gezellig. Fijn dat je paranimf wilt zijn.
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Ten slotte wil ik graag mijn familie en vrienden bedanken voor hun steun en belangstel-
ling. Mijn ouders wil ik bedanken voor hun onvoorwaardelijke steun en liefde. Mam, je 
moederlijke intuïtie heeft me vele malen geholpen en niet alleen in de laatste jaren. Pap, 
de keren dat ik wat betreft het afronden van mijn proefschrift de handdoek in de ring 
wilde gooien, weerhield jij me daarvan. Jouw doorzettingsvermogen gaat de mijne te 
boven, en daar ben ik je dankbaar voor. Ook mijn schoonouders wil ik graag bedanken 
voor alle steun en praktische hulp tijdens de afrondingsfase van mijn proefschrift, maar 
ook daar buiten.
Lieve Paul, bedankt voor alle ruimte die je me hebt gegeven om dit proefschrift in de 
avonden en weekenden af te ronden. Ik waardeer dat enorm! Lars en Vera, bedankt voor 
alle vrolijkheid en levendigheid die jullie me iedere dag meegeven. Ik ben dankbaar 
voor iedere dag die we samen kunnen zijn.
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